,ID,title,abstract,date,doi,author_corresponding,author_corresponding_institution,source,eligible
42,10416,Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report,"Abstract In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 g, 30 g, or 100 g of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8- to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.",01/07/2020,10.1101/2020.06.30.20142570,Judith Absalon,"Pfizer, Inc., Pearl River, NY",medrxiv,pubmed
86,32778225,"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus maca",28/08/2020,10.1016/j.cell.2020.06.008,Hui Wang,"Beijing Institute of Biological Products Company Limited, Beijing, China",pubmed,NHP
105,32722908,Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.,"Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Nonhuman primates received 10 or 100 ..g of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-C",28/08/2020,10.1056/NEJMoa2024671,Kizzmekia S Corbett,"From the Vaccine Research Center (K.S.C., B. Flynn, K.E.F., J.R.F., S.B.-B., A.P.W., B. Flach, S. O'Connell, A.T.N., N.D., M.M.D., N.N.N., G.S.A., D.R.F., E.L., N.A.D.-R., B.C.L., M.K.L., S. O'Dell, S.D.S., E.P., L.A.C., C.Y., J.-P.M.T., W.S., Y.Z., O.M.A., L.W., A.P., E.S.Y., K.L., T.Z., I.-T.T., A.W., I.G., L.N., R.A.G., R.J.L., J.I.M., W.-P.K., K.M.M., T.J.R., J.E.L., M.R.G., P.D.K., J.R.M., A.M., N.J.S., M.R., R.A.S., B.S.G.), the Infectious Disease Pathogenesis Section (K.W.B., M.M., B.M.N., M.G.L.), and the Biostatistics Research Branch, Division of Clinical Research (M.C.N.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, and Bioqual (H.A., L.P., A.V.R., S.B., J.G., T.P.-T., A.S., T.-A.C., A. Cook, A.D., K.S., I.N.M.) and the Public Health Service Commissioned Corps (M.R.G.), Rockville - both in Maryland",pubmed,NHP
199,32511340,ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.,"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in December 2019<sup>1,2</sup> and is responsible for the COVID-19 pandemic<sup>3</sup>. Vaccines are an essential countermeasure urgently needed to control the pandemic<sup>4</sup>. Here, we show that the adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2, is immunogenic in mice, eliciting a robust humoral and cell-mediated response. This response was not Th2 dominated, as demonstrated by IgG",27/08/2020,10.1101/2020.05.13.093195,Neeltje van Doremalen,"Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA",pubmed,NHP
132,32663912,An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 ..g, 100 ..g, or 250 ..g. There were 15 p",25/07/2020,10.1056/NEJMoa2022483,Lisa A Jackson,"From Kaiser Permanente Washington Health Research Institute (L.A.J.) and the Center for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute (R.N.C.) - both in Seattle",pubmed,1
49,11472,Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine,"An effective vaccine is needed to halt the spread of the SARS-CoV-2 pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 COVID-19 vaccine trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Here we present antibody and T cell responses after BNT162b1 vaccination from a second, non-randomized open-label phase 1/2 trial in healthy adults, 18-55 years of age. Two doses of 1 to 50 g of BNT162b1 elicited robust CD4+ and CD8+ T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those in a COVID-19 convalescent human serum panel (HCS). Day 43 SARS-CoV-2 serum neutralising geometric mean titers were 0.7-fold (1 g) to 3.5-fold (50 g) those of HCS. Immune sera broadly neutralised pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had TH1 skewed T cell immune responses with RBD-specific CD8+ and CD4+ T cell expansion. Interferon (IFN){gamma} was produced by a high fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.",20/07/2020,10.1101/2020.07.17.20140533,Ugur Sahin,BioNTech,medrxiv,1
79,32789505,Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.,"A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed. To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China. In the phase 1 trial, 96 participants were assigned to 1 of the 3 dose groups (2.5, 5, and 10 ..g/dose) and an aluminum hydroxide (alum) adjuvant-only group (n...=...24 in each group), and received 3 intramuscular injections at days 0, 28, and 56. In the phase 2 trial, 224 adults were randomized to 5 ..g/dose ",16/09/2020,10.1001/jama.2020.15543,Shengli Xia,"Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China",pubmed,1
57,12435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,"Background NVX-CoV2373 is a recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins. We present the Day 35 primary analysis of our trial of NVX-CoV2373 with or without the saponin-based Matrix-M1 adjuvant in healthy adults. Methods This is a randomized, observer-blinded, placebo-controlled, phase 1 trial in 131 healthy adults. Trial vaccination comprised two intramuscular injections, 21 days apart. Primary outcomes were reactogenicity, safety labs, and immunoglobulin G (IgG) anti-spike protein response. Secondary outcomes included adverse events, wild-type virus neutralizing antibody, and T-cell responses. Results Participants received NVX-CoV2373 with or without Matrix-M1 (n=106) or placebo (n=25). There were no serious adverse events. Reactogenicity was mainly mild in severity and of short duration (mean [&ge;] 2 days), with second vaccinations inducing greater local and systemic reactogenicity. The adjuvant significantly enhanced immune responses and was antigen dose-sparing, and the two-dose 5g NVX-CoV2373/Matrix-M1 vaccine induced mean anti-spike IgG and neutralizing antibody responses that exceeded the mean responses in convalescent sera from COVID-19 patients with clinically significant illnesses. The vaccine also induced antigen-specific T cells with a largely T helper 1 (Th1) phenotype. Conclusions NVX-CoV2373/Matrix-M1 was well tolerated and elicited robust immune responses (IgG and neutralization) four-fold higher than the mean observed in COVID-19 convalescent serum from participants with clinical symptoms requiring medical care and induced CD4+ T-cell responses biased toward a Th1 phenotype. These findings suggest that the vaccine may confer protection and support transition to efficacy evaluations to test this hypothesis. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988).",06/08/2020,10.1101/2020.08.05.20168435,Cheryl Keech,"Novavax, Inc.",medrxiv,1
115,32702299,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.","This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study. This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute re",24/08/2020,10.1016/S0140-6736(20)31605-6,Feng-Cai Zhu,"NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: jszfc@vip.sina",pubmed,1
54,12535,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial","BACKGROUND The top priority for the control of COVID-19 pandemic currently is the development of a vaccine. A phase 2 trial conducted to further evaluate the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac). METHODS We conducted a randomized, double-blind, placebo-controlled trial to evaluate the optimal dose, immunogenicity and safety of the CoronaVac. A total of 600 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine at a dose of 3 g/0.5 mL or 6 g /0.5mL, or placebo on Day 0,14 schedule or Day 0,28 schedule. For safety evaluation, solicited and unsolicited adverse events were collected after each vaccination within 7 days and 28 days, respectively. Blood samples were taken for antibody assay. RESULTS CoronaVac was well tolerated, and no dose-related safety concerns were observed. Most of the adverse reactions fell in the solicited category and were mild in severity. Pain at injection site was the most frequently reported symptoms. No Grade 3 adverse reaction or vaccine related SAEs were reported. CoronaVac showed good immunogenicity with the lower 3 g dose eliciting 92.4% seroconversion under Day 0,14 schedule and 97.4% under Day 0,28 schedule. 28 days after two-dose vaccination, the Nab levels of individual schedules range from 23.8 to 65.4 among different dosage and vaccination schedules. CONCLUSIONS Favorable safety and immunogenicity of CoronaVac was demonstrated on both schedules and both dosages, which support the conduction of phase 3 trial with optimum schedule/dosage per different scenarios.",10/08/2020,10.1101/2020.07.31.20161216,Feng-Cai Zhu,Jiangsu Provincial Center for Disease Control and Prevention,medrxiv,1
81,32785213,Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.,"In March 2020, the World Health Organization (WHO) declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)<sup>1</sup>. With rapidly accumulating cases and deaths reported globally<sup>2</sup>, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among 45 healthy adults, 18 to 55 years of age, randomized ",13/08/2020,10.1038/s41586-020-2639-4,Mark J Mulligan,"New York University Langone Vaccine Center, New York, NY, USA",pubmed,1
62,13018,RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study,"Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (COVID-19), have spread to millions of people globally. Multiple vaccine candidates are under development, but no vaccine is currently available. Methods: Healthy adults 18-55 and 65-85 years of age were randomized in an ongoing, placebo-controlled, observer-blinded dose-escalation study to receive 2 doses at 21-day intervals of placebo or either of 2 lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, which encodes a secreted trimerized SARS-CoV-2 receptor-binding domain, or BNT162b2, which encodes a prefusion stabilized membrane-anchored SARS-CoV-2 full-length spike. In each of 13 groups of 15 participants, 12 received vaccine and 3 received placebo. Groups were distinguished by vaccine candidate, age of participant, and vaccine dose level. Interim safety and immunogenicity data of BNT162b1 in younger adults have been reported previously from US and German trials. We now present additional safety and immunogenicity data from the US Phase 1 trial that supported selection of the vaccine candidate advanced to a pivotal Phase 2/3 safety and efficacy evaluation. Results: In both younger and older adults, the 2 vaccine candidates elicited similar dose-dependent SARS-CoV-2-neutralizing geometric mean titers (GMTs), comparable to or higher than the GMT of a panel of SARS-CoV-2 convalescent sera. BNT162b2 was associated with less systemic reactogenicity, particularly in older adults. Conclusion: These results support selection of the BNT162b2 vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation, currently underway.",20/08/2020,10.1101/2020.08.17.20176651,Judith Absalon,"Vaccine Research and Development, Pfizer, Inc.",medrxiv,1
116,32702298,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.","The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine",24/08/2020,10.1016/S0140-6736(20)31604-4,Pedro M Folegatti,"The Jenner Institute, University of Oxford, Oxford, UK",pubmed,1
227,32450106,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.","A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain. We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrol",17/06/2020,10.1016/S0140-6736(20)31208-3,Feng-Cai Zhu,"NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: jszfc@vip.sina",pubmed,1
1,2535,Dynamics of COVID-19 pandemic at constant and time-dependent contact rates,"We constructed a simple Susceptible-Infected-Infectious-Excluded model of the spread of COVID-19. The model is parametrised only by the average incubation period, {tau}, and two rate parameters: contact rate, r_E, and exclusion rate, r_E. The rates can be manipulated by non-therapeutic interventions and determine the basic reproduction number, R = r_C/r_E, and, together with {tau}, the daily multiplication coefficient at the early exponential phase, {beta}. Initial {beta} determines the reduction of r_C required to contain epidemic spread. In the long-term, we consider a scenario based on typical social behaviours, in which r_C first decreases in response to a surge of daily new cases, forcing people to self-isolate, and then slowly increases when people gradually accept higher risk. Consequently, initial abrupt epidemic spread is followed by a plateau and slow regression. This scenario, although economically and socially devastating, will grant time to develop, produce, and distribute a vaccine, or at least limit daily cases to a manageable number.",29/03/2020,10.1101/2020.03.13.20035485,Tomasz Lipniacki,Institute of Fundamental Technological Research,medrxiv,0
2,2976,Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray,"COVID-19 is caused by SARS-CoV-2, and has become a global pandemic. There is no highly effective medicine or vaccine, most of the patients were recovered by their own immune response, especially the virus specific IgG and IgM responses. However, the IgG/ IgM responses is barely known. To enable the global understanding of SARS-CoV-2 specific IgG/ IgM responses, a SARS-CoV-2 proteome microarray with 18 out of the 28 predicted proteins was constructed. The microarray was applied to profile the IgG/ IgM responses with 29 convalescent sera. The results suggest that at the convalescent phase 100% of patients had IgG/ IgM responses to SARS-CoV-2, especially to protein N, S1 but not S2. S1 purified from mammalian cell demonstrated the highest performance to differentiate COVID-19 patients from controls. Besides protein N and S1, significant antibody responses to ORF9b and NSP5 were also identified. In-depth analysis showed that the level of S1 IgG positively correlate to age and the level of LDH (lactate dehydrogenase), especially for women, while the level of S1 IgG negatively correlate to Ly% (Lymphocyte percentage). This study presents the first whole picture of the SARS-CoV-2 specific IgG/ IgM responses, and provides insights to develop precise immuno-diagnostics, effective treatment and vaccine.",27/03/2020,10.1101/2020.03.20.20039495,Sheng-Ce Tao,"Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China",medrxiv,0
3,3709,Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking,"Background The outbreak of the novel coronavirus disease COVID 19, caused by the SARS-CoV-2 virus has spread rapidly around the globe during the past 3 months. As the virus infected cases and mortality rate of this disease is increasing exponentially, scientists and researchers all over the world are relentlessly working to understand this new virus along with possible treatment regimens by discovering active therapeutic agents and vaccines. So, there is an urgent requirement of new and effective medications that can treat the disease caused by SARS CoV 2. Methods and findings We perform the study of drugs that are already available in the market and being used for other diseases to accelerate clinical recovery, in other words repurposing of existing drugs. The vast complexity in drug design and protocols regarding clinical trials often prohibit developing various new drug combinations for this epidemic disease in a limited time. Recently, remarkable improvements in computational power coupled with advancements in Machine Learning (ML) technology have been utilized to revolutionize the drug development process. Consequently, a detailed study using ML for the repurposing of therapeutic agents is urgently required. Here, we report the ML model based on the Naive Bayes algorithm, which has an accuracy of around 73% to predict the drugs that could be used for the treatment of COVID-19. Our study predicts around ten FDA approved commercial drugs that can be used for repurposing. Among all, we suggest that the antiretroviral drug Atazanavir (DrugBank ID DB01072) would probably be one of the most effective drugs based on the selected criterions. Conclusions Our study can help clinical scientists in being more selective in identifying and testing the therapeutic agents for COVID 19 treatment. The ML based approach for drug discovery as reported here can be a futuristic smart drug designing strategy for community applications.",23/04/2020,10.1101/2020.04.05.20054254,Soumitra Satapathi,Indian Institute of Technology Roorkee,medrxiv,0
4,4073,Nitric oxide gas inhalation to prevent COVID-2019 in healthcare providers,"Introduction: In human hosts, SARS-CoV-2 causes a respiratory syndrome (named COVID-19) which can range from a mild involvement of the upper airways to a severe pneumonia with acute respiratory syndrome that requires mechanical ventilation in an intensive care unit (ICU). Hospital-associated transmission is an important route of spreading for the SARS-CoV-2 virus and healthcare providers are at the highest risk. As of February 2020, 1716, Chinese healthcare workers had confirmed SARS-CoV-2 infections and at least 6 died. Unfortunately, there is currently no vaccine or pharmacological prophylaxis to decrease the risk of healthcare providers contracting the infection. Methods and analysis. We will randomize 470 healthcare providers scheduled to work with COVID 19 patients to receive nitric oxide gas administration (NO group, n=235) or no gas administration (control group, n=235). The primary endpoint of this study is the incidence of subjects with COVID-19 disease at 14 days from enrollment. Secondary endpoints are the proportion of healthcare providers who present a positive real time RT-PCR test for SARS-CoV-2 14 days after enrollment, the proportion of healthcare providers requiring quarantine, and the total number of quarantine days in the two groups. Ethics and dissemination. The trial protocol is under the approval of The Partners Human Research Committee of Massachusetts General Hospital (Boston, USA) and recruitment is expected to start in April 2020. The results of this study will be published in scientific journals and presented at scientific meetings.",11/04/2020,10.1101/2020.04.05.20054544,Lorenzo Berra,"Department of Anesthesia,Critical Care and Pain Medicine, Massachussets General Hospital, Boston, Massachussets, USA.",medrxiv,0
5,4065,Association Between BCG Policy is Significantly Confounded by Age and is Unlikely to Alter Infection or Mortality Rates,"Recently a number of publications looked at the association between COVID-19 morbidity and mortality on one hand and countries' policies with respect to BCG vaccination on the other. This connection arises from differences in the rates of infection in countries where BCG vaccination is mandatory compared to countries where mandatory vaccination no longer exists or was never implemented in the first place. In at least 2 preprint publications the authors expressed the view that the ""known immunological benefits"" of BCG vaccination may be behind the biological mechanism of such observation. One study accounted for different income levels in different groups. Another study did not attempted to do so, instead exploring the differences between countries where a booster shot is given vs others where no such practice exists (finding no connection). Both of these studies did not explore other potential confounding factors. Meanwhile the press has focused on these headlines and pushed the narrative that BCG vaccination is causally linked to infection and mortality rates. This poses a serious challenge, demonstrated by the recently initiated clinical trials on BCG vaccination within the COVID19 context. This study shows that population age is a very significant confounding factor that explains the rates of infections much better and has a solid biology mechanism which explains this correlation. It suggests that BCG vaccination may have little or no causal link to infection rates and advises that any follow up studies should control for several confounding factors, such as population age, ethnicity, rates of certain chronic diseases, time from community spread start date, major public policy decisions and income levels.",11/04/2020,10.1101/2020.04.06.20055616,Stefan Kirov,Bristol Myers Squibb,medrxiv,0
6,3786,Connecting BCG Vaccination and COVID-19: Additional Data,"The reasons for a wide variation in severity of coronavirus disease 2019 (COVID-19) across the affected countries of the world are not known. Two recent studies have suggested a link between the BCG vaccination policy and the morbidity and mortality due to COVID-19. In the present study we compared the impact of COVID-19 in terms of case fatality rates (CFR) between countries with high disease burden and those with BCG revaccination policies presuming that revaccination practices would have provided added protection to the population against severe COVID-19. We found a significant difference in the CFR between the two groups of countries. Our data further supports the view that universal BCG vaccination has a protective effect on the course of COVID-19 probably preventing progression to severe disease and death. Clinical trials of BCG vaccine are urgently needed to establish its beneficial role in COVID-19 as suggested by the epidemiological data, especially in countries without a universal BCG vaccination policy. Keywords: COVID-19, BCG vaccination, case fatality ratio, mortality, low resource countries",19/04/2020,10.1101/2020.04.07.20053272,Devi Dayal,"Postgraduate Institute of Medical Education and Research, Chandigarh, India",medrxiv,0
7,4085,Efficacy of remdesivir versus placebo for the treatment of COVID-19: A protocol for systematic review and meta-analysis of randomized controlled trials,"Background: In spite of the global containment on prevention efforts, the spread of coronavirus disease 2019 (COVID-19) is continuing to rise, with 1.1 million confirmed cases and 60,124 deaths recorded worldwide since 04 April 2020. The outbreak has a significant threat to international health and economy. At present, there is no approved vaccine or treatment for the disease, while efforts are underway. Remdesivir, a nucleotide-analogue antiviral drug developed for Ebola, is determined to prevent and stop infections with COVID-19, while results are yet controversial. Here, we aim to conduct a systematic review and meta-analysis of randomized controlled trials to compare the effectiveness of remdesivir and placebo in patients with COVID-19. Method and analysis: We will search MEDLINE-PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and Google scholar databases without restriction in year of publication. We will include randomized controlled trials that assessed the effectiveness of remdesivir versus placebo for patients confirmed with COVID-19. We will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA 2015) guidelines for the design and reporting of the results. The primary endpoint will be time to clinical recovery. The secondary endpoints will be all cause mortality, discharged date, frequency of respiratory progression, and treatment-emergent adverse events. Two independent authors will perform study selection, data extraction, and methodology quality assessment. RevMan 5.3 software will be used for statistical analysis. Random/fixed effect model will be carried out to calculate mean differences for continuous outcomes and risk ratio for dichotomous outcomes between remdesivir and placebo. Ethics and dissemination: This study does not require ethical approval, because no participants data will be involved in this systematic review and meta-analysis. The findings of this study will be published in reputable and peer-reviewed journal. Registration: This review protocol is submitted in PROSPERO database for registration and we will include the registration number in the revised version of the manuscript. Keywords: 2019 novel coronavirus, 2019-nCoV, Coronavirus diseases 2019, COVID-19, SARS-cov-2, Remdesivir, Randomized Controlled Trials. Systematic review, Meta-analysis, protocol",14/04/2020,10.1101/2020.04.09.20059196,Desye Gebrie,"1Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia 2School of ",medrxiv,0
8,4092,Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics,"A key driver in biopharmaceutical investment decisions is the probability of success of a drug development program. We estimate the probabilities of success (PoS) of clinical trials for vaccines and other anti-infective therapeutics using 43,414 unique triplets of clinical trial, drug, and disease between January 1, 2000, and January 7, 2020, yielding 2,544 vaccine programs and 6,829 non-vaccine programs targeting infectious diseases. The overall estimated PoS for an industry-sponsored vaccine program is 39.6%, and 16.3% for an industry-sponsored anti-infective therapeutic. Among industry-sponsored vaccines programs, only 12 out of 27 disease categories have seen at least one approval, with the most successful being against monkeypox (100%), rotavirus (78.7%), and Japanese encephalitis (67.6%). The three infectious diseases with the highest PoS for industry-sponsored non-vaccine therapeutics are smallpox (100%), CMV (31.8%), and onychomycosis (29.8%). Non-industry-sponsored vaccine and non-vaccine development programs have lower overall PoSs: 6.8% and 8.2%, respectively. Viruses involved in recent outbreaks---MERS, SARS, Ebola, Zika---have had a combined total of only 45 non-vaccine development programs initiated over the past two decades, and no approved therapy to date (Note: our data was obtained just before the COVID-19 outbreak and do not contain information about the programs targeting this disease.) These estimates offer guidance both to biopharma investors as well as to policymakers seeking to identify areas most likely to be undeserved by private-sector engagement and in need of public-sector support.",14/04/2020,10.1101/2020.04.09.20059600,Andrew W Lo,MIT,medrxiv,0
9,4229,Bayesian Adaptive Clinical Trials for Anti-Infective Therapeutics during Epidemic Outbreaks,"In the midst of epidemics such as COVID-19, therapeutic candidates are unlikely to be able to complete the usual multi-year clinical trial and regulatory approval process within the course of an outbreak. We apply a Bayesian adaptive patient-centered model---which minimizes the expected harm of false positives and false negatives---to optimize the clinical trial development path during such outbreaks. When the epidemic is more infectious and fatal, the Bayesian-optimal sample size in the clinical trial is lower and the optimal statistical significance level is higher. For COVID-19 (assuming a static R0=2 and initial infection percentage of 0.1%), the optimal significance level is 7.1% for a clinical trial of a non-vaccine anti-infective therapeutic clinical trial and 13.6% for that of a vaccine. For a dynamic R0 ranging from 2 to 4, the corresponding values are 14.4% and 26.4%, respectively. Our results illustrate the importance of adapting the clinical trial design and the regulatory approval process to the specific parameters and stage of the epidemic.",14/04/2020,10.1101/2020.04.09.20059634,Andrew W Lo,MIT,medrxiv,0
10,4214,Molecular mechanism of action of repurposed drugs and traditional Chinese medicine used for the treatment of patients infected with COVID-19: A systematic scoping review,"Background: The emergence of COVID-19 as a pandemic has resulted in the need for urgent development of vaccines and drugs and the conduction of clinical trials to fight the outbreak. Because of the time constraints associated with the development of vaccines and effective drugs, drug repurposing and other alternative treatment methods have been used to treat patients that have been infected by the SARS-CoV-2 virus and have acquired COVID-19. Objective: The objective of this systematic review was to provide an overview of the molecular mechanism of action of repurposed drugs or alternative treatment medicines used to attenuate COVID-19 disease. Data Sources: The research articles or grey literature, including theses, government reports, and official news online, were identified from 4 databases and 1 search engine. The full content of a total of 160 articles that fulfilled our inclusion criteria was analyzed and information about 6 drugs (ritonavir, lopinavir, oseltamivir, remdesivir, favipiravir, and chloroquine) and 4 traditional Chinese medicines (Shuang Huang Lian Kou Fu Ye, TCM combination of Bu Huan Jin Zheng Qi San and Da Yuan Yin, Xue Bi Jing Injection and Qing Fei Pai Du Tang) were extracted. Conclusions: All of the repurposed drugs that have been used for the treatment of COVID-19 depend on the ability of the drug to inhibit the proliferation of the SARS-CoV-2 virus by binding to enzyme active sites, viral chain termination, or triggering of the molecular pathway, whereas traditional Chinese medicine has a pivotal role in triggering the inflammation pathway, such as the neuraminidase blocker, to fight the SARS-CoV-2 virus. This review provides an insight to experimental validation of drugs and alternative medicine used for the treatment and control of COVID-19.",04/05/2020,10.1101/2020.04.10.20060376,Fui Fui Lem,Ministry of Health Malaysia,medrxiv,0
11,4298,Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records,"Objective: Absent a vaccine or any established treatments for the novel and highly infectious coronavirus-19 (COVID-19), rapid efforts to identify potential therapeutics are required. We sought to identify commonly prescribed medications that may be associated with lesser risk of morbidity with COVID-19 across 6 Eastern Massachusetts hospitals. Design: In silico cohort using electronic health records from individuals evaluated in the emergency department between March 4, 2020 and July 12, 2020. Setting: Emergency department and inpatient settings from 2 academic medical centers and 4 community hospitals. Participants: All individuals presenting to an emergency department and undergoing COVID-19 testing. Main Outcome or Measure: Inpatient hospitalization; documented requirement for mechanical ventilation. Results: Among 7,360 individuals with COVID-19 positive test results by PCR, 3,693 (50.2%) were hospitalized in one of 6 hospitals. In models adjusted for sociodemographic features and overall burden of medical illness, medications significantly associated with diminished risk for hospitalization included ibuprofen and sumatriptan. Among individuals who were hospitalized, 962(26.0%) were admitted to the intensive care unit and 608 (16.5%) died; ibuprofen and naproxen were also more commonly prescribed among individuals not requiring intensive care. Conclusions: These preliminary findings suggest that electronic health records may be applied to identify medications associated with lower risk of morbidity with COVID-19, but larger cohorts will be required to address the substantial problem of confounding by indication, such that extreme caution is warranted in interpreting nonrandomized results. Trial Registration: None",16/04/2020,10.1101/2020.04.11.20061994,Roy H Perlis,Massachusetts General Hospital,medrxiv,0
12,4497,Epidemic Landscape and Forecasting of SARS-CoV-2 in India,"BACKGROUND India was one of the countries to institute strict measures for SARS-CoV-2 control in early phase. Since, then, the epidemic growth trajectory was slow before registering an explosion of cases due to local cluster transmissions. METHODS We estimated growth rate and doubling time of SARS-CoV-2 for India and high burden states using crowd sourced time series data. Further, we also estimated Basic Reproductive Number (R0) and time dependent reproductive number (Rt) using serial intervals from the data. We compared the R0 estimated from five different methods and R0 from SB was further used in analysis. We modified standard SIR models to SIRD model to accommodate deaths using R0 with the Sequential Bayesian method (SBM) for simulation in SIRD models. RESULTS On an average, 2.8 individuals were infected by an index case. The mean serial interval was 3.9 days. The R0 estimated from different methods ranged from 1.43 to 1.85. The mean time to recovery was 14, SD 5.3 days. Daily epidemic growth rate of India was 0.16 [95%CI; 0.14, 0.17] with a doubling time of 4.30 days [95%CI; 3.96, 4.70]. From the SIRD model, it can be deduced that the peak of SARS-CoV-2 in India will be around mid-July to early August 2020 with around 12.5% likely to be infected at peak time of incidence. CONCLUSIONS The pattern of spread of SARS-CoV-2 in India is suggestive of community transmission. There is a need to increase fund for infectious disease research and epidemiologic studies. All the current gains may be reversed rapidly if air travel and social mixing resumes rapidly. For the time being, these must be resumed only in a phased manner, and should be back to normal levels only after we are prepared to deal with the disease with efficient tools like vaccine or a medicine.",17/04/2020,10.1101/2020.04.14.20065151,Muhammed Shaffi Fazaludeen Koya,"School of Public Health, Boston University, MA, USA",medrxiv,0
13,4750,Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19,"Importance: The COVID-19 Pandemic has literally left the world breathless in the chase for pharmacotherapy. With vaccine and novel drug development in early clinical trials, repurposing of existing drugs takes the center stage. Objective: A potential drug discussed in global scientific community is hydroxychloroquine. We intend to systematically explore, analyze, rate the existing evidence of hydroxychloroquine in the light of published, unpublished and clinical trial data. Evidence review: PubMed Ovid MEDLINE, EMBASE, Google scholar databases, pre-proof article repositories, clinical trial registries were comprehensively searched with focused question of use of hydroxychloroquine in COVID-19 patients. The literature was systematically explored as per PRISMA guidelines. Findings: Total 156 articles were available as of 7th May 2020; of which 11 articles of relevance were analyzed. Three in-vitro studies were reviewed. Two open label non-randomized trials, two open label randomized control trials, one large observational study, one follow-up study and two retrospective cohort studies were systematically analyzed and rated by oxford CEBM and GRADE framework for quality and strength of evidence. Also 27 clinical trials registered in three clinical trial registries were analyzed and summarized. Hydroxychloroquine seems to be efficient in inhibiting SARS-CoV-2 in in-vitro cell lines. However, there is lack of strong evidence from human studies. It was found that overall quality of available evidence ranges from ""very low"" to ""low"". Conclusions and relevance: The in-vitro cell culture based data of viral inhibition does not suffice for the use of hydroxychloroquine in the patients with COVID-19. Current literature shows inadequate, low level evidence in human studies. Scarcity of safety and efficacy data warrants medical communities, health care agencies and governments across the world against the widespread use of hydroxychloroquine in COVID-19 prophylaxis and treatment, until robust evidence becomes available.",13/05/2020,10.1101/2020.04.16.20068205,Umesh Devappa Suranagi,Lady Hardinge Medical College,medrxiv,0
14,4849,Self-burnout - a new path to the end of COVID-19,"In this work we use mathematical modeling to describe a possible route to the end of COVID-19, which does not feature either vaccination or herd immunity. We call this route self-burnout. We consider a region with (a) no influx of corona cases from the outside, (b) extensive social distancing, though not necessarily a full lockdown, and (c) high testing capacity relative to the actual number of new cases per day. These conditions can make it possible for the region to initiate the endgame phase of epidemic management, wherein the disease is slowly made to burn itself out through a combination of social distancing, sanitization, contact tracing and preventive testing. The dynamics of the case trajectories in this regime are governed by a single-variable first order linear delay differential equation, whose stability criterion can be obtained analytically. Basis this criterion, we conclude that the social mobility restrictions should be such as to ensure that on the average, one person interacts closely (from the transmission viewpoint) with at most one other person over a 4-5 day period. If the endgame can be played out for a long enough time, we claim that the Coronavirus can eventually get completely contained without affecting a significant fraction of the region's population. We present estimates of the duration for which the epidemic is expected to last, finding an interval of approximately 5-15 weeks after the self-burnout phase is initiated. South Korea, Austria, Australia, New Zealand and the states of Goa, Kerala and Odisha in India appear to be well on the way towards containing COVID by this method.",28/04/2020,10.1101/2020.04.17.20069443,B Shayak,Cornell University,medrxiv,0
15,5000,Immune defects and cardiovascular risk in X chromosome monosomy mosaicism mediated by loss of chromosome Y. A risk factor for SARS-CoV-2 vulnerability in elderly men?,"The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) has an estimated overall case fatality ratio of 1.38% in China, being 53% higher in males and increasing exponentially with age. Mosaicism for X chromosome monosomy (XCM) shows a similar increase in aging population mostly driven by loss of chromosome Y in males (LOY), and is associated with a raise in all-cause mortality. Using comparative transcriptomic data, we have defined that XCM/LOY is associated with abnormal peripheral blood cell counts with decreased progenitor cells and multiple biomarkers of immune system dysfunction, pro-coagulation activity and increased cardiovascular risk. Several differentially down-regulated genes in XCM/LOY individuals are involved in the initial immune response to SARS-CoV-2 (OR of enrichment=7.23, p=1.5x10-7), mainly interferon-induced genes that code for inhibitors of viral processes. Thus, our data suggest that XCM mosaicism underlies at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential relevance for modulating prognosis and therapeutic response, we propose that evaluation of LOY and XCM by currently established methods should be implemented as biomarkers in infected patients, including currently ongoing clinical trials with different medications and vaccines for COVID-19. Testing for LOY/XCM at large scale among elderly people may also be helpful to identify still unexposed people who may be especially vulnerable to severe Covid-19 disease.",24/04/2020,10.1101/2020.04.19.20071357,Juan R Gonzalez,Barcelona Institute for Global Health,medrxiv,0
16,4948,"Evidence-Based, Cost-Effective Interventions To Suppress The COVID-19 Pandemic: A Systematic Review","Background: In an unparalleled global response, during the COVID-19 pandemic, 90 countries asked 3.9 billion people to stay home. Yet some countries avoided lockdowns and focused on other strategies, like contact tracing and case isolation. How effective and cost-effective are these strategies? We aimed to provide a comprehensive summary of the evidence on pandemic control, with a focus on cost-effectiveness. Methods: Following PRISMA systematic review guidelines, MEDLINE (1946 to April week 2, 2020) and Embase (1974 to April 17, 2020) were searched using a range of terms related to pandemic control. Articles reporting on the effectiveness or cost-effectiveness of at least one intervention were included and grouped into higher-quality evidence (randomized trials) and lower-quality evidence (other study designs). Results: We found 1,653 papers; 62 were included. Higher-quality evidence was only available to support the effectiveness of hand washing and face masks. Modelling studies indicated that these measures are highly cost-effective. For other interventions, lower-quality evidence suggested that: (1) the most cost-effective interventions are swift contact tracing and case isolation, surveillance networks, protective equipment for healthcare workers, and early vaccination (when available); (2) home quarantines and stockpiling antivirals are less cost-effective; (3) social distancing measures like workplace and school closures are effective but costly, making them the least cost-effective options; (4) combinations are more cost-effective than single interventions; (5) interventions are more cost-effective when adopted early and for severe viruses like SARS-CoV-2. For H1N1 influenza, contact tracing was estimated to be 4,363 times more cost-effective than school closures ($2,260 vs. $9,860,000 per death prevented). Conclusions: A cautious interpretation of the evidence suggests that for COVID-19: (1) social distancing is effective but costly, especially when adopted late and (2) adopting as early as possible a combination of interventions that includes hand washing, face masks, ample protective equipment for healthcare workers, and swift contact tracing and case isolation is likely to be the most cost-effective strategy.",15/06/2020,10.1101/2020.04.20.20054726,Carl-Etienne Juneau,University of Montreal,medrxiv,0
17,5215,Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic,"Background: The world is facing the COVID-19 pandemic. Development of vaccine is challenging. Aim: To determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial. Methods: We conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial. Results: Three thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4 % of the responders, 670 (20.6 %) were under 30 years of age, 1,502 (46.1 %) between 30-49 years, 803 (24.6 %) between 50-64 years, 271 (8.3%) between 65-80 years, 13 (0.4%) over 80 years of age. According to their statements, 2.512 participants (77.6%, 95 % CI 76.2-79 %) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being healthcare workers and individual perceived risk were associated with COVID-19 vaccine acceptance Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty responders (47.6 % 95 % CI 45.9-49.3 %) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial. Conclusions and Relevance: Nearly 75 % and 48 % of the survey responders were likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake.",27/04/2020,10.1101/2020.04.23.20076513,Amandine Gagneux-Brunon,CHU de Saint-Etienne,medrxiv,0
18,5466,Custommune: a web tool to design personalized and population-targeted vaccine epitopes,"Computational prediction of immunogenic epitopes is a promising platform for therapeutic and preventive vaccine design. A potential target for this strategy is human immunodeficiency virus (HIV-1), for which, despite decades of efforts, no vaccine is available. In particular, a therapeutic vaccine devised to eliminate infected cells would represent a key component of cure strategies. HIV peptides designed based on individual viro-immunological data from people living with HIV/AIDS have recently shown able to induce post-therapy viral set point abatement. However, the reproducibility and scalability of this method is curtailed by the errors and arbitrariness associated with manual peptide design as well as by the time-consuming process. We herein introduce Custommune, a user-friendly web tool to design personalized and population-targeted vaccines. When applied to HIV-1, Custommune predicted personalized epitopes using patient specific Human Leukocyte Antigen (HLA) alleles and viral sequences, as well as the expected HLA-peptide binding strength and potential immune escape mutations. Of note, Custommune predictions compared favorably with manually designed peptides administered in a recent phase II clinical trial (NCT02961829). Furthermore, we utilized Custommune to design preventive vaccines targeted for populations highly affected by COVID-19. The results allowed the identification of peptides tailored for each population and predicted to elicit both CD8+ T-cell immunity and neutralizing antibodies against structurally conserved epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Overall, our data describe a new tool for rapid development of personalized or population-based immunotherapy against chronic and acute viral infections.",29/04/2020,10.1101/2020.04.25.20079426,Andrea Savarino,"Department of Infectious Diseases, Italian Institute of Health, Rome, Italy",medrxiv,0
19,6405,BCG Vaccine Protection from Severe Coronavirus Disease 2019 (COVID19),"A series of epidemiological explorations has suggested a negative association between national BCG vaccination policy and the prevalence and mortality of COVID-19. However, these comparisons are difficult to validate due to broad differences between countries such as socioeconomic status, demographic structure, rural vs. urban settings, time of arrival of the pandemic, number of diagnostic tests and criteria for testing, and national control strategies to limit the spread of COVID-19. We review evidence for a potential biological basis of BCG cross-protection from severe COVID-19, and refine the epidemiological analysis to mitigate effects of potentially confounding factors (e.g., stage of the COVID-19 epidemic, development, rurality, population density, and age structure). A strong correlation between the BCG index, an estimation of the degree of universal BCG vaccination deployment in a country, and COVID-19 mortality in different socially similar European countries was observed (r2 = 0.88; p = 8 X 10-7), indicating that every 10% increase in the BCG index was associated with a 10.4% reduction in COVID-19 mortality. Results fail to confirm the null hypothesis of no-association between BCG vaccination and COVID-19 mortality, and suggest that BCG could have a protective effect. Nevertheless, the analyses are restricted to coarse-scale signals and should be considered with caution. BCG vaccination clinical trials are required to corroborate the patterns detected here, and to establish causality between BCG vaccination and protection from severe COVID-19. Public health implications of a plausible BCG cross-protection from severe COVID-19 are discussed.",14/06/2020,10.1101/2020.05.05.20091975,Carolina Barillas-Mury,National Institutes of Health,medrxiv,0
20,6392,ProgNet: Covid-19 prognosis using recurrent andconvolutional neural networks,"Humanity is facing nowadays a dramatic pandemic episode with the Coronavirus propagation over all continents. The Covid-19 disease is still not well characterized, and many research teams all over the world are working on either ther- apeutic or vaccination issues. Massive testing is one of the main recommendations. In addition to laboratory tests, imagery- based tools are being widely investigated. Artificial intelligence is therefore contributing to the efforts made to face this pandemic phase. Regarding patients in hospitals, it is important to monitor the evolution of lung pathologies due to the virus. A prognosis is therefore of great interest for doctors to adapt their care strategy. In this paper, we propose a method for Covid-19 prognosis based on deep learning architectures. The proposed method is based on the combination of a convolutional and recurrent neural networks to classify multi-temporal chest X-ray images and predict the evolution of the observed lung pathology. When applied to radiological time-series, promising results are obtained with an accuracy rates higher than 92%.",08/05/2020,10.1101/2020.05.06.20092874,Lotfi Chaari,Institut National Polytechnique de Toulouse,medrxiv,0
21,6488,"Treatments administered to the first 9,152 reported cases of COVID19: a systematic review","Background The emergence of SARS-CoV-2/2019 novel coronavirus (COVID19) has created a global pandemic with no approved treatments or vaccines. Repurposing existing drugs and rapidly launching clinical trials present the greatest near-term opportunities for mitigating COVID19s impact. Many treatments have already been administered to COVID19 patients but have not been systematically evaluated. We performed a systematic literature review to identify and assess all treatments reported to be administered to COVID19 patients. Methods We searched PubMed, BioRxiv, MedRxiv, and ChinaXiv for articles reporting treatments for COVID19 patients published between Dec 1, 2019 and Mar 27, 2020. All studies reporting treatments were included. Data for each paper were manually extracted by two independent extractors. Outcomes included the duration from drug administration to clinically-meaningful response (complete symptom resolution or hospital discharge). Data were analysed descriptively. Results We identified 2,706 articles from single patient case reports to single-centre interventional studies. Of these, 155 studies met inclusion criteria, comprising 9,152 patients from 14 different countries. The cohort was 45.4% female and 98.3% hospitalised, and mean (SD) age was 44.4 years (SD 21.0). The most frequently administered drug classes were antivirals, antibiotics, and corticosteroids, and of the 115 reported drugs, the most frequently administered was combination lopinavir/ritonavir, which was associated with a response time of 11.7 (1.09) days. Discussion A large number of treatments have been administered to the first 9,152 reported cases of COVID19. Further work is needed to prioritise drugs for investigation in well-controlled clinical trials and treatment protocols. Funding None.",11/05/2020,10.1101/2020.05.07.20073981,David C Fajgenbaum,University of Pennsylvania Perelman School of Medicine,medrxiv,0
22,6600,DOUBLE POWER LAW FOR COVID-19: PREDICTION OF NEW CASES AND DEATH RATES IN ITALY AND SPAIN,"The novel corona virus SARS-CoV-2 appeared at the end of 2019, spreading rapidly and causing a severe respiratory syndrome (COVID-19) with high mortality (2-5%). Until a vaccine or therapy is found, the most effective method of prophylaxis has been to minimize transmission via rigorous social distancing and seclusion of all but essential workers. Such measures, implemented at different times and to varying degrees worldwide, have reduced the rate of transmission compared with early phases of the pandemic, resulting in flattening of the curve followed by a gradual reduction in mortality after >6 weeks of rigorous social distancing measures. The cost of rigorous social distancing has been seen in radically reduced economic activity, job losses, disruption of schooling and social institutions. A key question facing policy makers and individuals is when to resume normal economic and social activity in the face of persistent community transmission of SARS-CoV-2 . To help address this question, we have developed a model that accurately describes the entire transmission and mortality curves in Italy and Spain, two hard-hit countries that have maintained severe social distancing measures for over 2 months. Our model quantitatively describes the rapid rise and slow decay of new cases and deaths observed under stringent social distancing (the long tail effect). We predict that even when social distancing is rigorously maintained, the number of COVID-19 deaths after peak mortality may be 2-3 times larger than the total number of deaths up to the peak. Our model has important policy implications for countries currently debating how to ease social distancing measures.",11/05/2020,10.1101/2020.05.07.20094714,Lev Z. Osherovich,Versant Ventures,medrxiv,0
23,6814,Health literacy of inland population in the mitigation phase 3.2. of COVID-19's pandemic in Portugal - a descriptive cohort study,"Background: COVID-19 is a respiratory disease transmitted through respiratory droplets with a high transmission rate. There's still no effective and approved antiretroviral treatment or vaccine, thus, preventive measures are the main key to contain this pandemic. Portugal is now in phase 3.2 of the mitigation of COVID-19, being imperative to understand the health literacy of our country and how to prevent the lack of information, through community empowerment. Material and methods: A cross-sectional study with a cohort from a primary care facility was conducted. We collected demographic and epidemiological data and carried out a questionnaire by phone call. Descriptive statistics and nonparametric tests were used to assess associations between the independent variables and the level of health literacy. The level of significance was set at p<0.05. Results: Our cohort includes 222 subjects (median age: 62 years old), mostly females (131), undergraduate (193) and with at least one risk factor for COVID-19 (144). Globally, younger individuals, females, graduates and the Non-Risk Group appear to have higher levels of health literacy, with some exceptions to this pattern. Conclusions: We observe a well-informed population. However, being a pandemic situation, we intend to identify and correct outliers/misconceptions. This work allows a perspective of the current state/pattern of health literacy as well as its possible predictors. Furthermore, this study makes aware of how relevant the specific communication approaches are. Further studies to understand the predictors of health literacy are necessary. Key-Words: COVID-19, pandemic, SARS-CoV2, Portugal, Health literacy.",14/05/2020,10.1101/2020.05.11.20098061,Joana Gomes Da Silva,Centro de Saude Mirandela II,medrxiv,0
24,7018,Symptomatic SARS-CoV-2 infections display specific IgG Fc structures,"The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused a public health crisis that is exacerbated by our poor understanding of correlates of immunity. SARS-CoV-2 infection can cause Coronavirus Disease 2019 (COVID-19), with a spectrum of symptoms ranging from asymptomatic carriage to life threatening pneumonia and cytokine dysregulation [1-3]. Although antibodies have been shown in a variety of in vitro assays to promote coronavirus infections through mechanisms requiring interactions between IgG antibodies and Fc gamma receptors (Fc{gamma}Rs), the relevance of these observations to coronavirus infections in humans is not known [4-7]. In light of ongoing clinical trials examining convalescent serum therapy for COVID-19 patients and expedited SARS-CoV-2 vaccine testing in humans, it is essential to clarify the role of antibodies in the pathogenesis of COVID-19. Here we show that adults with PCR-diagnosed COVID-19 produce IgG antibodies with a specific Fc domain repertoire that is characterized by reduced fucosylation, a modification that enhances interactions with the activating Fc{gamma}R, Fc{gamma}RIIIa. Fc fucosylation was reduced when compared with SARS-CoV-2-seropositive children and relative to adults with symptomatic influenza virus infections. These results demonstrate an antibody correlate of symptomatic SARS-CoV-2 infections in adults and have implications for novel therapeutic strategies targeting Fc{gamma}RIIIa pathways.",18/05/2020,10.1101/2020.05.15.20103341,Taia T. Wang,Stanford University,medrxiv,0
25,7398,Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19,"The rapid global spread of SARS-CoV-2 and resultant mortality and social disruption have highlighted the need to better understand coronavirus immunity to expedite vaccine development efforts. Multiple candidate vaccines, designed to elicit protective neutralising antibodies targeting the viral spike glycoprotein, are rapidly advancing to clinical trial. However, the immunogenic properties of the spike protein in humans are unresolved. To address this, we undertook an in-depth characterisation of humoral and cellular immunity against SARS-CoV-2 spike in humans following mild to moderate SARS-CoV-2 infection. We find serological antibody responses against spike are routinely elicited by infection and correlate with plasma neutralising activity and capacity to block ACE2/RBD interaction. Expanded populations of spike-specific memory B cells and circulating T follicular helper cells (cTFH) were detected within convalescent donors, while responses to the receptor binding domain (RBD) constitute a minor fraction. Using regression analysis, we find high plasma neutralisation activity was associated with increased spike-specific antibody, but notably also with the relative distribution of spike-specific cTFH subsets. Thus both qualitative and quantitative features of B and T cell immunity to spike constitute informative biomarkers of the protective potential of novel SARS-CoV-2 vaccines.",21/05/2020,10.1101/2020.05.17.20104869,Adam K Wheatley,University of Melbourne,medrxiv,0
26,7869,Tensions between research and public health: modelling the risks and benefits of SARS-CoV-2 vaccine field trials versus human infection challenge studies.,"Background: Human infection challenge studies (HICS) with SARS-CoV-2 are under consideration as a way of accelerating vaccine development. We evaluate potential vaccine research strategies under a range of epidemic conditions determined, in part, by the intensity of public health interventions. Methods: We constructed a compartmental epidemiological model incorporating public health interventions, vaccine efficacy trials and a post-trial population vaccination campaign. The model was used to estimate the duration and benefits of large-scale field trials in comparison with HICS accompanied by an expanded safety trial, and to assess the marginal risk faced by HICS participants. Results: Field trials may demonstrate vaccine efficacy more rapidly than a HICS strategy under epidemic conditions consistent with moderate mitigation policies. A HICS strategy is the only feasible option for testing vaccine efficacy under epidemic suppression, and maximises the benefits of post-trial vaccination. Less successful or absent mitigation results in minimal or no benefit from post-trial vaccination, irrespective of trial design. Conclusions: SARS-CoV-2 HICS are the optimal method of vaccine testing for populations maintained under epidemic suppression, where vaccination offers the greatest benefits to the local population.",27/05/2020,10.1101/2020.05.18.20106187,George S Heriot,Monash University,medrxiv,0
27,7838,"Mechanistic rationale of drugs, Primary endpoints, Geographical distribution of clinical trials against Severe acute respiratory syndrome-related coronavirus-2: A Systematic Review","Objective To do a systematic review and critical appraisal of the ongoing clinical trials that are assessing various therapeutic interventions against SARS-CoV-2 with an aim to provide insight into the various interventions tested, clinical rationale, geographical distribution of the trials as well as the endpoints assessed in the studies. Design Rapid systematic review and critical appraisal of the ongoing clinical trials against SARS-CoV-2. Data sources ClinicalTrials.gov, World health organization (WHO) International Clinical Trials Registry Platform (ICTRP) and Cochrane COVID registry were assessed till May 11th 2020. Study selection Studies on any intervention based randomized controlled trials (RCTs), prospective clinical studies on SARS-CoV-2 in patients [&ge;]18 years of age. Studies on autopsy series, preclinical studies, diagnostic methods, mathematical modelling, epidemiology and health services research, pediatric populations were excluded. Data extraction The data was extracted by two authors independently into pre-defined forms based on the SPIRIT 2013 checklist. The data was extracted on various domains such as trial number, study title, abstract of the study, interventions assessed, sample size, phase of the study, study sponsor, primary endpoint assessed and country of study. Results The search resulted in 3242 ongoing studies of which 829 studies were included. There are 134 different drug-based interventions being assessed in 463 clinical trials as treatment options. Seventy-two studies assessed preventive options of which 53 are drug-based prophylaxis and 19 assessed vaccines. Herbal medicines are being assessed in 79 studies; convalescent plasma therapy in 56 studies; stem cell based interventions in 42 studies; anesthesia-based interventions in 31 studies, machine-based interventions in 24 studies, mental health- based interventions in18 studies, rehabilitation based interventions in 12 studies and miscellaneous interventions in 32 studies. China accounts for 35% of all ongoing clinical studies followed by USA 23%, France 7%, Spain 3.3%,Canada 2%, multi-country studies account only for 1.5% (13) and other countries together account for 28%.Amongst the 463 studies assessing drug-based treatment options, studies that are funded by federal and academic institutions are 79.6%, pharmaceutical company funded studies are 15.11% and no funding information is available in 5.10%. The definitive outcomes like mortality are being assessed as primary outcome in 22.8% of the studies only and need for ventilator in 6.2% of the studies. Rest of the studies has primary outcomes such as clinical recovery (15.9%), viral clearance(17.4%), time to recovery (10.1%), oxygen improvement (5.6%), ICU admission (1.9%), lab and imaging(6.4%), adverse effects (5.3%) and symptom reduction(1.5%),no outcome reported(6.2%) which account for 71% of the studies. Amongst the pharmaceutical company funded drug-based studies, only 20% of the studies had mortality as the primary outcome. Only 5.5% of the ongoing clinical trials are specifically designed to assess the most vulnerable population like elderly, patients with comorbidities and cancer. The most common intervention being tested against COVID-19 are antimalarial medications with 105 clinical studies. Hydroxychloroquine is the most common drug being tested with 83 ongoing studies. Conclusion Multiple intervention based clinical studies against SARS-CoV-2 are being performed throughout the world with a high concentration of clinical trials in the developed world. There is a high concern that most of the studies maybe repetitive; elderly and patients with comorbidities are being underrepresented; definite endpoints like mortality are being assessed in only one-fifth of the studies.",26/05/2020,10.1101/2020.05.24.20112169,Bhanu Prasad Venkatesulu,Henry Ford Hospital,medrxiv,0
28,8002,Improved detection of antibody against SARS-CoV-2 by microsphere-based antibody assay,"Objective: Currently available COVID-19 antibody tests using enzyme immunoassay (EIA) or immunochromatographic assay have variable sensitivity and specificity. Here, we developed and evaluated a novel microsphere-based antibody assay (MBA) for the detection of immunoglobulin G (IgG) against SARS-CoV-2 nucleoprotein (NP) and spike protein receptor binding domain (RBD). Method: We developed a microsphere-based assay (MBA) to determine the levels of IgG against SARS-CoV-2 NP and spike RBD. The seropositive cut-off mean fluorescent intensity (MFI) was set using a cohort of 294 anonymous serum specimens collected in 2018. The specificity was assessed using serum specimens collected from organ donors or influenza patients before 2020. Seropositive rate was determined among patients with COVID-19. Time-to-seropositivity and signal-to-cutoff (S/CO) ratio were compared between MBA and EIA. Results: MBA had a specificity of 100% (93/93; 95% confidence interval [CI], 96-100%) for anti-NP IgG and 98.9% (92/93; 95% CI 94.2-100%) for anti-RBD IgG. The MBA seropositive rate for convalescent serum specimens of COVID-19 patients were 89.8% (35/39) for anti-NP IgG and 79.5% (31/39) for anti-RBD IgG. The time-to-seropositivity was shorter with MBA than that of EIA. When compared with EIA, MBA could better differentiate between COVID-19 patients and negative controls with significantly higher S/CO ratio for COVID-19 patients and lower S/CO ratio with negative controls. MBA also had fewer specimens in the equivocal range (S/CO 0.9-1.1) than EIA. Conclusion: MBA is robust and simple, and is suitable for clinical microbiology laboratory for the accurate determination of anti-SARS-CoV-2 antibody for retrospective diagnosis, serosurveillance, and vaccine trials.",26/05/2020,10.1101/2020.05.26.20113191,Kelvin Kai-Wang To,University of Hong Kong,medrxiv,0
29,8062,The Potential Impact of Intensified Community Hand Hygiene Interventions on Respiratory tract Infections: A Modelling Study,"Increased hand hygiene amongst the general public has been widely promoted as one of the most important non-pharmaceutical interventions for reducing transmission during the ongoing COVID-19 pandemic and is likely to continue to play a key role in long-term efforts to suppress transmission before a vaccine can be deployed. For other respiratory tract infections community hand hygiene interventions are supported by evidence from randomised trials, but information on how effectiveness in reducing transmission scales with achieved changes in hand hygiene behaviour is lacking. This information is of critical importance when considering the potential value of substantially enhancing community hand hygiene frequency to help suppress COVID-19. Here, we developed a simple model-based framework for understanding the key determinants of the effectiveness of changes in hand hygiene behaviour in reducing transmission and use it to explore the potential impact of interventions aimed at achieving large-scale population-wide changes in hand hygiene behaviour. Our analyses show that the effect of hand hygiene is highly dependent on the duration of viral persistence on hands and that hand washing needs to be performed very frequently or immediately after hand contamination events in order to substantially reduce the probability of infection. Hand washing at a lower frequency, such as every 30 minutes or with a delay of 15 minutes after contamination events, may be adequate to reduce the probability of infection when viral survival on hands is longer, such as when hands are contaminated with mucus. Immediate hand washing after contamination is more effective than hand washing at fixed-time intervals even when the total number of hand washing events is similar. This event-prompted hand washing strategy is consistently more effective than fixed-time strategy regardless of hand contamination rates and should be highlighted in hand hygiene campaigns.",27/05/2020,10.1101/2020.05.26.20113464,Thi Mui Pham,Julius Center for Health Sciences and Primary Care of the UMC Utrecht,medrxiv,0
30,8488,A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19,"ABSTRACT BACKGROUND. The spread of COVID-19 from Wuhan China, has been alarmingly rapid. Epi-demiologic techniques succeeded in containing the disease in China, but efforts have not been as suc-cessful in the rest of the World, with a total of 29,155,581 confirmed cases of COVID-19, including 926,544 deaths worldwide as of September 15, 2020. Projections are for continued new infections and deaths if no effective therapeutic interventions can be initiated over the next several months. We per-formed a systematic review to determine the potential time course for development of treatments and vaccines, focusing on availability now and continuing in the last half of 2020. METHODS Clinical Trials: We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop agents. We focused on trials completed as of September 1, 2020 on identified agents We used several different sources: (A) covid-trials.org, then validated results on (B) clinicaltrials.gov and the (C) World Health Organization's Inter-national Clinical Trials Registry Platform (WHO ICTRP). We excluded studies which were clearly ob-servational, with no randomization, control, or comparison group. We further set a cutoff of 100 for numbers of subjects, since smaller trial size could lack statistical power to establish superiority of the intervention over the control. Publications: We searched for published trial results on pubmed.gov and on medRxiv, the preprint serv-er, and used a targeted Google search to find announcements of unpublished trial results RESULTS Clinical Trials in Recruitment: As of our cutoff date of April 1, 2020, we found 409 trials meeting our minimum requirement of 100 subjects. The WHO Solidarity megatrial for hospitalized patients was launched in over 100 countries, actively comparing hydroxychloroquine (HCQ), lopanovir/ritonavir (LPV/r) alone and in combination with interferon beta-1, and remdesivir. The LPV/r alone and HCQ arms have already been discontinued. Of these, only 9 were conducted on outpatients. A few vaccine trials are hoping to complete Phase 3 enrollment by the end of the third quarter 2020, but a prolonged follow-up of patients will likely be required. Clinical trials Completed: As of September 1, 2020, there were 231 trials reporting completion, Of these, only 59 studies enrolled 100 or more subjects. There were 34 trials in hospitalized patients, 9 di-rected at outpatients, and 8 prevention studies, Published Data: As of September 1, 2020 we found 70 publications reporting findings in human studies on 13 classes of drugs and on 6 vaccines. There were 33 randomized placebo or active control studies; the rest were retrospective observational. Only seven publications dealt with outpatient care, the rest all in hospitalized patients. Available Treatments. At this time, remdesivir and convalescent plasma have been granted emergency use authorization in the U.S.A., solely for hospitalized patients. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. No treatments or prophylaxis are offered for outpatients. CONCLUSION. COVID-19 is propagated primarily by infected ambulatory individuals. There have been no options brought forward for prevention and non-hospital treatment with only a few random-ized, controlled outpatient studies expected to yield results in time to impact on the continuing pan-demic by the end of 2020. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease. The choices will be hardest when dealing with possible early release of safe and effective vaccines which would, of course, be of greatest benefit to the World's population. Keywords: Coronavirus, COVID-19, SARS-Cov-2, remdesivir, hydroxychloroquine, favipiravir",19/08/2020,10.1101/2020.05.27.20115238,Marc Rendell,The Rose Salter Medical Research Foundation,medrxiv,0
31,8580,Repurposed prophylaxis strategies for COVID-19: a systematic review,"Introduction Efficient therapeutic strategies are needed to counter the COVID-19 pandemic, caused by the SARS- CoV-2 virus. In a context where specific vaccines are not yet available, the containment of the pandemic would be facilitated with efficient prophylaxis. Methods We screened several clinical trials repositories and platforms in search of the prophylactic strategies that are investigated against COVID-19 in late April 2020. Results Up to April 27, 2020, we found 68 clinical trials targeting medical workers (n=43, 63%), patients relatives (n=16, 24%) or individuals at risk of severe COVID-19 (n=5, 7%). (Hydroxy)chloroquine was the most frequently evaluated treatment (n=46, 68%), before BCG vaccine (n=5, 7%). Sixty-one (90%) clinical trials were randomized with a median of planned inclusions of 600 (IQR 255-1515). Conclusion The investigated prophylaxis strategies cover both pre- and post-exposure prophylaxis and study numerous immune enhancers and antivirals, although most research efforts are focused on (hydroxy)chloroquine.",03/06/2020,10.1101/2020.05.30.20117937,Nathan Peiffer-Smadja,"Universite de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hopitaux de Paris, Bichat- Clau",medrxiv,0
32,8999,Serological Analysis of New York City COVID19 Convalescent Plasma Donors,"The development of neutralizing antibodies (nAb) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19 pandemic. A large number of serologic tests, platforms and methodologies are being employed to determine seroprevalence in populations to select convalescent plasmas for therapeutic trials, and to guide policies about reopening. However, tests have substantial variability in sensitivity and specificity, and their ability to quantitatively predict levels of nAb is unknown. We collected 370 unique donors enrolled in the New York Blood Center Convalescent Plasma Program between April and May of 2020. We measured levels of antibodies in convalescent plasma using commercially available SARS-CoV-2 detection tests and in-house ELISA assays and correlated serological measurements with nAb activity measured using pseudotyped virus particles, which offer the most informative assessment of antiviral activity of patient sera against viral infection. Our data show that a large proportion of convalescent plasma samples have modest antibody levels and that commercially available tests have varying degrees of accuracy in predicting nAb activity. We found the Ortho Anti-SARS-CoV-2 Total Ig and IgG high throughput serological assays (HTSAs), as well as the Abbott SARS-CoV-2 IgG assay, quantify levels of antibodies that strongly correlate with nAb assays and are consistent with gold-standard ELISA assay results. These findings provide immediate clinical relevance to serology results that can be equated to nAb activity and could serve as a valuable roadmap to guide the choice and interpretation of serological tests for SARS-CoV-2.",09/06/2020,10.1101/2020.06.08.20124792,Larry L Luchsinger,New York Blood Center,medrxiv,0
33,9150,Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers - a Retrospective cohort,"Abstract Background: While several trials are ongoing for treatment of COVID-19, scientific research on chemoprophylaxis is still lacking even though it has potential to delay the pandemic allowing us time to complete research on vaccines. Methods: We have conducted a cohort study amongst Health Care Workers (HCW) exposed to COVID-19 patients, at a tertiary care center in India where there was an abrupt cluster outbreak within on duty personnel. HCWs who had voluntarily taken hydroxychloroquine (HCQ) prior to exposure were considered one cohort while those who had not were considered to be another. All participants with a verifiable contact history were tested for COVID-19 by rtPCR. The two cohorts were comparable in terms of age, gender, comorbidities and exposure. The primary outcome was incidence rates of rtPCR positive COVID-19 infection amongst HCQ users and non - users. Results: 106 healthcare workers were examined in this cohort study of whom 54 were HCQ users and rest were not. The comparative analysis of incidence of infection between the two groups demonstrated that voluntary HCQ usage was associated with lesser likelihood of developing SARS-CoV-2 infection, compared to those who were not on it, X2=14.59, p<0.001. None of the HCQ users noted any serious adverse effects. Conclusions: This study demonstrated that voluntary HCQ consumption as pre-exposure prophylaxis by HCWs is associated with a statistically significant reduction in risk of SARS-CoV-2. These promising findings therefore highlight the need to examine this association in greater detail among a larger sample using Randomised Controlled Trials (RCT).",22/06/2020,10.1101/2020.06.09.20116806,Anita Nandi,Medical College Kolkata,medrxiv,0
34,9407,Global research trend in the treatment of the new Coronavirus diseases (COVID-19) : bibliometric analysis.,"The Coronavirus 2019 (COVID-19) pandemic has caused worldwide concern and has become a major medical problem. Vaccines and therapeutics are important interventions for the management of this outbreak. This study aims to used bibliometric methods to identify research trends in the domain of therapeutics and vaccines to cure patients with COVID-19 since the beginning of the pandemic. The Web of Science Core Collection database was retrieved for articles on therapeutic approaches to coronavirus disease management published between January 1, 2020 and May 20, 2020. Identified and analyzed the data included title, corresponding author, language, publication time, publication type, research focus. A total of 1569 articles on coronavirus therapeutic means from 84 countries were published in 620 journals. We note the remarkable progressive increase in the number of publications related to research on therapies and vaccines for COVID-19. The United States provided the largest number of articles (405), followed by China (364). Journal of Medical Virology published most of them (n=40). 1005 (64.05%) were articles, 286 (18.23%) were letters, 230 (14.66%) were reviews. The terms ""COVID- 19"" or ""SARS-CoV-2"" or ""Coronavirus"" or ""hydroxychloroquine"" or ""chloroquine"" or ""2019-nCOV"" or ""ACE2"" or ""treatment"" or ""remdesivir"" or ""pneumonia"" were most frequently used, as shown in the density visualization map. A network analysis based on keyword co-occurrence revealed five distinct types of studies: clinical, biological, epidemiological, pandemic management, and therapeutics (vaccines and treatments). COVID-19 is a major disease that has had an impact on international public health at the global level. Several avenues for treatment and vaccines have been explored. Most of them focus on older drugs used to treat other diseases that have been effective for other types of coronaviruses. There is a discrepancy in the results obtained from the studies of the drugs included in this study. Randomized clinical trials are needed to evaluate older drugs and develop new treatment options.",14/06/2020,10.1101/2020.06.13.20122762,Maxime Descartes Mbogning Fonkou,Aix Marseille Universite,medrxiv,0
35,9536,"Explore the Possible Impact of BCG Vaccination Policy on the Morbidity, Mortality, and Recovery Rates due to COVID-19 Infection.","BACKGROUND The Coronavirus Disease-19 (COVID-19) is the new form of an acute infectious respiratory disease and has quickly spread over most continents in the world. Recently, it has been shown that Bacille Calmette-Guerin (BCG) might protect against COVID-19. This study aims to investigate the possible correlation between BCG vaccination and morbidity/mortality/recovery rate associated with COVID-19 infection. METHODS Data of COVID-19 confirmed cases, deaths, recoveries, and population were obtained from https://www.worldometers.info/coronavirus/ (Accessed on 12 June, 2020). To have meaningful comparisons among countries' mortality and recovery rates, we only choose those countries with COVID-19 infected cases at least 200. The Poisson regression and logistic regression were used to explore the relationship between BCG vaccination and morbidity, mortality and recovery rates. RESULTS Among those 158 countries with at least 200 COVID-19 infected cases, there were 141 countries with BCG vaccination information available. The adjusted rates ratio of COVID-19 confirmed cases for Current BCG vaccination vs. non-Current BCG vaccination was 0.339 (with 95% CI= (0.338,0.340)). Moreover, the adjusted odds ratio (OR) of death and recovery after coronavirus infected for Current BCG vaccination vs. non-Current BCG vaccination were 0.258 (with 95% CI= (0.254,0.261)) and 2.151 (with 95% CI= (2.140,2.163)), respectively. CONCLUSIONS That data in this study show the BCG might provide the protection against COVID-19, with consequent less COVID-19 infection and deaths and more rapid recovery. BCG vaccine might bridge the gap before the disease-specific vaccine is developed, but this hypothesis needs to be further tested in rigorous randomized clinical trials.",18/06/2020,10.1101/2020.06.14.20131268,Yue-Cune Chang,Tamkang University,medrxiv,0
36,9672,Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis,"Background Since the emergence of COVID-19, the world has been desperate to find effective therapeutics and vaccinations to treat hundreds of thousands of affected patients and to suppress the spread of this global pandemic. Lopinavir-ritonavir (LPV/RTV) is an HIV antiviral combination that has been considered for treatment of this disease. Aim of the study This systematic review and meta-analysis aimed to assess the efficacy and safety of lopinavir/ritonavir in COVID-19 patients in the extant published research. A systematic review protocol was developed based on PRISMA-P and the PRISMA statement. Published English and non-English articles written since December 1, 2019 were selected for review from 8 electronic databases. Readily accessible full articles (cohort studies and clinical trials) which specifically mentioned lopinavir/ritonavir and patients with lab-confirmed SARS-CoV-2 or COVOID-19 of any age were included. Three researchers separately evaluated the bias in the reported articles. We conducted a systematic review and meta-analysis with the objective of evaluation of the safety and efficacy of LPV/RTV alone or in combination with other drugs with regard to time to becoming PCR negative, time to body temperature normalization and cough relief, radiological progression, and safety. Review Manager (RevMan) was used to conduct all statistical analyses and generate the forest plots. Meta-analyses were performed using the Mantel Hazel method or the inverse variance method for dichotomous data and continuous data respectively. Results Non-duplicate articles (n=76) were evaluated for possible inclusion. A consensus was reached to select 29 articles for full-text screening, only 11 articles comprised 1,192 patients were included in this study, and six of which were included for meta-analysis. In terms of virological cure (PCR negative), three studies reported less time in days to achieve a virological cure for LPV/RTV arm relative to no antiviral therapy (conventional) (mean difference = -0.81 day; 95% CI, -4.44 to 2.81; P = 0.007, I2 = 80%). However, the overall effect was not significant (P = 0.66). When comparing LPV/RTV arm to umifenovir arm, a favorable affect was observed for umifenovir arm, but not statically significant (mean difference = 0.95 day; 95% CI, -1.11 to 3.01; P = 0.09, I2 = 58%). In terms of time to body normalization and cough relief (clinical cure), two studies reported on time to temperature normalization with no significant effect of LPV/RTV (n = 93) versus umifenovir (n = 71) arm), (OR = 0.87 day; 95% CI, 0.42 to 1.78; (P = 0.70), I2 = 0%), or alleviation of cough duration (p = 0.69). In terms of CT evidence of radiological progression of pneumonia/lung damage, treatment with lopinavir/ritonavir resulted in no significant decrease in the radiological progression (OR = 0.80; 95% CI, 0.42 to 1.54; P = 0.59, I2 = 81%), In terms of safety, a greater number of adverse events were reported for lopinavir/ritonavir (n=45) relative to the umifenovir arm (n=14) and conventional treatments (n=10 ), P = 0.004, 0,0007, respectively Conclusions The small number of studies included in this systematic review and meta-analysis study did not reveal any statistically significant advantage in efficacy of lopinavir-ritonavir in COVID-19 patients, over conventional or other antiviral treatments. This result might not reflect the actual evidence.",19/06/2020,10.1101/2020.06.16.20133298,Mansour Tobaiqy,"Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia",medrxiv,0
37,9969,BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden.,"Background The Bacille Calmette-Guerin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized that it may have a protective effect against COVID-19. Recent research found that countries with universal BCG childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders. Instead, this paper takes advantage of a rare nationwide natural experiment that took place in Sweden in 1975, where discontinuation of newborns BCG vaccination led to a dramatic fall of the BCG coverage rate from 92% to 2% , thus allowing us to estimate the BCG's effect without all the biases associated with cross-country comparisons. Methods Numbers of COVID-19 cases and hospitalizations were recorded for birth cohorts born just before and just after that change, representing 1,026,304 and 1,018,544 individuals, respectively. We used regression discontinuity to assess the effect of BCG vaccination on Covid-19 related outcomes. This method used on such a large population allows for a high precision that would be hard to achieve using a classical randomized controlled trial. Results The odds ratio for Covid-19 cases and Covid-19 related hospitalizations were 0.9997 (CI95: [0.8002-1.1992]) and 1.1931 (CI95: [0.7558-1.6304]), respectively. We can thus reject with 95% confidence that universal BCG vaccination reduces the number of cases by more than 20% and the number of hospitalizations by more than 24% Conclusions While the effect of a recent vaccination must be evaluated, we provide strong evidence that receiving the BCG vaccine at birth does not have a protective effect against COVID-19.",23/06/2020,10.1101/2020.06.22.20137802,Clement De Chaisemartin,UC Santa Barbara,medrxiv,0
38,10106,Phylogenomics and phylodynamics of SARS-CoV-2 retrieved genomes from India,"The ongoing SARS-CoV-2 pandemic is one of the biggest outbreaks after the Spanish flu of 1918. Understanding the epidemiology of viral outbreaks is the first step towards vaccine development programs. This is the first phylodynamics study attempted on of SARS-CoV-2 genomes from India to infer its current evolution in the context of an ongoing pandemic. Out of 286 retrieved SARS-CoV-2 whole genomes from India, 138 haplotypes were generated and analyzed. Median-joining network was built to investigate the relatedness of SARS-CoV-2 haplotypes in India. The BDSIR package of BEAST2 was used to calculate the reproduction number (R0) and the infectious rate of the virus. Past and current population trend was investigated using the stamp date method in coalescent Bayesian skyline plot, implemented in BEAST2 and by exponential growth prior in BEAST 1.10.4. Median-joining network reveals two distinct ancestral clusters A and B showing genetic affinities with Wuhan outbreak sample. The network also illustrates the autochthonous development of isolates in a few instances. High basic reproduction number of SARS-nCoV-2 in India points towards the phase of active community transmission. The Bayesian skyline plot revel exponential rise in the effective population size (Ne) of Indian isolates from the first week of January to the first week of April 2020. More genome sequencing and analyses of the virus will be required in coming days to monitor COVID19 after the upliftment of lock down in India.",26/06/2020,10.1101/2020.06.23.20138222,Mumtaz Baig,"Department of Zoology, Laboratory of Molecular and Conservation Genetics, Govt. Vidarbha Institute of Science and Humanities, Amravati-444604-India; Department ",medrxiv,0
39,9990,HAS COUNTRYWIDE LOCKDOWN WORKED AS A FEASIBLE MEASURE IN BENDING THE COVID-19 CURVE IN DEVELOPING COUNTRIES?,"In the absence of any effective vaccine and clinically proven treatment, experts thought that strict lockdown measures could be an effective way to slow down the spread of novel coronavirus. Despite the strict lockdown measures in several developing countries, the number of newly infected cases is getting unbridled as time progresses. This anomaly ignites questions about the effectiveness of the prolonged strict confinement measures. In light of the above view, with an aim to find the answer to this question, trends of four epidemiological parameters: growth factor of daily reported COVID-19 cases, daily incidence proportion, daily cumulative index and effective reproduction number in five developing countries named Bangladesh, Brazil, Chile, Pakistan and South Africa have been analysed meticulously considering the different phases of their national lockdowns. Any compelling evidence has not been found in favor of country-wide lockdown effectiveness in the above-mentioned countries. Numerical results illustrate that stringent nationwide lockdown measures have failed bringing the epidemic threshold (Re) of COVID-19 under unity. In addition, citizens of the aforementioned countries have been struggling with catastrophic socio-economic consequences due to prolonged confinement measures. Our study suggests that a new policy should be proposed for developing countries to battle against future disease outbreaks ensuring a perfect balance between saving lives and confirming livelihoods.",24/06/2020,10.1101/2020.06.23.20138685,Khondoker Nazmoon Nabi,Bangladesh University of Engineering and Technology,medrxiv,0
40,10195,Cost Benefit Analysis of Limited Reopening Relative to a Herd Immunity Strategy or Shelter in Place for SARS-CoV-2 in the United States,"Background: Fierce debate about the health and financial tradeoffs presented by different COVID-19 pandemic mitigation strategies highlights the need for rigorous quantitative evaluation of policy options. Objective: To quantify the economic value of the costs and benefits of a policy of continued limited reopening with social distancing relative to alternative COVID-19 response strategies in the United States. Design: We estimate the number and value of quality-adjusted life-years (QALY) gained from mortality averted, with a value of $125,000 per QALY, and compare these benefits to the associated costs in terms of plausible effects on US GDP under a policy of continued limited reopening with social distancing relative to a policy of full reopening toward herd immunity. Using the same QALY value assumptions, we further evaluate cost-effectiveness of a return to Shelter-in-Place relative to a policy of limited reopening. Setting: United States Measurements: QALY and cost as percent of GDP of limited reopening with continued social distancing relative to a strategy of full reopening aimed at achieving herd immunity; a limited reopening budget measured in the number of months before this strategy fails to demonstrate cost-effectiveness relative to a full reopening; a shelter-in-place threshold measured in the number of lives saved at which a month of sheltering in place demonstrates cost effectiveness relative to the limited reopening strategy. Results: QALY benefits from mortality averted by continued social distancing and limited reopening relative to a policy of full reopening exceed projected GDP costs if an effective vaccine or therapeutic can be developed within 11.1 months from late May 2020. White House vaccine projections fall within this date, supporting a partial reopening strategy. One month of shelter-in-place restrictions provides QALY benefits from averted mortality that exceed the associated GDP costs relative to limited reopening if the restrictions prevent at least 154,586 additional COVID-19 deaths over the course of the pandemic. Current models of disease progression suggest that limited reopening will not cause this many additional deaths, again supporting a limited reopening strategy. Limitation: Limited horizon of COVID-19 mortality projections; infection fatality ratio stable across strategies, ignoring both the potential for ICU overload to increase mortality and the deployment of partially effective therapeutics to decrease mortality; effect on GDP modeled as constant within a given phase of the pandemic; accounts for age and sex distribution of QALYs, but not effect of comorbidities; only considers impact from QALY lost due to mortality and from changes in GDP, excluding numerous other considerations, such as non-fatal COVID-19 morbidity, reduced quality of life caused by prolonged social distancing, or educational regression associated with prolonged school closures and restrictions. Conclusions: A limited reopening to achieve partial mitigation of COVID-19 is cost effective relative to a full reopening if an effective therapeutic or vaccine can be deployed within 11.1 months of late May 2020. One additional month of shelter-in-place restrictions should only be imposed if it saves at least 154,586 lives per month before the development of an effective therapeutic or vaccine relative to limited reopening.",28/06/2020,10.1101/2020.06.26.20141044,Robert B Schonberger,Yale School of Medicine,medrxiv,0
41,10302,Mapping the Global Research and Clinical Trials in COVID-19,"COVID-19 has created an unprecedented level of research and innovation activity globally to bring out drug to control or cure the disease, and develop vaccine for long time prevention. A 'new/better normal' is emerging that is trying to push this time period for drug development and vaccine within a year and earlier than that from typical 8 to 10 years for drugs and 10 to 15 years for vaccine. This is happening due to multiple factors: strong policy push by different government that includes dedicated investment, speeding up regulation process, multiple agencies involvement, and multilateral bodies led by WHO trying to create a global platform, huge grants from private funding bodies, strategic linkages across the whole research and innovation value chain between firms, academic, research organisations and start-ups. The paper maps the research papers and ongoing clinical trials to provide an informed view of the current status of the research and drug development activity as seen through the lens of research papers and clinical trials. The intended goal of this study is to help the research community and policy makers to keep track of highly relevant research and drug development in COVID-19.",29/06/2020,10.1101/2020.06.27.20141788,Sujit Bhattacharya,CSIR-National Institute of Science Technology and Development Studies,medrxiv,0
43,10678,Study of the Dependence of Effective Reproduction Number of COVID-19 on the Temperature and Humidity: A Case Study with the Indian States,"Corona Virus Disease 2019 (COVID-19) started in Wuhan province of China in November 2019 and within a short time, it was declared as a worldwide pandemic by World Health Organisation due to very fast worldwide spread of the virus. In the absence of any vaccine, various mitigation measures were used. In the past, the effect of temperature and humidity on the spread of the virus was studied for a very early phase of the data with mixed results. We are studying the impact of COVID-19 on the maximum temperature and relative humidity of a place using Indian states as test cases for SIR, SIRD, and SEIR models. We used a linear regression method to look for any dependency between effective reproduction number with maximum temperature and relative humidity. Most of the states show a correlation with the negative slope between the effective reproduction number with the maximum temperature and the relative humidity. It indicates that the effective reproduction number goes down as maximum temperature or relative humidity rise. But, the regression coefficient R2 is low for these correlations which means that the correlation is not strong.",06/07/2020,10.1101/2020.07.05.20146324,Sabyasachi Pal,Midnapore City College,medrxiv,0
44,11049,'Trained immunity' from  Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes,"Protective variables for COVID-19 are unknown. 'Trained immunity' of the populace as a result of BCG immunization policy implementation and coverage had been suggested to be one of the factors responsible for the differential impact of COVID-19 on different countries. Several trials are underway to evaluate the potential protective role of BCG vaccination in COVID-19. However, the lack of clarity on the use of appropriate controls concerning 'trained immunity' or the heterologous cell-mediated immunity conferred by BCG vaccination has been a cause of concern leading to more confusion as exemplified by a recently concluded trial in Israel that failed to find any protective correlation with regard to BCG vaccination. Whereas, when we analyze the COVID-19 data of European countries without any regard for BCG vaccination policy but with similar age distribution, comparable confounding variables, and the stage of the pandemic, the prevalence of tuberculin immunoreactivity - a measure of cell-mediated immunity persistence as a result of Mycobacterium spp.(including BCG vaccine) exposure of the populations, is found consistently negatively correlated with COVID-19 infections and mortality per million population, at all the time points evaluated. We propose that on-going and future studies evaluating the effect of BCG vaccination on COVID-19 outcomes may actively consider, if not already, the inclusion of 'controls' for underlying 'trained immunity'and heterologous cell-mediated immunity prevalence that may be pre-existing or resulting from the intervention (e.g., BCG vaccine) in such trials to arrive at more dependable conclusions concerning their potential benefit.",14/07/2020,10.1101/2020.07.11.20151308,Samer Singh,Banaras Hindu University Institute of Medical Sciences,medrxiv,0
45,11474,"Qing Fei Pai Du Tang, a Chinese multi-herbal medicine formulated against COVID-19, elevates the plasma levels of IL-1, IL-18, TNF-, and IL-8","There are currently no specific vaccine or drugs proven to be effective against COVID-19. Traditional Chinese herbal medicine has been integrated into the official therapeutic protocol against COVID-19 in China. Qing Fei Pai Du Tang (QFPDT) is a Chinese multi-herbal formula newly developed and specifically optimized for the treatment of COVID-19. Therapeutic administration of QFPDT resulted in an improved cure rate in mild to critically-ill patients. However, the immunological mechanism for the efficacy of QFPDT has been poorly understood. Furthermore, the feasibility of prophylactic use in uninfected individuals remain unconfirmed. We thus examined whether the administration of QFPDT at a dose lower than recommended for therapeutic use alters hematological and/or immunological measures in healthy individuals. We found that QFPDT elevates the plasma levels of IL-1{beta}, IL-18, TNF-, and IL-8, which are key mediators of acute inflammatory responses to ssRNA viruses. No apparent adverse effects were observed during the trial. Our finding suggests that the pharmacological action of QFPDT is associated with the upregulation of a subset of proinflammatory cytokines despite its clinical benefits for COVID-19 patients. We should therefore be careful in its prophylactic use in uninfected individuals until we have a better understanding of the immunopharmacological action of QFPDT through further clinical studies with larger cohorts.",20/07/2020,10.1101/2020.07.13.20146175,Tsutomu Nakamura,"Institute for Quantitative Biosciences, The University of Tokyo",medrxiv,0
46,11120,"Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants","Background: With the demand for rapid COVID-19 vaccine development and evaluation, this paper aimed to describe the prevalence and correlates of willingness to participate in COVID-19 vaccine trials among university students in China. Methods: A cross-sectional survey with 1,912 Chinese university students was conducted during March and April 2020. Bivariate and multivariate analyses were performed to identify variables associated with willingness to participate. Results: The majority of participants (64.01%) indicated willingness to participate in COVID-19 vaccine trials. Hesitancy over signing informed consent documents, concerns over time necessary for participating in a medical study, and perceived COVID-19 societal stigma were identified as deterrents, whereas lower socioeconomic status, female gender, perception of likely COVID-19 infection during the pandemic, and COVID-19 prosocial behaviors were facilitative factors. Further, public health mistrust and hesitancy over signing informed consent documents had a significant interactive effect on vaccine trial willingness. Conclusions: High standards of ethical and scientific practice are needed in COVID-19 vaccine research, including providing potential participants full and accurate information and ensuring participation free of coercion, socioeconomic inequality, and stigma. Attending to the needs of marginalized groups and addressing psychosocial factors including stigma and public health mistrust may also be important to COVID-19 vaccine development and future uptake.",14/07/2020,10.1101/2020.07.13.20152678,Danhua Lin,Beijing Normal University,medrxiv,0
47,11276,Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection,"Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of SARS-CoV-2-specific neutralizing antibodies (NAbs) in COVID-19 patients. Methods Blood samples (n=173) were collected from 30 COVID-19 patients over a 3-month period after symptom onset and analyzed for SARS-CoV-2-specific NAbs, using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines. Results SARS-CoV-2-specific NAb titers were low for the first 7-10 d after symtom onset and increased after 2-3 weeks. The median peak time for NAbs was 33 d (IQR 24-59 d) after symptom onset. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR 19.6-42.4%). NAb titers increased over time in parallel with the rise in IgG antibody levels, correlating well at week 3 (r = 0.41, p < 0.05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including SCF, TRAIL, and M-CSF. Conclusions These data provide useful information regarding dynamic changes in NAbs in COVID-19 patients during the acute and convalescent phases.",17/07/2020,10.1101/2020.07.14.20151159,Ai-Long Huang,Chongqing Medical University,medrxiv,0
48,11303,Reconciling model predictions with low reported cases of COVID-19 in Sub-Saharan Africa: Insights from Madagascar,"The COVID-19 pandemic has wreaked havoc globally, and there has been a particular concern for sub-Saharan Africa (SSA), where models suggest that the majority of the population will become infected. Conventional wisdom suggests that the continent will bear a higher burden of COVID-19 for the same reasons it suffers high burdens of other infectious diseases: ecology, socio-economic conditions, lack of water and sanitation infrastructure, and weak health systems. However, so far SSA has reported lower incidence and fatalities compared to the predictions of standard models and the experience of other regions of the world. There are three leading explanations, each with very different implications for the final epidemic burden: (1) low case detection, (2) differences in COVID-19 epidemiology (e.g. low R0), and (3) policy interventions. The low number of cases to date have led some SSA governments to relax these policy interventions. Will this result in a resurgence of cases? To understand how to interpret the lower-than-expected COVID-19 case data in Madagascar, we use a simple age-structured model to explore each of these explanations and predict the epidemic impact associated with them. We show that the current incidence of COVID-19 cases can be explained by any combination of the late introduction of first imported cases, early implementation of non-pharmaceutical interventions (NPIs), and low case detection rates. This analysis reinforces that Madagascar, along with other countries in SSA, remains at risk of an impending health crisis. If NPIs remain enforced, up to 50,000 lives may be saved. Even with NPIs, without vaccines and new therapies, COVID-19 could infect up to 30% of the population, making it the largest public health threat in Madagascar until early 2021, hence the importance of conducting clinical trials and continually improving access to healthcare.",20/07/2020,10.1101/2020.07.15.20149195,Michelle V Evans,University of Georgia,medrxiv,0
50,11526,Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases,"Knowledge of the host immune response after natural SARS-CoV-2 infection is essential for informing directions of vaccination and epidemiological control strategies against COVID-19. In this study, thirty-four COVID-19 patients were enrolled with 244 serial blood specimens (38.1% after hospital discharge) collected to explore the chronological evolution of neutralizing (NAb), total (TAb), IgM, IgG and IgA antibody in parallel. IgG titers reached a peak later (approximately 35 days postonset) than those of Nab, Ab, IgM and IgA (20~25 days postonset). After peaking, IgM levels declined with an estimated average half-life of 10.36 days, which was more rapid than those of IgA (51.25 days) and IgG (177.39 days). Based on these half-life data, we estimate that the median times for IgM, IgA and IgG to become seronegative are 4.59 (IQR 4.12-5.03), 7.78 (IQR 6.71-9.16) and 42.72 (IQR 33.75-47.96) months post disease onset. The relative contribution of IgM to NAb was higher than that of IgG (standardized {beta} regression coefficient: 0.53 vs 0.48), so the rapid decline in NAb may be attributed to the rapid decay of IgM in acute phase. However, the relative contribution of IgG to NAb increased and that of IgM further decreased after 6 weeks postonset. It's assumed that the decline rate of NAb might slow down to the same level as that of IgG over time. This study suggests that SARS-CoV-2 infection induces robust neutralizing and binding antibody responses in patients and that humoral immunity against SARS-CoV-2 acquired by infection may persist for a relatively long time.",21/07/2020,10.1101/2020.07.18.20156810,Sheng-Xiang Ge,"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strai",medrxiv,0
51,11833,"Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study","Background Managing discharged COVID-19 (DC) patients with recurrent positive (RP) SARS-CoV-2 RNA test results is challenging. We aimed to comprehensively characterize the viral RNA level and serum antibody responses in RP-DC patients and evaluate their viral transmission risk. Methods A population-based observational cohort study was performed on 479 DC patients discharged from February 1 to May 5, 2020 in Shenzhen, China. We conducted RT-qPCR, antibody assays, neutralisation assays, virus isolation, whole genome sequencing (WGS), and epidemiological investigation of close contacts. Findings Of 479 DC patients, the 93 (19%) RP individuals, including 36 with multiple RP results, were characterised by young age (median age: 34 years, 95% confidence interval [CI]: 29-38 years). The median discharge-to-RP length was 8 days (95% CI: 7-14 days; maximum: 90 days). After readmission, RP-DC patients exhibited mild (28%) or absent (72%) symptoms, with no disease progression. The viral RNA level in RP-DC patients ranged from 1.9-5.7 log10 copies/mL (median: 3.2, 95% CI: 3.1-3.5). At RP detection, the IgM, IgG, IgA, total antibody, and neutralising antibody (NAb) seropositivity rates in RP-DC patients were 38% (18/48), 98% (47/48), 63% (30/48), 100% (48/48), and 91% (39/43), respectively. Regarding antibody levels, there was no significant difference between RP-DC and non-RP-DC patients. The antibody level remained constant in RP-DC patients pre- and post-RP detection. Virus isolation of nine representative specimens returned negative results. WGS of six specimens yielded only genomic fragments. No clinical symptoms were exhibited by 96 close contacts of 23 RP-DC patients; their viral RNA (96/96) and antibody (20/20) test results were negative. After full recovery, 60% of patients (n=162, 78 no longer RP RP-DC and 84 non-RP-DC) had NAb titres of [&ge;]1:32. Interpretation RP may occur in DC patients following intermittent and non-stable excretion of low viral RNA levels. RP-DC patients pose a low risk of transmitting SARS-CoV-2. An NAb titre of [&ge;]1:32 may provide a reference indicator for evaluating humoral responses in COVID-19 vaccine clinical trials.",26/07/2020,10.1101/2020.07.21.20125138,Qinghua Hu,"Shenzhen Center for Disease Control and Prevention, Shenzhen, China",medrxiv,0
52,11694,D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.,"The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-19 pandemic that appears to confer on the virus greater infectivity and is now the globally dominant form of the virus. Certain of the current vaccines entering phase 3 trials are based on the original D614 form of Spike with the goal of eliciting protective neutralizing antibodies. To determine whether D614G mediates neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 Spike on their surface. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by monoclonal antibodies against the receptor binding domain and by convalescent sera from people known to be infected with either the D614 or G614 form of the virus. These results indicate that a gain in infectivity provided by D614G came at the cost of making the virus more vulnerable to neutralizing antibodies, and that the mutation is not expected to be an obstacle for current vaccine development.",24/07/2020,10.1101/2020.07.22.20159905,Drew Weissman,University of Pennsylvania,medrxiv,0
53,11923,A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,"Background Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19. Ayurveda has been recommended by preventative and clinical management guidelines in India and several clinical trials are ongoing. But there is no study to assess impact of Ayurveda on Covid-19. Methods Objective of present study was to evaluate the clinical outcome in Covid-19 confirmed asymptomatic to mild symptomatic patients who had received Ayurveda and compare with control (who has not received Ayurveda or any support therapy). Patients having Ayurveda intervention (Guduchi Ghan Vati-extract of Tinospora cordifolia) were included from Jodhpur Covid Care Centre and non-recipients were taken from Jaipur Covid Care Centre between May 15 to June 15, 2020. Total 91 patients, who were asymptomatic at the time of hospital admission and between 18 -75 years of age, were included in the study to analyse retrospectively. Results In control group, 11.7% developed mild symptoms after average 1.8 days and none in Ayurveda group reported any symptoms. Significant difference was reported between the group of patients taking Guduchi Ghan Vati (n=40) and patients in standard care (n=51) in terms of virologic clearance at day-7 (97.5% vs 15.6% respectively; p=0.000), at day 14 (100% vs 82.3%) days to stay in hospital ( 6.4 vs 12.8 respectively; p< 0.0001) . Conclusion Results of the study suggest that Guduchi Ghan Vati, a common and widely used Ayurveda preparation, could benefit treating asymptomatic Covid-19 patients. Larger, randomised controlled Trials are required to confirm the findings. Keywords: Ayurveda, Guduchi Ghan",29/07/2020,10.1101/2020.07.23.20160424,Neha Sharma,Aarogyam (UK) CIC,medrxiv,0
55,12203,Safety and effectiveness of dose-sparing strategies for seasonal influenza vaccine: a rapid scoping review of fractional dosing of the intramuscular influenza vaccine,"Background: The objective of this rapid scoping review was to identify potentially safe and effective dose-sparing strategies for intramuscular administration of seasonal influenza vaccines in healthy individuals of all ages. Methods: Comprehensive literature searches were developed and executed in MEDLINE, EMBASE, and the Cochrane library, and grey literature was searched via international clinical trial registries for relevant studies published in English in the last 20 years. References of relevant systematic reviews and included studies were also scanned. Title/abstract and full-text screening were carried out by pairs of reviewers independently and data charting conducted by a single reviewer and verified by a second reviewer. Results were presented narratively. Results: A total of 13 studies with 10,351 participants were included in the review and all studies were randomized control trials conducted between 2006 and 2019. The most common interventions were the trivalent influenza vaccine (n=10), followed by quadrivalent influenza vaccine (n=4). Nine studies included infants/toddlers 6-36 months old and one of these studies also included children and adolescents. In these nine studies, no clinical effectiveness outcomes were reported and no difference was found in local and systemic reactogenicity between dosing strategies. Of the four adult studies ([&ge;] 18 years), the two studies that reported on effectiveness outcomes found similar results between the half-dose and full-dose vaccination groups and all four studies reported no differences in safety outcomes between groups. Conclusion: The current evidence for the administration of intramuscular influenza vaccines suggests there is no significant difference in safety and clinical effectiveness with the use of low-dose compared to full-dose vaccines, which is promising given the predicted resource constraints in the upcoming influenza season due to the 2019 novel coronavirus. Due to the low number of studies in adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation.",04/08/2020,10.1101/2020.07.31.20163717,Andrea C Tricco,"Li Ka Shing Knowledge Institute, St. Michael\'s Hospital, Unity Health Toronto, Epidemiology Division, Dalla Lana School of Public Health, University of Toronto",medrxiv,0
56,12206,"Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial","Background: COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma (CP) from infected patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections (SARI) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma in adult patients with severe COVID-19 pneumonia. Methods/Design: The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The protocol has been prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. The study has been planned to include 278 adult patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to categories 5, 6 or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. Discussion: This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma for the treatment of adult patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP in the therapeutics for a new viral disease. Trial registration: Trial registration at clinicaltrials.gov; Registration Number: NCT04345523; https://clinicaltrials.gov/ct2/show/NCT04345523; Registered on 30 March, 2020. First posted date: April 14, 2020. Keywords: COVID-19, randomized, controlled trial, protocol, convalescent plasma (CP), antibodies.",04/08/2020,10.1101/2020.07.31.20165720,Aranzazu Sancho-Lopez,"Clinical Pharmacology Department. Hospital Univ. Puerta de Hierro Majadahonda, IISPHSA, Madrid, Spain",medrxiv,0
58,12525,Public perceptions and preventive behaviours during the early phase of the COVID-19 pandemic: a comparative study between Hong Kong and the United Kingdom,"Background: In the absence of treatments and vaccines, the mitigation of COVID-19 relies on population engagement in non-pharmaceutical interventions, which is driven by their risk perception, anxiety level and knowledge. There may also be regional discrepancies in these drivers due to different historical exposure to disease outbreaks, government responses and cultures. As such, this study compared psycho-behavioral responses in two regions during the early phase of the pandemic. Methods: Comparable cross-sectional surveys were administered among adults in Hong Kong (HK) and the United Kingdom (UK) during the early phase of each respective epidemic. Explanatory variables included demographics, risk perception and knowledge of COVID-19, anxiety level and preventive behaviors. Responses were weighted according to census data. Logistic regression models, including interaction terms to quantify regional differences, were used to assess the association between explanatory variables and the adoption of social-distancing measures. Results: Data of 3431 complete responses (HK:1663; UK:1768) were analysed. Perceived severity differed by region (HK: 97.5%; UK: 20.7%). A large proportion of respondents were abnormally/borderline anxious (HK:64.8%; UK:45.9%) and regarded direct contact with infected individuals as the transmission route of COVID-19 (HK:94.0-98.5%; UK:69.2-93.5%), with HK identifying additional routes. HK reported high levels of adoption of social-distancing (HK:32.4-93.7%; UK:17.6-59.0%) and mask-wearing (HK:98.8%; UK:3.1%). The impact of perceived severity and perceived ease of transmission on the adoption of social-distancing varied by region. In HK, they had no impact, whereas in the UK, those who perceived severity as 'high' were more likely to adopt social-distancing (aOR:1.58-3.01), and those who perceived transmission as 'easy' were prone to both general social-distancing (aOR:2.00, 95% CI:1.57, 2.55) and contact avoidance (aOR:1.80, 95% CI: 1.41, 2.30). The impact of anxiety on adopting social-distancing did not vary by region. Discussion: These results suggest that health officials should ascertain and consider baseline levels of risk perception and knowledge in the populations, as well as prior sensitisation to infectious disease outbreaks, during the development of mitigation strategies. Risk communication should be done through suitable media channels - and trust should be maintained - while early intervention remains the cornerstone of effective outbreak response.",07/08/2020,10.1101/2020.08.06.20169409,Kin On Kwok,The Chinese University of Hong Kong,medrxiv,0
59,12600,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,"Significant progress has already been made in development and testing of SARS-CoV-2 vaccines, and Phase III clinical trials have begun for 6 novel vaccine candidates to date. These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients. However, vaccination is also known to bring about indirect benefits to a population through the reduction of virus circulation. The indirect effects of SARS-CoV-2 vaccination can play a key role in reducing case counts and COVID-19 deaths. To illustrate this point, we show through simulation that a vaccine with strong indirect effects has the potential to reduce SARS-CoV-2 circulation and COVID-19 deaths to a greater extent than an alternative vaccine with stronger direct effects but weaker indirect effects. Protection via indirect effects may be of particular importance in the context of this virus, because elderly individuals are at an elevated risk of death but are also less likely to be directly protected by vaccination due to immune senescence. We therefore encourage ongoing data collection and model development aimed at evaluating the indirect effects of forthcoming SARS-CoV-2 vaccines.",11/08/2020,10.1101/2020.08.07.20170456,Molly E. Gallagher,Emory University,medrxiv,0
60,12802,Local protection bubbles: an interpretation of the decrease in the velocity of coronavirus's spread in the city of Sao Paulo,"After four months of dealing with the pandemic, the city of Sao Paulo entered a phase of relaxed social-distancing measures in July 2020, and saw its social isolation rate fall at the same time as the number of cases, deaths, and hospital bed occupation declined. We use a calibrated multi-agent model to describe these dynamics. We assert here that this phenomenon can be understood as the result of local protective bubbles formed in the city's sub-environments at the same time that there was an exhaustion of contagion networks. Both reduce the velocity of the virus's spread, causing temporary reductions in the epidemic curve, albeit in an unstable equilibrium. These local bubbles can burst anytime and anywhere due to the reintroduction of a few infected people at the same time that there is a reduction in non-pharmaceutical interventions (NPI), such as social-distancing practices. It is important to stress that this hypothesis aligns with the dynamics of the virus's spread observed so far, without needing ad hoc suppositions about natural collective immunity thresholds or heterogeneity in the population's transmission rate, which come with the risk of making mistaken predictions that may could lead to the loss of many lives. The safe way to move ahead is to continue doing all we can to avoid new infections until a vaccine is found that properly and safely creates herd immunity.",14/08/2020,10.1101/2020.08.11.20173039,Jose Paulo Guedes Pinto,Federal University of ABC (UFABC),medrxiv,0
61,12861,Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera,"The on-going coronavirus disease 2019 (COVID-19) pandemic has mobilized a global effort to develop vaccines and therapeutics that inhibit viral entry by inducing or transferring antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (CoV2-S). Phase I/II vaccine clinical trials, monoclonal antibodies, and convalescent sera have all shown promise. However, these efforts often require extensive screening with the live virus under onerous high biocontainment conditions (BSL-3). Virus neutralization assays (VNAs) remain the gold standard for evaluating the anti-viral potency of antibodies and entry inhibitors. The proliferation of pseudotyped virus systems that can be used in BSL-2 compatible VNAs is a positive development. Yet, there is marked variability between VNAs and how the findings are presented, making inter-group comparisons difficult. To address these limitations, we developed a standardized VNA using VSVdeltaG based CoV-2-S pseudotyped particles (CoV2pp) that can be robustly produced at scale. We used our CoV2pp to interrogate the role of exogenous and endogenous proteases in CoV-2-S mediated entry and standardized our VNA based on that understanding. Our CoV2pp VNA showed a strong positive correlation with CoV2-S ELISA and live virus neutralizations in a validated set of patient sera. Our system was subsequently validated by three independent groups as an out-of-the-box VNA. More than 120 patient sera were screened, and we report descriptive statistics for absolute (abs) IC50, IC80, and IC90 values from all positive patient sera. Lastly, we used our CoV2pp in a screen to identify ultrapermissive 293T clones that stably express ACE2 or ACE2+TMPRSS2. When used in combination with our CoV2pp, we can now produce CoV2pp sufficient for 150,000 standardized VNA/week.",15/08/2020,10.1101/2020.08.13.20157222,Benhur Lee,Icahn School of Medicine at Mount Sinai,medrxiv,0
63,13180,Dynamic causal modeling of the COVID-19 pandemic in northern Italy predicts possible scenarios for the second wave,"The COVID-19 pandemic has sparked an intense debate about the factors underlying the dynamics of the outbreak. Mitigating virus spread could benefit from reliable predictive models that inform effective social and healthcare strategies. Crucially, the predictive validity of these models depends upon incorporating behavioral and social responses to infection that underwrite ongoing social and healthcare strategies. Formally, the problem at hand is not unlike the one faced in neuroscience when modelling brain dynamics in terms of the activity of a neural network: the recent COVID19 pandemic develops in epicenters (e.g. cities or regions) and diffuses through transmission channels (e.g., population fluxes). Indeed, the analytic framework known as ""Dynamic Causal Modeling"" (DCM) has recently been applied to the COVID-19 pandemic, shedding new light on the mechanisms and latent factors driving its evolution. The DCM approach rests on a time-series generative model that provides - through Bayesian model inversion and inference - estimates of the factors underlying the progression of the pandemic. We have applied DCM to data from northern Italian regions, which were the first areas in Europe to contend with the COVID-19 outbreak. We used official data on the number of daily confirmed cases, recovered cases, deaths and performed tests. The model - parameterized using data from the first months of the pandemic phase - was able to accurately predict its subsequent evolution (including social mobility, as assessed through GPS monitoring, and seroprevalence, as assessed through serologic testing) and revealed the potential factors underlying regional heterogeneity. Importantly, the model predicts that a second wave could arise due to a loss of effective immunity after about 7 months. This second wave was predicted to be substantially worse if outbreaks are not promptly isolated and contained. In short, dynamic causal modelling appears to be a reliable tool to shape and predict the spread of the COVID-19, and to identify the containment and control strategies that could efficiently counteract its second wave, until effective vaccines become available.",23/08/2020,10.1101/2020.08.20.20178798,Daniela Gandolfi,University of Modena and Reggio Emilia,medrxiv,0
64,13186,Poor knowledge of COVID-19 and unfavourable perception of the response to the pandemic by healthcare workers at the Bafoussam Regional Hospital (West Region - Cameroon),"Background The World Health Organization has warned against a dramatic impact of COVID'19 in subSaharan Africa unless adequate response strategies are implemented. Whatever the strategy, the role of health care workers is pivotal. We undertook this study to assess knowledge of COVID'19 and perception of the response to the pandemic among the staff of a regional hospital in charge of COVID'19 patients in West Cameroon. Methods We used a convenience non probabilistic sampling method to carry out a survey with a self administered questionnaire from April 14, 2020 to April 29, 2020 at the Bafoussam Regional Hospital (BRH). All the staff was invited to participate. Statistical analyses were done using Microsoft Excel 2010 and Epi Info version 7.1.5.2 software. Results Response rate was 76.1% (464/610). Mean age (SD) and average work experience (SD) were 35.0 (8.9) and 8.4 (7.4) years respectively. Sex ratio (M/F) was 101/356. Nursing and midwifery staff (56.8%) and in patients units (49.94%) were predominant. Knowledge on origin and transmission of SARS'CoV'2 was poor but knowledge of clinical signs and the role of laboratory tests were good. 53.2% of respondents said all therapeutic regimens are only supportive and only a third of them trusted drugs recommended by health authorities. For 36.9% of respondents, herbal remedies can prevent/cure COVID'19. 70% of staffs felt they were not knowledgeable enough to handle COVID'19 cases. 85.6% of respondents thought the BRH had insufficient resources to adequately respond to COVID'19 and 55.6% were dissatisfied with its response to the pandemic (weaknesses: medicines/technologies (74.5%), service delivery (28.1%), human resource (10.9%)). 68% of staff felt insufficiently protected on duty and 76.5% reported that the pandemic significantly reduced non-COVID-19 services. 85.5% said they complied with preventive measures while in the community. For 44% of respondents Cameroonian regulations on COVID'19 corpses should be made more culture sensitive. 51.2% of respondents were against vaccine trial in their community. Conclusion Knowledge of COVID'19 was poor and perception of the response to the pandemic was unfavorable. Key words Health care workers ; Bafoussam ; Knowledge ; Perception ; COVID'19",23/08/2020,10.1101/2020.08.20.20178970,Jovanny Tsuala Fouogue,Faculty of Medicine and pharmaceutical sciences_ university of Dschang,medrxiv,0
77,32792373,Antibodies may curb pandemic before vaccines.,NA,14/09/2020,10.1126/science.369.6505.752,Jon Cohen,NA,pubmed,0
102,32727468,A new passive immune strategy based on IgY antibodies as a key element to control neonatal calf diarrhea in dairy farms.,"Neonatal diarrhea remains one of the main causes of morbi-mortality in dairy calves under artificial rearing. It is often caused by infectious agents of viral, bacterial, or parasitic origin. Cows vaccination and colostrum intake by calves during the first 6...h of life are critical strategies to prevent severe diarrhea but these are still insufficient. Here we report the field evaluation of a product based on IgY antibodies against group A rotavirus (RVA), coronavirus (CoV), enterotoxigenic Esc",18/09/2020,10.1186/s12917-020-02476-3,Celina Guadalupe Vega,"Incuinta, Instituto Nacional de Tecnolog..a Agropecuaria (INTA), Buenos Aires, Argentina. vega.celina@inta.gob",pubmed,0
137,32658841,Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.,"The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a global pandemic. Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies (EpAbs) put forward a sound alternative. The new generation of processed and purified ",07/08/2020,,Vanesa Zylberman,"Inmunova S.A., San Mart..n, Provincia de Buenos Aires, Argentina",pubmed,0
150,32636542,Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical UIse.,"Diagnostic tests for the coronavirus infection 2019 (COVID-19) are critical for prompt diagnosis, treatment and isolation to break the cycle of transmission. A positive real-time reverse-transcriptase polymerase chain reaction (RT-PCR), in conjunction with clinical and epidemiologic data, is the current standard for diagnosis, but several challenges still exist. Serological assays help to understand epidemiology better and to evaluate vaccine responses but they are unreliable for diagnosis in th",13/07/2020,,Daniel Shyu,"Department of Medicine, University of Missouri - Columbia, Columbia, Missouri",pubmed,0
158,32615862,Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.,"The COVID-19 pandemic has caused a global public health crisis. There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the COVID-19 pandemic. The Chinese scientists supported by private and government resources have adopted extensive efforts to identify effective drugs against the virus. To date, a large number of clinical trials addressing various aspects of COVID19 have been registered in the Chinese Clinical Trial Registry (C",04/08/2020,10.1080/22221751.2020.1791736,Peng Xu,"Neurology Department, The A...liated Hospital to Changchun University of Chinese Medicine, Changchun, People's Republic of China",pubmed,0
183,32554907,Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials.,"COVID-19 has become one of the biggest health concern, along with huge economic burden. With no clear remedies to treat the disease, doctors are repurposing drugs like chloroquine and remdesivir to treat COVID-19 patients. In parallel, research institutes in collaboration with biotech companies have identified strategies to use viral proteins as vaccine candidates for COVID-19. Although this looks promising, they still need to pass the test of challenge studies in animal models. As various model",25/06/2020,,Bijayeeta Deb,"Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517 507, India",pubmed,0
189,32535032,Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.,"Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and",14/09/2020,10.1016/j.jsbmb.2020.105719,Jose Manuel Quesada-Gomez,"Instituto Maim..nides de Investigaci..n Biom..dica de C..rdoba (IMIBIC). Hospital Universitario Reina Sof..a, Universidad de C..rdoba, Fundaci..n Progreso y Salud, Avda. Men..ndez Pidal s/n, 14004, C..rdoba, Spain",pubmed,0
196,32515685,Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19.,"Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and quickly spread globally. In this study, we investigated the characteristics of viral shedding from different sites and the neutralizing antibody (NAb) response during the acute and convalescent phases of nine children with COVID-19. SARS-CoV-2 was detected in their nasopharyngeal swabs (9/9, 100%), stool samples (8/9, 89%), and oropharyngeal swabs (3/9, 33%) but was not",12/06/2020,10.1080/22221751.2020.1772677,Pengcheng Liu,"Department of Clinical Laboratory, Children's Hospital of Fudan University, Shanghai, People's Republic of China",pubmed,0
224,32459574,"The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19.","In spite of the relatively high morbidity and mortality, there is no approved medication yet for COVID-19. There are more than 200 ongoing trials on different drugs or vaccines, but new medications may take until 2021 to develop. Defining the optimal number of patients to be included in a study is a considerable challenge in these interventional researches. Ethical considerations prompt researchers to minimize the number of patients included in a trial. This gains particular importance when the ",08/06/2020,10.1080/19932820.2020.1770518,Adel El Taguri,"National Center for Accreditation of Health Establishments- , Tripoli-Libya, Libya",pubmed,0
226,32452350,Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination.,NA,04/06/2020,,Maurizio Cutolo,"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine DiMI, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy. mcutolo@unige",pubmed,0
314,32232214,Potential Treatments for COVID-19; a Narrative Literature Review.,"SARS-CoV-2 is a newly emerging human infectious coronavirus that causes COVID-19, which has been recognized as a pandemic by the World Health Organization (WHO) on March 11<sup>th</sup>. There is still no vaccine or definitive treatment for this virus because its pathogenesis and proliferation pathways are still unknown. Therefore, in this article, new potential COVID-19 therapies are briefly reviewed.",04/04/2020,,Ali Rismanbaf,"Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran",pubmed,0
333,32288873,Immune response of mature cows subjected to annual booster vaccination against neonatal calf diarrhoea with two different commercial vaccines: A non-inferiority study.,"Neonatal calf diarrhoea can have important economic consequences. Scour vaccines are available against some of the most frequent pathogens responsible for this disease: Bovine Rotavirus (BoRV), Bovine Coronavirus (BoCV) and E. coli K99. In this multi-centre, randomised, blinded study, adult cows vaccinated with a trivalent vaccine marketed for years (Rotavec... Corona, MSD Animal Health - RC) prior to last parturition were revaccinated 12-15 months later, prior to the upcoming parturition",05/06/2020,10.1016/j.livsci.2017.08.011,Luc Durel,"Virbac S.A., 13..me rue L.I.D., F-06511 Carros Cedex, France",pubmed,0
65,32829400,BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden.,"The Bacille Calmette-Gu..rin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized to have a protective effect against COVID-19. Recent research found that countries with universal BCG childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders. Instead, this paper takes advantage of a rare nationwide natural experiment that took place in Swed",23/08/2020,10.1093/cid/ciaa1223,Cl..ment de Chaisemartin,"Department of Economics, University of California, Santa Barbara, Santa Barbara, CA 93106, USA",pubmed,0
66,32821086,A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.,"The novel coronavirus 2019 (2019-nCoV), formally named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel human infectious coronavirus. The disease caused by SARS-CoV-2 is named COVID-19. Development and manufacturing of specific therapeutics and vaccines to treat COVID-19 are time-consuming processes. At this time, using available conventional therapeutics along with other treatment options may be useful to fight COVID-19. In different clinical trials, efficacy of remdesiv",27/08/2020,10.2147/DDDT.S261154,Seyed MohammadReza Hashemian,"Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran",pubmed,0
67,32820746,"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season.","This report updates the 2019-20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ...6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live atten",25/08/2020,10.15585/mmwr.rr6908a1,Lisa A Grohskopf,NA,pubmed,0
68,32817958,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates.,"Significant progress has already been made in development and testing of SARS-CoV-2 vaccines, and Phase III clinical trials have begun for 6 novel vaccine candidates to date. These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients. However, vaccination is also known to bring about indirect benefits to a population through the reduction of virus circulation. The indirect effects of SARS-CoV-2 vaccination can play a key role in reducing case counts and COVID-1",22/08/2020,10.1101/2020.08.07.20170456,Molly E Gallagher,NA,pubmed,0
69,32813843,Study of ongoing registered clinical trials on COVID-19: a narrative review.,"The dangerous SARS-CoV-2 virus first emerged in China in December 2019 and has rapidly spread worldwide. Currently, it has affected more than 2,850,000 people. No vaccine or drug is available yet, and therefore researchers and scientists are striving to identify potential drugs or vaccines for combating this virus. We were unable to find any review of the literature or analysis on ongoing registered clinical trials that reported diagnostic tests, therapeutics, vaccines and devices for COVID-19 a",19/08/2020,10.1590/1516-3180.2020.0208.r1.15062020,Md Insiat Islam Rabby,"Department of Mechanical and Manufacturing Engineering, Universiti Putra Malaysia, Seri Kembangan, Selangor, Malaysia",pubmed,0
70,32808095,Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy.,Researchers have been working quickly and collaboratively for the development of vaccines against the COVID-19 virus. The effort of the scientific community in searching a vaccine for COVID-19 may be hampered by a diffused vaccine hesitancy. Two waves of data collection on representative samples of the Italian population (during the &quot;first&quot; and &quot;second&quot; phase of the Italian Covid-19 mitigation strategy) were conducted to understand citizens' perceptions and behaviors about pr,16/09/2020,10.1007/s10654-020-00675-8,Lorenzo Palamenghi,"Department of Psychology, EngageMinds HUB - Consumer, Food and Health Engagement Research Center, Universit.. Cattolica del Sacro Cuore, Milan, Italy",pubmed,0
71,32802896,The Application of Single-Cell RNA Sequencing in Vaccinology.,"Single-cell RNA sequencing allows highly detailed profiling of cellular immune responses from limited-volume samples, advancing prospects of a new era of systems immunology. The power of single-cell RNA sequencing offers various opportunities to decipher the immune response to infectious diseases and vaccines. Here, we describe the potential uses of single-cell RNA sequencing methods in prophylactic vaccine development, concentrating on infectious diseases including COVID-19. Using examples from",24/08/2020,10.1155/2020/8624963,Andr..s No..,"The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK",pubmed,0
72,32798320,Considerations for stakeholder engagement and COVID-19 related clinical trials' conduct in sub-Saharan Africa.,"The aim of this study is to determine how stakeholder engagement can be adapted for the conduct of COVID-19-related clinical trials in sub-Saharan Africa. Nine essential stakeholder engagement practices were reviewed: formative research; stakeholder engagement plan; communications and issues management plan; protocol development; informed consent process; standard of prevention for vaccine research and standard of care for treatment research; policies on trial-related physical, psychological, fi",09/09/2020,10.1111/dewb.12283,Morenike Oluwatoyin Folayan,NA,pubmed,0
73,32795830,Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19.,"The delayed lung damage after SARS-CoV-2 infection may be caused by an autoimmune response to ACE2 induced by forced presentation of the ACE2 protein in a complex with CoV Spike in Fc Receptor positive Antigen Presenting Cells in the lung. The likelihood that this hypothesis is valid is low, but it is easily tested. 1) Autoantibodies and T cells to ACE2 may be found in patients with the lung damage but not in those without 2) There may be an HLA linkage with the delayed lung disease 3) Vaccines ",19/08/2020,10.1016/j.mehy.2020.110043,Alain Townsend,"Human Immunology Unit, Weatherall Institute, Oxford OX39DS, United Kingdom. Electronic address: Alain.townsend@imm.ox.ac",pubmed,0
74,32795413,A Thermostable mRNA Vaccine against COVID-19.,"There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutra",17/09/2020,10.1016/j.cell.2020.07.024,Na-Na Zhang,"State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China",pubmed,0
75,32793504,Urological Care and COVID-19: Looking Forward.,"The recent COVID-19 pandemic represents a worldwide emergency and it is affecting healthcare at every level, including also urological care and especially oncologic patients. Recent epidemiological models show that, without effective treatment or vaccine, there will be a long-lasting phase of cohabitation with the virus. Current experts' opinions recommend performing only non-deferrable uro-oncological surgery and postponing other activities until the end of the emergency, with particular concer",18/08/2020,10.3389/fonc.2020.01313,Tommaso Prayer-Galetti,"Clinica Urologica, Department of Surgical and Oncological Sciences, University of Padua, Padua, Italy",pubmed,0
76,32792417,Convalescent Plasma Therapy for COVID-19: State of the Art.,Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared,20/08/2020,10.1128/CMR.00072-20,Daniele Focosi,"North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy daniele.focosi@gmail",pubmed,0
78,32792167,Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).,"Coronavirus disease 2019 (COVID-19) is a major public health concern currently. To date, there are no approved antiviral drugs or vaccines against this transmissible disease. This report sheds light on available information for a better understanding of clinical trials and pharmacotherapy related to COVID-19. MEDLINE, PubMed, EMBASE, Scopus databases, Web of Science, WHO, and EU clinical trial sites were used to perform comparative analysis. Information was collected on the use of therapeutic ag",09/09/2020,10.1016/j.bj.2020.07.008,Henu Kumar Verma,"Institute of Experimental Endocrinology and Oncology CNR, Naples, Italy. Electronic address: henu.verma@yahoo",pubmed,0
80,32787752,Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.,"Viral diseases are responsible for several deaths around the world. Over the past few years, the world has seen several outbreaks caused by viral diseases that for a long time seemed to possess no risk. These are diseases that have been forgotten for a long time and, until nowadays, there are no approved drugs or vaccines, leading the pharmaceutical industry and several research groups to run out of time in the search for new pharmacological treatments or prevention methods. In this context, dru",13/08/2020,10.2174/0929867327666200812215852,Igor Jos.. Dos Santos Nascimento,"Chemistry and Biotechnology Institute, Federal University of Alagoas, Macei... Brazil",pubmed,0
82,32784685,Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?,"Seven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS, researchers have been trying to draw lessons from previous outbreaks to find a potential cure. Although there were five Phase I human vaccine trials against SARS and MERS, the lack of data in humans ",09/09/2020,10.3390/v12080861,Jawad Al-Kassmy,"Department of Experimental Surgery, McGill University, Montreal General Hospital 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada",pubmed,0
83,32782402,Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?,NA,26/08/2020,10.1038/d41586-020-02360-y,Heidi Ledford,NA,pubmed,0
84,32782400,Russia's fast-track coronavirus vaccine draws outrage over safety.,NA,26/08/2020,10.1038/d41586-020-02386-2,Ewen Callaway,NA,pubmed,0
85,32780300,Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.,The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic agent on the immune system is imperative during this special time. The infectious side-effect profile as well as the route and frequency of administration of each therapeutic agent s,08/09/2020,10.1007/s40263-020-00756-y,Crystal Zheng,"Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA",pubmed,0
87,32770854,Clinical trial to test the efficacy of melatonin in COVID-19.,"The pharmacological properties of melatonin are well known. However, there is noticeable the lack of clinical trials that confirm the efficacy, security, absence of side effects in the short and long term, and the effective doses of melatonin. This point is especially important in diseases with high morbidity and mortality including COVID-19. There is not treatment for COVID-19, and several anti-inflammatory and antiviral molecules are being tested, and different vaccines are in preparation. Alt",20/09/2020,10.1111/jpi.12683,Dario Acu..a-Castroviejo,"Faculty of Medicine, Department of Physiology, Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain",pubmed,0
88,32769322,COVID-19: An up-to-date review - from morphology to pathogenesis.,"The entire world is under a devastating pandemic caused by COVID-19 with a high mortality rate. Knowledge of the viral structure, factors that help in its progression and spread, pathological findings, diagnostic methods and, treatment modalities helps in understanding the viral disease and also in treating the patients in a better way besides preventing the community spread of this deadly infection. The causative agent is a single- stranded RNA virus. The clinical spectrum varies in symptomatic",17/08/2020,10.4103/IJPM.IJPM_779_20,Amanjit Bal,"Department of Pathology, PGIMER, Chandigarh, India",pubmed,0
89,32756549,SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.,"A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved the expression and immunogenicity of betacoronavirus spike proteins<sup>1</sup>. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the",06/08/2020,10.1038/s41586-020-2622-0,Kizzmekia S Corbett,Vaccine Research Center,pubmed,0
90,32756480,COVID-19: The Immune Responses and Clinical Therapy Candidates.,"The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US",12/08/2020,10.3390/ijms21155559,Sareh Zhand,"School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia",pubmed,0
91,32756371,BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study.,"Ecological studies have suggested fewer COVID-19 morbidities and mortalities in Bacillus Calmette-Gu..rin (BCG)-vaccinated countries than BCG-non-vaccinated countries. However, these studies obtained data during the early phase of the pandemic and did not adjust for potential confounders, including PCR-test numbers per population (PCR-tests). Currently-more than four months after declaration of the pandemic-the BCG-hypothesis needs reexamining. An ecological study was conducted by obtaining data",21/08/2020,10.3390/ijerph17155589,Mitsuyoshi Urashima,"Division of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo 105-8461, Japan",pubmed,0
92,32749496,The Development of COVID-19 Vaccines: Safeguards Needed.,NA,17/08/2020,10.1001/jama.2020.12461,Nicole Lurie,"Coalition for Epidemic Preparedness Innovations (CEPI), Harvard Medical School, Boston, Massachusetts",pubmed,0
93,32746653,Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.,"The coronavirus disease 2019 (COVID-19) pandemic has spread globally since it outbroke in December 2019. The urgent pandemic presents an unprecedented challenge to develop and identify effective medication therapy strategies to combat the COVID-19. Here, we summarized and evaluated the current treatment drugs and regimens, and put forward the treatment recommendations, including using the potential repurposed or experimental drugs against COVID-19, e.g. chloroquine (CQ), hydroxychloroquine (HCQ)",01/09/2020,10.1080/17512433.2020.1805315,Xiaolei Yang,"School of Pharmacy, Fudan University , Shanghai, P.R. China",pubmed,0
94,32742241,Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.,"Biotin-labeled molecular probes, comprising specific regions of the SARS-CoV-2 spike, would be helpful in the isolation and characterization of antibodies targeting this recently emerged pathogen. To develop such probes, we designed constructs incorporating an N-terminal purification tag, a site-specific protease-cleavage site, the probe region of interest, and a C-terminal sequence targeted by biotin ligase. Probe regions included full-length spike ectodomain as well as various subregions, and ",09/08/2020,10.2139/ssrn.3639618,Tongqing Zhou,Vaccine Research Center,pubmed,0
95,32742146,Impact of COVID-19 on Clinical Research and Inclusion of Diverse Populations.,"The randomized clinical trial (RCT) has long been recognized as the 'gold standard' for developing evidence for clinical treatments and vaccines; however, the successful implementation and translation of these findings is predicated upon external validity. The generalization of RCT findings are jeopardized by the lack of participation of at-risk groups such as African Americans, with long-recognized disproportional representation. Distinct factors that deter participation in RCTs include distrus",13/08/2020,10.18865/ed.30.3.429,Daniel T Lackland,"Division of Translational Neurosciences and Population Studies, Department of Neurology, Medical University of South Carolina, Charleston, SC",pubmed,0
96,32741312,Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.,"A new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and become pandemic with thousands new deaths and infected cases globally. To treat the patients with coronavirus disease (COVID-19), currently no effective drug or vaccine is available. This necessity motivated us to explore potential lead compounds based natural products targeting main protease (M<sup>pro</sup>) enzyme of SARS-CoV-2. The M<sup>pro</sup> enzyme plays a key role in mediating viral re",03/08/2020,10.1080/07391102.2020.1801510,Zeynab Fakhar,"Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa",pubmed,0
97,32739342,"COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials.","COVID-19, the greatest public health emergency of the 21st century, has affected 215 countries and territories around the world resulting in 15,151,738 confirmed cases and 621,121 deaths. The outbreak has continued at breakneck pace despite stringent public health measures, ravaging the global economy and causing profound human casualties. Vaccination is currently the best bet for the prevention of COVID-19. Still, in its absence, there has been considerable interest in repurposing existing ther",03/09/2020,10.1016/j.bcp.2020.114184,Rohan Chakraborty,"Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India",pubmed,0
98,32737453,China's coronavirus vaccines are leaping ahead - but face challenges as virus wanes.,NA,03/09/2020,10.1038/d41586-020-02244-1,David Cyranoski,NA,pubmed,0
99,32734670,Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov.,"Since the beginning of the COVID-19 outbreak in China in December 2019, the epidemic has continued to spread globally. Despite continuous reports of clinical trials being launched, no studies have yet systematically summarized and analysed their characteristics. Our objective is to do this by reviewing trials registered at ClinicalTrials.gov. We searched the ClinicalTrials.gov database and retrieved all clinical trials on COVID-19 registered up to and including 3 April 2020. We summarized the ch",31/07/2020,10.1111/jcpt.13222,Yuhui Wang,"Department of Pharmacy, Zhengzhou University First Affiliated Hospital, Zhengzhou, China",pubmed,0
100,32731192,COVID-19: Understanding the science of antibody testing and lessons from the HIV epidemic.,"Potential pitfalls in the development, deployment and interpretation of antibody tests for COVID-19 are discussed. Lessons learned from the experience with the introduction of antibody tests for HIV are highlighted.Each test will need to be separately vetted for performance and clinical implementation based upon rigorous clinical trial data. The issues we highlight will also be similarly important for vaccine and therapeutic drug efficacy trials.",17/08/2020,10.1016/j.diagmicrobio.2020.115078,Stanley H Weiss,"Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, U.S.A.",pubmed,0
101,32729281,COVID-19 Intervention Scenarios for a Long-term Disease Management.,"The first outbreak of coronavirus disease 2019 (COVID-19) was successfully restrained in many countries around the world by means of a severe lockdown. Now, we are entering the second phase of the pandemics in which the spread of the virus needs to be contained within the limits that national health systems can cope with. This second phase of the epidemics is expected to last until a vaccination is available or herd immunity is reached. Long-term management strategies thus need to be developed. ",30/07/2020,10.34172/ijhpm.2020.130,Gudrun Wallentin,"Department of Geoinformatics - Z_GIS, University of Salzburg, Salzburg, Austria",pubmed,0
103,32726230,Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.,"In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intraveno",05/08/2020,10.5811/westjem.2020.5.47658,Arif Musa,"Wayne State University School of Medicine, Detroit, Michigan",pubmed,0
104,32725080,"Past, present, and future of COVID-19: a review.","SARS-CoV-2 has recently emerged, becoming a global threat, affecting directly all human beings owing to its morbidity and mortality and indirectly, due to the enormous economic and psychological impact produced by social isolation, the most effective measure so far, but unsustainable for a long period. The scientific effort to understand and control SARS-CoV-2 transmission and clinical impact has been huge, and important achievements are highlighted in this review. Diagnosis is central and is th",31/07/2020,10.1590/1414-431x202010475,C M Romano,"Hospital das Clinicas HCFMUSP (LIM52), Faculdade de Medicina, Universidade de S..o Paulo, S..o Paulo, SP, Brasil",pubmed,0
106,32719684,COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.,"To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane (M) protein, have been tested for vaccine development against SARS and MERS. However, these vaccine candidates might lack the induction of complete protection and have safe",03/08/2020,10.3389/fimmu.2020.01581,Edison Ong,"Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, United States",pubmed,0
107,32719619,"While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?","At the time of reception of this article (April 2, 2020), efforts to develop a specific vaccine against SARS-Cov-2, the causative agent of the coronavirus disease 2019 (COVID-19), had just begun trial phase 1, but full validation of this and other current developments is likely to take many more months to reach completion. The ongoing pandemic constitutes a major health burden of world proportions that is also having a devastating impact on whole economies worldwide, the knock-on effects of whic",29/07/2020,10.3389/fphys.2020.00820,Francisco J Barrantes,"Biomedical Research Institute (BIOMED), Argentina Pontifical Catholic University of Argentina (UCA) and National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina",pubmed,0
108,32718772,Considerations for the Surgical Management of Early Stage Lung Cancer During the COVID-19 Pandemic.,"The highly transmissible novel coronavirus (COVID-19) has infected over 8.8 million people globally and has upended the delivery of health care in the United States, creating unprecedented challenges to providing care to patients with early stage non-small cell lung cancer (NSCLC). The initial surge of patients with COVID-19 that have flooded hospitals has put a strain on physical space, workforce, and supplies. In addition, social distancing and the risk of COVID-19 transmission has created sig",28/07/2020,10.1016/j.cllc.2020.06.024,Robert E Merritt,"Thoracic Surgery Division, The Ohio State University Wexner Medical Center, Columbus, OH. Electronic address: Robert.Merritt@osumc",pubmed,0
109,32718020,"Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.","The ongoing pandemic of coronavirus disease-2019 (COVID-19) is being caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The disease continues to present significant challenges to the health care systems around the world. This is primarily because of the lack of vaccines to protect against the infection and the lack of highly effective therapeutics to prevent and/or treat the illness. Nevertheless, researchers have swiftly responded to the pandemic by advancing old and new po",12/08/2020,10.3390/ijms21155224,Rami A Al-Horani,"Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA",pubmed,0
110,32717321,Genomics approaches to synthesis plant-based biomolecules for therapeutic applications to combat SARS-CoV-2.,"COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is devastative to the humankind for which neither vaccines nor precise therapeutic molecules for treatment are identified. The search for new drugs and repurposing of existing drugs are being performed; however, at the same time, research on plants to identify novel therapeutic compounds or testing the existing ones is progressing at a slower phase. In this context, genomics and biotechnology offer various tools and ",31/07/2020,10.1016/j.ygeno.2020.07.033,Namisha Sharma,"National Institute of Plant Genome Research, Aruna Asaf Ali Marg, New Delhi 110067, India",pubmed,0
111,32711692,Monitoring approaches for health-care workers during the COVID-19 pandemic.,"Health-care workers are crucial to any health-care system. During the ongoing COVID-19 pandemic, health-care workers are at a substantially increased risk of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and could come to considerable harm as a result. Depending on the phase of the pandemic, patients with COVID-19 might not be the main source of SARS-CoV-2 infection and health-care workers could be exposed to atypical patients, infected family members, conta",09/09/2020,10.1016/S1473-3099(20)30458-8,Julia A Bielicki,"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's University of London, London, UK",pubmed,0
112,32710003,Coronavirus vaccines leap through safety trials - but which will work is anybody's guess.,NA,04/09/2020,10.1038/d41586-020-02174-y,Ewen Callaway,NA,pubmed,0
113,32702822,Efficacy of integrative Traditional Chinese and Western medicine for the treatment of patients infected with 2019 novel coronavirus (COVID-19): A protocol for systematic review and meta analysis.,"No specific anti-virus drugs or vaccines have been available for the treatment of COVID-19. Integrative traditional Chinese and western medicine has been proposed as a therapeutic option with substantial applications in China. This protocol is proposed for a systematic review and meta-analysis that aims to evaluate the efficacy of integrative traditional Chinese and western medicine treatment on patients with COVID-19. Ten databases including PubMed, EMBASE, Cochrane Library, CIHAHL, Web of Scie",31/07/2020,10.1097/MD.0000000000020781,Dan Liu,"aWest China Hospital, Sichuan University, South Renmin Road, Wu Hou District, Chengdu bChengdu University of Traditional Chinese Medicine, Chengdu, China cCollege of Traditional Chinese Medicine, Hainan Medical University, Haikou, China",pubmed,0
114,32702300,Encouraging results from phase 1/2 COVID-19 vaccine trials.,NA,19/08/2020,10.1016/S0140-6736(20)31611-1,Naor Bar-Zeev,"International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA. Electronic address: nbarzee1@jhu",pubmed,0
117,32701395,Designing Pull Funding For A COVID-19 Vaccine.,"A widely accessible vaccine is essential to mitigate the health and economic ravages of coronavirus disease 2019 (COVID-19). Without appropriate incentives and coordination, however, firms might not respond at sufficient speed or scale, and competition among countries for limited supply could drive up prices and undercut efficient allocation. Programs relying on &quot;push&quot; incentives (direct cost reimbursement) can be complicated by the funder's inability to observe firms' private cost inf",10/09/2020,10.1377/hlthaff.2020.00646,Christopher M Snyder,"Christopher M. Snyder (chris.snyder@dartmouth.edu) is the Hyatt Professor of Economics, Department of Economics, Dartmouth College, in Hanover, New Hampshire",pubmed,0
118,32699860,"Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants.","With the demand for rapid COVID-19 vaccine development and evaluation, this paper aimed to describe the prevalence and correlates of willingness to participate in COVID-19 vaccine trials among university students in China. A cross-sectional survey with 1,912 Chinese university students was conducted during March and April 2020. Bivariate and multivariate analyses were performed to identify variables associated with willingness to participate. The majority of participants (64.01%) indicated willi",28/07/2020,10.1101/2020.07.13.20152678,Shufang Sun,NA,pubmed,0
119,32699167,Artificial intelligence mobile health platform for early detection of COVID-19 in quarantine subjects using a wearable biosensor: protocol for a randomised controlled trial.,"There is an outbreak of COVID-19 worldwide. As there is no effective therapy or vaccine yet, rigorous implementation of traditional public health measures such as isolation and quarantine remains the most effective tool to control the outbreak. When an asymptomatic individual with COVID-19 exposure is being quarantined, it is necessary to perform temperature and symptom surveillance. As such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiven",30/07/2020,10.1136/bmjopen-2020-038555,Chun Ka Wong,"Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong",pubmed,0
120,32699147,Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones.,NA,28/08/2020,10.1073/pnas.2014154117,Nir Eyal,"Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ 08901",pubmed,0
121,32698494,Self-Amplifying RNA Viruses as RNA Vaccines.,"Single-stranded RNA viruses such as alphaviruses, flaviviruses, measles viruses and rhabdoviruses are characterized by their capacity of highly efficient self-amplification of RNA in host cells, which make them attractive vehicles for vaccine development. Particularly, alphaviruses and flaviviruses can be administered as recombinant particles, layered DNA/RNA plasmid vectors carrying the RNA replicon and even RNA replicon molecules. Self-amplifying RNA viral vectors have been used for high level",03/08/2020,10.3390/ijms21145130,Kenneth Lundstrom,"PanTherapeutics, CH1095 Lutry, Switzerland",pubmed,0
122,32698479,Point-of-Use Rapid Detection of SARS-CoV-2: Nanotechnology-Enabled Solutions for the COVID-19 Pandemic.,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the COVID-19 pandemic that has been spreading around the world since December 2019. More than 10 million affected cases and more than half a million deaths have been reported so far, while no vaccine is yet available as a treatment. Considering the global healthcare urgency, several techniques, including whole genome sequencing and computed tomography imaging have been employed for diagnosing infected people. Considerable effort",03/08/2020,10.3390/ijms21145126,Navid Rabiee,"Department of Chemistry, Sharif University of Technology, Tehran 11155-3516, Iran",pubmed,0
123,32696862,Use of remdesivir for patients with Covid-19: a review article.,"The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, ",28/07/2020,10.1590/1806-9282.66.6.838,Thom..s Cavalcanti Pires de Azevedo,"Centro Universit..rio Cesmac, Macei.., AL, Brasil",pubmed,0
124,32694847,Coronavirus vaccines get a biotech boost.,NA,29/07/2020,10.1038/d41586-020-02154-2,Amber Dance,NA,pubmed,0
125,32694043,Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.,"Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infec",09/09/2020,10.1016/j.transci.2020.102875,Hassan Abolghasemi,"Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran",pubmed,0
126,32687112,COVID-19 pandemic: A global health burden.,"Coronavirus disease 2019 (COVID-19) pandemic began in China with a group of severe pneumonia cases, later identified to be caused by the severe acute respiratory syndrome coronavirus 2 in December 2019. Thailand reported the first COVID-19 case outside of China on 13<sup>th</sup> January 2020, Africa reported its first case in Egypt on 14<sup>th</sup> February 2020 and Nigeria reported its index case of COVID-19 on 27<sup>th</sup> February 2020. Virtually, all countries in the world are affected",23/07/2020,10.4103/npmj.npmj_157_20,Oluwatosin Wuraola Akande,"Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria",pubmed,0
127,32671831,COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.,"Although most autoimmune diseases are considered to be CD4 T cell- or antibody-mediated, many respond to CD20-depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off-label in a large number of other autoimmunities and ocrelizumab in multiple sclerosis. Recently, the COVID-19 pandemic created concerns about immunosuppression in autoimmunity, leading to cessation or a delay",09/09/2020,10.1111/cei.13495,D Baker,"Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK",pubmed,0
128,32669462,Human Infection Challenge Studies: a Test for the Social Value Criterion of Research Ethics.,"Human infection challenge studies involving the intentional infection of research participants with a disease-causing agent have recently been suggested as a means to speed up the search for a vaccine for the ongoing coronavirus disease 2019 (COVID-19) outbreak. Calls for challenge studies, however, rely on the expected social value of these studies. This value represents more than the simple possibility that a successful study will lead to the rapid development and dissemination of vaccines but",27/07/2020,10.1128/mSphere.00669-20,Nicholas G Evans,"Department of Philosophy, University of Massachusetts Lowell, Lowell, Massachusetts, USA Nicholas_evans@uml",pubmed,0
129,32667492,"Trained innate immunity, COVID-19 therapeutic dilemma, and fake science.",NA,21/07/2020,10.6061/clinics/2020/e2124,Jos.. Ernesto Beliz..rio,"Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR",pubmed,0
130,32667191,Hard Nanomaterials in Time of Viral Pandemics.,"The SARS-Cov-2 pandemic has spread worldwide during 2020, setting up an uncertain start of this decade. The measures to contain infection taken by many governments have been extremely severe by imposing home lockdown and industrial production shutdown, making this the biggest crisis since the second world war. Additionally, the continuous colonization of wild natural lands may touch unknown virus reservoirs, causing the spread of epidemics. Apart from SARS-Cov-2, the recent history has seen the ",14/09/2020,10.1021/acsnano.0c04117,Giacomo Reina,"CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France",pubmed,0
131,32664543,Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation.,"Recently, the world has been dealing with a devastating global pandemic coronavirus infection, with more than 12 million infected worldwide and over 300,000 deaths as of May 15th 2020, related to a novel coronavirus (2019-nCoV), characterized by a spherical morphology and identified through next-generation sequencing. Although the respiratory tract is the primary portal of entry of SARS-CoV-2, gastrointestinal involvement associated with nausea, vomiting and diarrhoea may also occur. No drug or ",24/07/2020,10.3390/ijms21144903,Elena Campione,"Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy",pubmed,0
133,32662677,The combination of artificial intelligence and systems biology for intelligent vaccine design.,"A new body of evidence depicts the applications of artificial intelligence and systems biology in vaccine design and development. The combination of both approaches shall revolutionize healthcare, accelerating clinical trial processes and reducing the costs and time involved in drug research and development. This review explores the basics of artificial intelligence and systems biology approaches in the vaccine development pipeline. The topics include a detailed description of epitope prediction",20/07/2020,10.1080/17460441.2020.1791076,Giulia Russo,"Department of Drug Sciences, University of Catania , Catania, Italy",pubmed,0
134,32661140,The SARS-CoV-2 N Protein Is a Good Component in a Vaccine.,NA,03/09/2020,10.1128/JVI.01279-20,Gustaf Ahl..n,"Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden",pubmed,0
135,32661074,Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.,"To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development through controlled human infection (or 'challenge') trials. These trials would involve the deliberate exposure of relatively few young, healthy volunteers to SARS-CoV-2. We defend this proposal against the charge that there is still too much uncertainty surrounding the risks of COVID-19 to responsibly run such a trial.",12/09/2020,10.1136/medethics-2020-106501,Robert Steel,"Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, New Jersey, USA",pubmed,0
136,32658877,[The naked king in the pandemic: about the production and communication of scientific knowledge at the time of SARS-CoV-2.],"The SARS-CoV-2 pandemic has lifted the veil about how medical knowledge is produced and disseminated. Action Bias, together with economic, academic and media-related interests, has concurred to generate and spread low-value and even unreliable information about some hypothetical therapeutic interventions for CoViD-19. Not only this &quot;infodemic&quot; has weakened people's ability to make informed health choices, but it also has influenced the process of new evidence generation through the vio",24/07/2020,10.1701/3407.33920,Camilla Alderighi,Ordine dei Medici Chirurghi e degli Odontoiatri della Provincia di Firenze,pubmed,0
138,32653662,Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2.,"Asymptomatic patients, together with those with mild symptoms of coronavirus disease 2019 (COVID-19), may play an important role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. However, the dynamics of virus shedding during the various phases of the clinical course of COVID-19 remains unclear at this stage. A total of 18 patients found to be positive for SARS-CoV-2 infection by real-time reverse transcription PCR (RT-PCR) assay and admitted to Chongqing University C",09/09/2020,10.1016/j.cmi.2020.07.008,W Li,"Chongqing University Central Hospital, China",pubmed,0
139,32653511,Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.,"Studies have shown that infection, excessive coagulation, cytokine storm, leukopenia, lymphopenia, hypoxemia and oxidative stress have also been observed in critically ill Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) patients in addition to the onset symptoms. There are still no approved drugs or vaccines. Dietary supplements could possibly improve the patient's recovery. Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), present an anti",27/08/2020,10.1016/j.freeradbiomed.2020.07.005,Marcelo M Rogero,"Nutritional Genomics and Inflammation Laboratory, Department of Nutrition, School of Public Health, University of S..o Paulo, 01246-904, S..o Paulo, Brazil",pubmed,0
140,32653463,Vaccines for COVID-19: The current state of play.,"There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 - the virus that causes COVID-19 - currently undergoing early phase human trials. We also consider the many challenges o",04/09/2020,10.1016/j.prrv.2020.06.010,Archana Koirala,"National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia",pubmed,0
141,32653040,"The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.","Bacillus Calmette-Gu..rin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conduc",21/07/2020,10.1186/s12931-020-01439-4,Marcos Pereira,"Institute of Collective Health, Federal University of Bahia, Salvador, Brazil. pereira.santosm@yahoo",pubmed,0
142,32650355,Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept.,"COVID-19 disease is the most recent pandemic, since it has affected more than four and a half million people and caused more than 300,000 deaths. It is a very complex systemic disease in terms of pathogenesis, treatment, and prognosis. Pharmacological treatment may include antiviral and antimalarial drugs, antibiotics, monoclonal antibodies, corticosteroids as well as low-molecular-weight heparins to prevent the evolution of the disease from reaching the severe inflammatory phase that can lead t",20/07/2020,10.15586/jptcp.v27iSP1.689,Marco Valentini,"Rheumatology Unit, San Pier Damiano Hospital, Faenza (RA), Italy",pubmed,0
143,32649315,Autopsy Services and Emergency Preparedness of a Tertiary Academic Hospital Mortuary for the COVID-19 Public Health Emergency: The Yale Plan.,Pathology Autopsy and Mortuary Services have been front and center in the severe acute respiratory syndrome coronavirus 2 (SARS-Co-V-2) pandemic. The sheer number of fatalities from the pandemic have been unlike any other in recent memory and needed the rapid creation of new protocols and paradigms to manage the situation. This required rapidly escalating mortuary capacity to manage the increased fatalities from the pandemic with the establishment of lines of communication and networking with go,22/07/2020,10.1097/PAP.0000000000000274,Declan McGuone,"Department of Pathology, Yale Medical School, New Haven",pubmed,0
144,32648899,"Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.","The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19. SARS-CoV-2 is spread primarily via respiratory droplets during close face-to-face contact. Infection can be spread by asymptomatic, pr",16/09/2020,10.1001/jama.2020.12839,W Joost Wiersinga,"Division of Infectious Diseases, Department of Medicine, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, the Netherlands",pubmed,0
145,32646869,Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.,NA,02/09/2020,10.1503/cmaj.201237,Bahaa Abu-Raya,"Vaccine Evaluation Center, BC Children's Hospital Research Institute, and Division of Infectious Diseases, Department of Pediatrics, University of British Columbia, Vancouver, BC baburaya@bcchr.ubc",pubmed,0
146,32645630,"Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.","There is no vaccine or specific antiviral treatment for HCoVs infection. The use of type I interferons for coronavirus is still under great debate in clinical practice. A literature search of all relevant studies published on PubMed, Cochrane library, Web of Science database, Science Direct, Wanfang Data, and China National Knowledge Infrastructure (CNKI) until February 2020 was performed. Of the 1081 identified articles, only 15 studies were included in the final analysis. Comorbidities and del",24/08/2020,10.1016/j.intimp.2020.106740,Chengjun Yu,"Children's Hospital of Chongqing Medical University, Chongqing, China",pubmed,0
147,32643436,"Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19.","A global outbreak of the SARS-CoV-2 virus has infected millions of people over a short period of time. The communicability and increased mortality from the SARS-CoV-2 infection mandated the WHO to declare COVID-19 a worldwide pandemic. The virus outbreak has spread when there are no approved vaccines, treatments, or prophylactic therapies available. Researchers from all over the world have prioritised development of vaccines and antivirals. Several vaccine projects have seen successes in preclin",07/09/2020,10.1080/1061186X.2020.1793990,Mohammed M Alvi,"Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA, USA",pubmed,0
148,32638362,The European response to the WHO call to eliminate cervical cancer as a public health problem.,"The age-standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All Eur",28/08/2020,10.1002/ijc.33189,Marc Arbyn,"Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium",pubmed,0
149,32636754,A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.,"A novel coronavirus SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) has entered the human population and has spread rapidly around the world in the first half of 2020 causing a global pandemic. The virus uses its spike glycoprotein receptor-binding domain to interact with host cell angiotensin-converting enzyme 2 (ACE2) sites to initiate a cascade of events that culminate in severe acute respiratory syndrome in some individuals. In efforts to curtail viral spread, authorities initiated fa",09/07/2020,10.3389/fphar.2020.00937,Colin D Funk,"Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada",pubmed,0
151,32632960,Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.,"Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID-19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines",09/09/2020,10.1002/ddr.21709,Abdullah Al Mamun Sohag,"Department of Biochemistry and Molecular Biology, Bangladesh Agricultural University, Mymensingh, 2202, Bangladesh",pubmed,0
152,32628748,Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.,"Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 vaccine development. We identify and discuss three potential use cases of HCTs in the current pandemic: evaluating efficacy, converging on correlates of protection, and improving understanding of pathogenesis and the human immune response. We outline the limitations of HCTs and find that HCTs are likely to be most useful for vaccine candidates currently in preclinical stages of development. We conclude that, whi",01/09/2020,10.1093/cid/ciaa935,Linh Chi Nguyen,"Department of Politics and International Relations, University of Oxford, Oxford, OX1 3UQ, United Kingdom",pubmed,0
153,32625198,Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?,"Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on Immunization (EPI)-linked malaria vaccine implementation was underway. However, in December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many clinical, epidemiological, and biological parallels to malaria, was reported in Wuhan,",07/07/2020,10.3389/fmicb.2020.01476,Nora Nganyewo Nghochuzie,"West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana",pubmed,0
154,32624257,Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.,"The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help ",25/08/2020,10.1016/j.jaci.2020.05.033,Koa Hosoki,"Department of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex",pubmed,0
155,32623082,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.","The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies. The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19. Multi-center retrospective observational study. The Henry Ford Health System (HFHS) in Southeast Michigan: la",30/07/2020,10.1016/j.ijid.2020.06.099,Samia Arshad,"Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States",pubmed,0
156,32622723,Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.,"Currently, coronavirus disease 2019 (COVID-19), which can lead to severe respiratory failure and death, is now a global pandemic with no specific anti-viral drugs or vaccines. However, It is worth noting that traditional Chinese medicine (TCM), especially Chinese herbal medicine (CHM), has been widely applied in mainland China since outbreak, bringing new hope for the prevention and control of COVID-19. A comprehensive literature searching was conducted in 7 electronic databases from their incep",20/09/2020,10.1016/j.phrs.2020.105056,Xingjiang Xiong,"Department of Cardiovascular Care Unit, Guang'Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: xiongxingjiangtcm@163",pubmed,0
157,32620409,Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.,Convalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19. CP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days ,09/09/2020,10.1016/j.transci.2020.102867,Mehmet Ali Erkurt,"Inonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address: erkurtali@hotmail",pubmed,0
159,32610334,COVID-19 Infection and Neurological Complications: Present Findings and Future Predictions.,"The present outbreak caused by SARS-CoV-2, an influenza virus with neurotropic potential, presents with neurological manifestations in a large proportion of the affected individuals. Disorders of the central and peripheral nervous system are all present, while stroke, ataxia, seizures, and depressed level of consciousness are more common in severely affected patients. People with these severe complications are most likely elderly with medical comorbidities, especially hypertension and other vasc",27/08/2020,10.1159/000508991,Ettore Beghi,"Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy, ettore.beghi@marionegri",pubmed,0
160,32607526,Cost Benefit Analysis of Limited Reopening Relative to a Herd Immunity Strategy or Shelter in Place for SARS-CoV-2 in the United States.,"Fierce debate about the health and financial tradeoffs presented by different COVID-19 pandemic mitigation strategies highlights the need for rigorous quantitative evaluation of policy options. To quantify the economic value of the costs and benefits of a policy of continued limited reopening with social distancing relative to alternative COVID-19 response strategies in the United States. We estimate the number and value of quality-adjusted life-years (QALY) gained from mortality averted, with a",04/07/2020,10.1101/2020.06.26.20141044,Robert B Schonberger,NA,pubmed,0
161,32607505,COVID-19 Clinical Research.,"While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency. We searched the NCI website and Medline and summarize various national a",03/07/2020,10.33696/Signaling.1.006,Jeffrey Chi,"Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra, Feinstein Institute for Medical Research, Lake Success, NY, USA",pubmed,0
162,32605278,Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19.,"Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboem",27/08/2020,10.3390/jcm9072030,Beatriz Fernandez-Fernandez,"IIS-Fundaci..n Jim..nez Diaz, Department of Medicine, School of Medicine, Universidad Aut..noma de Madrid, 28029 Madrid, Spain",pubmed,0
163,32604775,A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era.,"Background and objective: Despite medical advances, we are facing the unprecedented disaster of the coronavirus disease 2019 (COVID-19) pandemic without available treatments and effective vaccines. As the COVID-19 pandemic has approached its culmination, desperate efforts have been made to seek proper treatments and response strategies, and the number of clinical trials has been rapidly increasing. In this time of the pandemic, it is believed that learning lessons from it would be meaning",07/07/2020,10.3390/medicina56060315,Jinhee Lee,"Department of Psychiatry, Yonsei University, Wonju College of Medicine, Wonju Kangwon 26426, Korea",pubmed,0
164,32601655,Enhancing global health communication during a crisis: lessons from the COVID-19 pandemic.,"The understanding and practice of public health crisis communication are improved through the study of responses to past crises, but require retooling for present challenges. The 'Addressing Ebola and other outbreaks' checklist contains guiding principles built upon maxims developed from a World Health Organization consultation in response to the mad cow (bovine spongiform encephalopathy) crisis that were later adopted for Ebola. The purpose of this article is to adapt the checklist for the heal",06/07/2020,10.17061/phrp3022010,Scott C Ratzan,"CUNY Graduate School of Public Health and Health Policy, City University of New York, US",pubmed,0
165,32600908,"Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.","The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vac",20/07/2020,10.1016/j.vaccine.2020.06.022,Sonia Pagliusi,"DCVMN International, Route de Crassier 7, 1262 Eysins-Nyon, Switzerland. Electronic address: s.pagliusi@dcvmn",pubmed,0
166,32591957,"Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.",NA,20/08/2020,10.1007/s10198-020-01208-6,Sebastian Neumann-B..hme,"Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. neumann@eshpm.eur",pubmed,0
167,32584199,Human and novel coronavirus infections in children: a review.,"Coronaviruses, seven of which are known to infect humans, can cause a spectrum of clinical presentations ranging from asymptomatic infection to severe illness and death. Four human coronaviruses (hCoVs)-229E, HKU1, NL63 and OC43-circulate globally, commonly infect children and typically cause mild upper respiratory tract infections. Three novel coronaviruses of zoonotic origin have emerged during the past two decades: severe acute respiratory syndrome coronavirus (SARS-CoV-1), Middle East respir",25/06/2020,10.1080/20469047.2020.1781356,Nipunie Rajapakse,"Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic , Rochester, MN, USA",pubmed,0
168,32577634,SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.,"A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both po",27/08/2020,10.1101/2020.06.11.145920,Kizzmekia S Corbett,Vaccine Research Center,pubmed,0
169,32575350,Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.,"Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characterized with cytokine storm syndrome that can cause severe and irreversible damage to organs leading to multi-organ failure and death. Therefore, it is critical to control both programmed cell death (ap",23/07/2020,10.3390/vaccines8020320,Subbaya Subramanian,"Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA",pubmed,0
170,32574267,COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.,NA,10/07/2020,10.3389/fimmu.2020.01196,Scott B Halstead,"Independent Researcher, Bethesda, MD, United States",pubmed,0
171,32574236,Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?,"The novel coronavirus strain, severe acute respiratory syndrome coronavirus-2, the causative agent of COVID-19 emerged in Wuhan, China, in December 2019 and is skyrocketing throughout the globe and become a global public health emergency. Despite promising preventive measures being taken, there is no vaccine or drug therapy officially approved to prevent or treat the infection. Everybody is waiting the findings of ongoing clinical trials in various chemical and biological products. This review i",23/06/2020,10.3389/fphar.2020.00791,Mekonnen Sisay,"Department of Pharmacology and Toxicology, School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia",pubmed,0
172,32571773,"Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.","Patients infected with the novel coronavirus (SARS-CoV-2) are being treated empirically with oseltamivir, but there is little evidence from randomised controlled trials to support the treatment of coronavirus infections with oseltamivir. To determine whether adding oseltamivir to usual care reduces time to recovery in symptomatic patients who have tested positive for coronavirus (not including SARS-CoV-2). Exploratory analysis of data from an open-label, pragmatic, randomised controlled trial du",17/07/2020,10.3399/bjgp20X711941,Samuel Coenen,"Centre for General Practice, Department of Family Medicine &amp",pubmed,0
173,32571007,Nanotechnology for COVID-19: Therapeutics and Vaccine Research.,The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this &quot;virus&quot; nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using en,01/09/2020,10.1021/acsnano.0c04006,Gaurav Chauhan,"School of Engineering and Sciences, Tecnologico de Monterrey, Av. Eugenio Garza Sada 2501 Sur, 64849 Monterrey, Nuevo Le..n, Mexico",pubmed,0
174,32567818,Respiratory viral coinfection in a birth cohort of infants in rural Nepal.,"Acute respiratory illnesses are a leading cause of global morbidity and mortality in children. Coinfection with multiple respiratory viruses is common. Although the effects of each virus have been studied individually, the impacts of coinfection on disease severity are less understood. A secondary analysis was performed of a maternal influenza vaccine trial conducted between 2011 and 2014 in Nepal. Prospective weekly household-based active surveillance of infants was conducted from birth to 180.",22/06/2020,10.1111/irv.12775,Anne Emanuels,"Department of Epidemiology, University of Washington, Seattle, WA, USA",pubmed,0
175,32565096,"Anticipating Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Testing, Licensure, and Recommendations for Use.",NA,11/09/2020,10.1016/j.jpeds.2020.06.048,Kathryn M Edwards,"Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN. Electronic address: Kathryn.edwards@vumc",pubmed,0
176,32563999,"Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19).","Coronavirus has emerged as a global health threat due to its accelerated geographic spread over the last two decades. This article reviews the current state of knowledge concerning the origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Historically, it has caused two pandemics: severe acute respiratory syndrome and Middle East respiratory syndrome followed by the present COVID-19 that emerged from China. The virus is believed to be acquired from zoonotic sourc",10/07/2020,10.1136/postgradmedj-2020-138234,Srikanth Umakanthan,"Paraclinical Sciences, The University of the West Indies at Saint Augustine Faculty of Medical Sciences, Saint Augustine, Trinidad and Tobago Srikanth.Umakanthan@sta.uwi.edu dr.u.srikanth@gmail",pubmed,0
177,32563940,Analyzing barriers for implementation of public health and social measures to prevent the transmission of COVID-19 disease using DEMATEL method.,"COVID-19 is a contagious disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till now there are no vaccines and explicit medicines available for the treatment of COVID-19 disease, therefore the initiatives like public health and social measures are helpful in limiting the quantity of contaminations and saving lives. Keeping this in view, an attempt has been made in the present work to identify the barriers which hinder the implementation of ",19/09/2020,10.1016/j.dsx.2020.06.024,Annayath Maqbool,"Department of Mechanical Engineering, National Institute of Technology Srinagar, Jammu and Kashmir, 190006, India. Electronic address: annayat_13phd19@nitsri",pubmed,0
178,32563547,Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.,"Coronavirus disease 2019 (COVID-19) has been categorized as evolving in overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the majority, perhaps 80% of patients. The pathophysiological mechanisms resulting in minimal disease in this initial phase are not well known. In the remaining 20% of cases, the disease may become severe and/or critical. In most patients of this latter group, there is a phase characterized by the hyperresponsiveness of the immune syst",09/09/2020,10.1016/j.jaut.2020.102506,Yhojan Rodr..guez,"Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia",pubmed,0
179,32562594,Pregnant Women in Trials of Covid-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.,"Ethical issues abound during this unprecedented international public health crisis of Covid-19. While the trade-off between societal and individual interests that occurs at the intersection of public health ethics and clinical ethics affects all populations, this calculus has particular relevance for pregnant women and the question of when they will have access to new Covid-19 therapies and vaccines. Pregnant women are a &quot;scientifically complex&quot; population whose inclusion in clinical r",27/07/2020,10.1002/eahr.500060,Ruth Farrell,Vice chair of research in the OB/GYN &amp,pubmed,0
180,32562316,A proposed role for the SARS-CoV-2 nucleocapsid protein in the formation and regulation of biomolecular condensates.,"To date, the recently discovered SARS-CoV-2 virus has afflicted &gt;6.9 million people worldwide and disrupted the global economy. Development of effective vaccines or treatments for SARS-CoV-2 infection will be aided by a molecular-level understanding of SARS-CoV-2 proteins and their interactions with host cell proteins. The SARS-CoV-2 nucleocapsid (N) protein is highly homologous to the N protein of SARS-CoV, which is essential for viral RNA replication and packaging into new virions. Emerging",11/09/2020,10.1096/fj.202001351,Sean M Cascarina,"Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO, USA",pubmed,0
181,32561657,Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?,"We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing &quot;trained&quot; nonspecific innate immune cells for improved host responses against subsequent i",29/06/2020,10.1128/mBio.00907-20,Paul L Fidel,"Department of Oral and Craniofacial Biology, Louisiana State University Health-School of Dentistry, New Orleans, Louisiana, USA pfidel@lsuhsc",pubmed,0
182,32557771,How to expedite early-phase SARS-CoV-2 vaccine trials in pandemic setting-A practical perspective.,NA,02/07/2020,10.1111/bcp.14435,Johan L van der Plas,"Centre for Human Drug Research (CHDR), Leiden, The Netherlands",pubmed,0
184,32554572,Pandemic vaccines are about to face the real test.,NA,08/07/2020,10.1126/science.368.6497.1295,Jon Cohen,NA,pubmed,0
185,32548679,Calling for an exponential escalation scheme in vaccine development for COVID-19.,"COVID-19 as a pandemic calls for rapid development of vaccines. Here a proposal of a seamless, adaptive, phase 1-3 trial for accelerated vaccine development is described. Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2..weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16..weeks, general vaccination would be feasible if supply meets the demand. A COVID-19 vaccine would be rapidly available",10/09/2020,10.1007/s00228-020-02933-w,Martin Wehling,"Institute of Clinical Pharmacology Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. martin.wehling@medma.uni-heidelberg",pubmed,0
186,32544799,Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.,"While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with host",28/07/2020,10.1016/j.ejca.2020.05.026,Serena Di Cosimo,"Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy",pubmed,0
187,32540733,Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies.,"Many patients with coronavirus disease 2019 (COVID-19) have comorbidities related to metabolic syndrome (MS) during the disease course. Its presence in different ethnicities and continents places MS as an important risk factor for COVID-19. Adequate understanding of the interplay between MS, COVID-19 and proposed therapies is required for optimum management of these patients. We systematically searched the PubMed and Google Scholar databases until June 1st, 2020 and accessed the full text on COV",19/09/2020,10.1016/j.dsx.2020.06.016,Fernanda Farias Costa,"Department of Biomedicine, CEUMA University (UNICEUMA), R. Bar..o do Rio Branco, 100, Entroncamento, Imperatriz, MA, 65903-093, Brazil",pubmed,0
188,32540367,A review of potential treatments to date in COVID-19 patients according to the stage of the disease.,"Since the end of 2019, the COVID-19 pandemic has affected millions of people worldwide. With the rapid spread of this virus, an immense burden has fallen upon both healthcare and economic systems. As a consequence, there is an unprecedented urgency for researchers and scientific committees from all over the world to find an effective treatment and vaccine. Many potential therapies are currently under investigation, with some, like Hydroxychloroquine, being authorized for emergency use in some co",02/09/2020,10.1016/j.retram.2020.05.004,Tamim Alsuliman,"Service d'H..matologie, h..pital Saint-Antoine, AP-HP, Sorbonne Universit.., 75012, Paris, France. Electronic address: dr.tameem.soliman@gmail",pubmed,0
190,32529703,The WetNet: What the Oral Polio Vaccine Hypothesis Exposes about Globalized Interspecies Fluid Bonds.,"The author analyzes the aftermath of Edward..Hooper's suggestion that the trial of an oral polio vaccine (OPV) in the Belgian colonies of Africa engendered the pandemic form of the AIDS virus, HIV-1. In response to..Hooper's book,..The River (1999),..the Royal Society in London held a conference to debate the origins of HIV. Examination of the quick dismissal of the OPV theory opens a space for legitimately challenging the widely held belief that the vaccine contamination question was convincing",04/08/2020,10.1111/maq.12587,S Lochlann Jain,"Department of Anthropology, Stanford University",pubmed,0
191,32527823,Aggregating data from COVID-19 trials.,NA,17/06/2020,10.1126/science.abc8993,Elizabeth L Ogburn,"Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. eogburn@jhsph",pubmed,0
192,32527819,Can existing live vaccines prevent COVID-19?,NA,17/06/2020,10.1126/science.abc4262,Konstantin Chumakov,"Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. konstantin.chumakov@fda.hhs",pubmed,0
193,32527804,"COVID-19 and flu, a perfect storm.",NA,17/06/2020,10.1126/science.abd2220,Edward A Belongia,"Edward A. Belongia is the director of the Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA. belongia.edward@marshfieldclinic",pubmed,0
194,32525830,A vaccine is not too far for COVID-19.,NA,22/06/2020,10.3855/jidc.12744,Shailesh Kumar Patel,"Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India. shaileshpatel624@gmail",pubmed,0
195,32520683,Review on the clinical pharmacology of hydroxychloroquine sulfate for the treatment of COVID-19.,"As the number of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infected people is skyrocketing worldwide, the international medical situation becomes very serious. Potential therapeutic drugs, vaccine and stem cell replacement methods are emerging, it is urgent to find specific therapeutic drugs and the best treatment regimens. After the publication of hydroxychloroquine (HCQ) with anti-SARS-COV-2 activity in vitro, a small, non-randomized, open-label clinical trial showed that HC",10/06/2020,10.2174/1389200221666200610172929,Cheng Cui,"Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191. China",pubmed,0
197,32515404,Comprehensive overview of COVID-19 clinical trials.,"Here, we present an overview of the clinical trials that are currently being conducted or have concluded to date on COVID-19 globally. A comprehensive search was conducted to present 16 trial registries from around the world. Collectively, there are 1,528 trials reported for COVID-19 to date. Out of them, 50 studies included paediatric age group from day 0 to less than or equal to 18 years of age. A few 18 studies involve only females and 20 only males. There are 2 trials currently underway in B",18/06/2020,10.5455/JPMA.37,Kiran Ejaz,"School of Medicine, Emory University Atlanta, GA, USA",pubmed,0
198,32513202,From COVID-19 research to vaccine application: why might it take 17...months not 17...years and what are the wider lessons?,"It is often said that it takes 17...years to move medical research from bench to bedside. In a coronavirus disease (COVID-19) world, such time-lags feel intolerable. In these extraordinary circumstances could years be made into months? If so, could those lessons be used to accelerate medical research when the crisis eases?To measure time-lags in health and biomedical research as well as to identify ways of reducing them, we developed and published (in 2015) a matrix consisting of overlapping tra",11/06/2020,10.1186/s12961-020-00571-3,Stephen R Hanney,"Health Economics Research Group, Brunel University London, Kingston Lane, Uxbridge, UK. stephen.hanney@brunel.ac",pubmed,0
200,32511333,COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning.,"To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane protein, have been tested for vaccine development against SARS and MERS. We further used the Vaxign reverse vaccinology tool and the newly developed Vaxign-ML machine learn",27/08/2020,10.1101/2020.03.20.000141,Edison Ong,"Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA",pubmed,0
201,32507409,"Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.","A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six",22/06/2020,10.1016/j.vaccine.2020.05.064,Paul-Henri Lambert,"Centre of Vaccinology, University of Geneva, Switzerland",pubmed,0
202,32505245,COVID-19 vaccine development pipeline gears up.,NA,10/06/2020,10.1016/S0140-6736(20)31252-6,Asher Mullard,NA,pubmed,0
203,32503874,Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.,"Despite global containment measures to fight the coronavirus disease 2019 (COVID-19), the pandemic continued to rise, rapidly spread across the world, and resulting in 2.6...million confirmed cases and 185 061 deaths worldwide as of 23 April 2020. Yet, there are no approved vaccines or drugs to make the disease less deadly, while efforts are underway. Remdesivir, a nucleotide-analogue antiviral drug developed for Ebola, is determined to prevent and stop infections with COVID-19, while results ar",16/06/2020,10.1136/bmjopen-2020-039159,Desye Gebrie,"School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia desye.gebrie@mu.edu",pubmed,0
204,32503817,Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.,"Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), initially termed 2019-new CoV (2019-nCoV), is a novel coronavirus responsible for the severe respiratory illness currently ongoing worldwide from the beginning of December 2019. This beta gene virus, very close to bat coronaviruses (bat-CoV-RaTG13) and bat-SL-CoVZC45, causes a severe disease, similar to those caused by Middle East respiratory syndrome (MERS)-CoV and SARS-CoV viruses, featured by low to moderate mortality rate. Unfortu",22/06/2020,10.21873/invivo.11949,Sabrina Bimonte,"Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori - IRCCS - &quot",pubmed,0
205,32503602,Two Randomized Controlled Trials of Bacillus Calmette-Gu..rin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials.,The objectives of these two separate trials are: (1) to reduce health care workers (HCWs) absenteeism; and (2) to reduce hospital admission among the elderly during the COVID-19 pandemic through BCG vaccination. Two separate multi-centre placebo-controlled parallel group randomized trials PARTICIPANTS: (1) Health care personnel working in the hospital or ambulance service where they will take care of patients with the COVID-19 infection and (2) elderly ...60 years. The HCW trial is being underta,30/06/2020,10.1186/s13063-020-04389-w,Thijs Ten Doesschate,"University Medical Center, Utrecht, The Netherlands. t.tendoesschate@umcutrecht",pubmed,0
206,32501411,SARS-CoV-2 infection serology: a useful tool to overcome lockdown?,"The outbreak of 2019 novel coronavirus disease (Covid-19) caused by SARS-CoV-2 has spread rapidly, inducing a progressive growth in infected patients number. Social isolation (lockdown) has been assessed to prevent and control virus diffusion, leading to a worldwide financial and political crisis. Currently, SARS-CoV-2 RNA detection in nasopharyngeal swab takes place by real-time PCR (RT-qPCR). However, molecular tests can give some false-negative results. In this context, serological assays can",08/06/2020,10.1038/s41420-020-0275-2,Marzia Nuccetelli,"Tor Vergata University Hospital, Rome, Italy",pubmed,0
207,32496246,Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.,"As of May 4, 2020, India has reported 42,836 confirmed cases and 1,389 deaths from COVID-19. India's multipronged response included nonpharmacological interventions (NPIs) like intensive case-based surveillance, expanding testing capacity, social distancing, health promotion, and progressive travel restrictions leading to a complete halt of international and domestic movements (lockdown). We studied the impact of NPI on transmission dynamics of COVID-19 epidemic in India and estimated the minimu",17/06/2020,10.4103/ijph.IJPH_510_20,Purvi Patel,"India Epidemic Intelligence Service Officer, National Centre for Disease Control, Delhi, India",pubmed,0
208,32496238,COVID-19 vaccine development and the way forward.,"The whole globe is reeling under the COVID-19 pandemic now. With the scale and severity of infection, number of deaths and lack of any definite therapeutic armamentarium, the vaccine development has been accelerated at a never-before pace. A wide variety of vaccine technologies and platforms are being attempted. Out of the over 108 efforts, 100 are in preclinical and eight in Phase 1 or 2 trial stage. While the availability of newer technologies has facilitated development, there are several cha",17/06/2020,10.4103/ijph.IJPH_520_20,Narendra Kumar Arora,"Executive Director, The INCLEN Trust International, New Delhi, India",pubmed,0
209,32495979,Emergence of novel coronavirus and progress toward treatment and vaccine.,"In late December 2019, a group of patients was observed with pneumonia-like symptoms that were linked with a wet market in Wuhan, China. The patients were found to have a novel coronavirus genetically related to a bat coronavirus that was termed SARS-CoV-2. The virus gradually spread worldwide and was declared a pandemic by WHO. Scientists have started trials on potential preventive and treatment options. Currently, there is no specific approved treatment for SARS-CoV-2, and various clinical tri",20/07/2020,10.1002/rmv.2116,Muhammad Muzamil Khan,"Department of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan",pubmed,0
210,32495226,Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?,"The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical vent",17/07/2020,10.1007/s10067-020-05202-4,Sebasti..n Ib....ez,"Medicine Faculty Cl..nica Alemana, Universidad del Desarrollo, Av. Manquehue Norte 1410, piso 7,, 7650567, Vitacura, Santiago, Chile. sibanez@alemana",pubmed,0
211,32494546,Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.,"The ongoing novel coronavirus disease 2019 (COVID-19) pandemic has been responsible for millions of infections and hundreds of thousands of deaths. To date, there is no approved targeted treatment, and many investigational therapeutic agents and vaccine candidates are being considered for the treatment of COVID-19. To extract and summarize information on potential vaccines and therapeutic agents against COVID-19 at different stages of clinical trials from January to March 2020, we reviewed major",06/06/2020,10.7759/cureus.8342,Akshaya S Bhagavathula,"Public Health, Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, ARE",pubmed,0
212,32493494,"Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.","SARS-CoV-2 infection presents a high transmission in the group of health professionals in Spain (12-15% infected). Currently there is no accepted chemoprophylaxis but hydroxychloroquine (HDQ) is known to inhibit the coronavirus in vitro. Our hypothesis is that oral administration of hydroxychloroquine to healthcare professionals can reduce the incidence and prevalence of infection as well as its severity in this group. Design: Prospective, single center, double blind, randomised, controlled tria",10/06/2020,10.1186/s13063-020-04400-4,Antonio Cuadrado-Lav..n,"Department of Gastroenterology and Hepatology, Marqu..s de Valdecilla University Hospital, School of Medicine, University of Cantabria, Av. Valdecilla, 25, 39008, Santander, Cantabria, Spain",pubmed,0
213,32493478,Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.,"Primary Objective ... To test the efficacy of Hydroxychloroquine (HCQ) (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete 14 days) to prevent incident SARS-CoV-2 infection, compared to ascorbic acid among contacts of persons with SARS-CoV-2 infection Secondary objectives ... To determine the safety and tolerability of HCQ as SARS-CoV-2 Post-exposure Prophylaxis (PEP) in adults ... To test the efficacy of HCQ (400 mg orally daily for 3 days then 200 mg",10/06/2020,10.1186/s13063-020-04446-4,Ruanne V Barnabas,"Department of Global Health,International Clinical Research Center (ICRC), University of Washington, UW Box 359927, 325 Ninth Avenue, Seattle, WA, 98104, USA. rbarnaba@uw",pubmed,0
214,32492743,[SARS-CoV-2 infection (COVID-19): what can we expect?],"- Case numbers in China are clearly declining, case numbers in many European regions are no longer increasing exponentially.- Data on mortality from SARS-CoV-2 infection are contradictory; mortality is certainly lower than for SARS and MERS, but probably higher than for most seasonal flu outbreaks in recent years- The main complication of SARS-CoV-2 infection is pneumonia with development of acute respiratory distress syndrome (ARDS)- Asymptomatic and oligosymptomatic courses with virus shedding",09/06/2020,10.1055/a-1114-3699,Winfried V Kern,"Abteilung Infektiologie, Klinik f..r Innere Medizin II, Universit..tsklinikum Freiburg",pubmed,0
215,32492144,The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials.,"In response to provocative comments by 2 European clinicians and scientists, the World Health Organization Director General has declared that Africa will not host COVID-19 vaccine trials. Such a stance risks stigmatizing COVID-19 vaccine trials in Africa and depriving Africa of critical research. To the contrary, there is a critical need for Africa to host COVID-19 vaccine trials on public health, scientific, and ethics grounds.",21/07/2020,10.1093/infdis/jiaa303,Jerome Amir Singh,"Centre for the AIDS Programme of Research in South Africa, Durban, South Africa",pubmed,0
216,32489136,COVID-19 quarantine: Post-traumatic stress symptomatology among Lebanese citizens.,"In the light of the global spread of the novel Coronavirus known as COVID-19 and in the absence of an approved treatment and vaccination, Lebanon has taken national measures, among which was home quarantine of the general public in an attempt to flatten the epidemic curve and avoid flooding the health care system. This study aimed at evaluating the prevalence of post-traumatic stress symptomatology (PTSS) during the times of COVID-19 quarantine among Lebanese citizens. This quantitative cross-se",01/09/2020,10.1177/0020764020932207,Mirna Fawaz,"Nursing Department, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon",pubmed,0
217,32474009,"COVID-19: Transmission, prevention, and potential therapeutic opportunities.","The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense research efforts worldwide, an effective vaccine and viable treatment options have eluded investigators. Therefore, infection prevention, early viral detection and identification of successful treatment protocols provide the best approach in controlling disease spread. In this review, current therapeutic options, preventive methods",22/07/2020,10.1016/j.cca.2020.05.044,Melika Lotfi,"School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran",pubmed,0
218,32469280,COVID-19: Gene Transfer to the Rescue?,NA,25/06/2020,10.1089/hum.2020.29125.lhv,Luk H Vandenberghe,"Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA",pubmed,0
219,32466458,Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.,"The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, a",02/06/2020,10.3390/v12060582,Nadin Younes,"Biomedical Research Center, Qatar University, P.O. Box 2713 Doha, Qatar",pubmed,0
220,32466392,Model for Taking Care of Patients with Early Childhood Caries during the SARS-Cov-2 Pandemic.,"Pending the availability of vaccines to contain the SARS-CoV-2 pandemic, the current solution is &quot;social distancing&quot; with a reduction of dental treatments to those assessed as urgent and emergency cases. These treatments also involve Early Childhood Caries (ECC) due to the fact that this disease affects preschool children (a vulnerable population) and, in addition, shows a propensity to evolve into more serious complications (dental pain, infections). A narrative review was carried out",17/06/2020,10.3390/ijerph17113751,Stefano Cianetti,"Biomedical Sciences, Unit of Paediatric Dentistry, University of Perugia, 06100 Perugia, Italy",pubmed,0
221,32461245,Ethical guidelines for deliberately infecting volunteers with COVID-19.,"Global fatalities related to COVID-19 are expected to be high in 2020-2021. Developing and delivering a vaccine may be the most likely way to end the pandemic. If it were possible to shorten this development time by weeks or months, this may have a significant effect on reducing deaths. Phase II and phase III trials could take less long to conduct if they used human challenge methods-that is, deliberately infecting participants with COVID-19 following inoculation. This article analyses arguments",18/08/2020,10.1136/medethics-2020-106322,Adair D Richards,"Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK Adair.Richards@warwick.ac",pubmed,0
222,32460358,The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.,"Since the first World Health Organization notification on 31 December 2019, coronavirus disease 2019 (COVID-19), the respiratory disease caused by the coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been responsible for over four million confirmed infections and almost 300..000 deaths worldwide. The pandemic has led to over half of the world's population living under lockdown conditions. To allow normal life to resume, public health interventions will be needed to p",13/07/2020,10.1111/imm.13222,Hannah R Sharpe,"The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK",pubmed,0
223,32459832,Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.,Pediatric patients are excluded from most COVID-19 therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials with enabled us to include children of all ages in a therapeutic COVID-19 trial at our institution.,26/06/2020,10.1093/cid/ciaa656,Vanessa N Raabe,"Department of Pediatrics, Division of Pediatric Infectious Diseases, New York University Grossman School of Medicine, New York, NY, USA",pubmed,0
225,32456404,The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.,"Since December 2019, there has been an outbreak of a novel beta-coronavirus (SARS-CoV-2) in Wuhan, China. On March the 11th the World Health Organization (WHO) declared COVID-19 as a pandemic, with over 118,000 cases in more than 110 countries around the world. In response to the global coronavirus disease 2019 (COVID-19) emergency, clinical trial research assessing the efficacy and safety of experimental vaccines to prevent COVID-19 are emerging at an unprecedented rate. The aim of this systema",27/05/2020,10.23736/S0031-0808.20.03958-0,Enrico Checcucci,"Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy - checcu.e@hotmail",pubmed,0
228,32444382,Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.,"Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-CoV-2), suggesting that rapid preclinical animal studies are required to identify potential antiviral ",03/06/2020,10.1128/mBio.01114-20,Su-Jin Park,"Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea",pubmed,0
229,32442040,"SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.",NA,10/08/2020,10.1080/14740338.2020.1773789,Domenico Merante,"Global Clinical Development , Amersham, UK",pubmed,0
230,32441894,Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.,"Human challenge trials to test the efficacy of vaccine candidates against SARS-CoV-2, the novel coronavirus behind Covid-19, could save considerable time and many lives. But they may initially seem unethical because they expose healthy volunteers to a live virus that is killing many people and for which no cure exists. This article argues that this is not the correct test of their ethics. The correct test is comparative. And in the special circumstances of the Covid-19 pandemic, human challenge ",27/07/2020,10.1002/eahr.500056,Nir Eyal,"Directs the Center for Population-Level Bioethics at Rutgers University and is the Henry Rutgers professor of bioethics in the Department of Health Behavior, Society and Policy at Rutgers School of Public Health and in the Department of Philosophy at Rutgers's School of Arts and Sciences",pubmed,0
231,32439768,Long-acting drug acts like a short-term AIDS vaccine.,NA,11/06/2020,10.1126/science.368.6493.807,Jon Cohen,NA,pubmed,0
232,32437659,Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.,"SARS-CoV-2 infection is mild in the majority of individuals but progresses into severe pneumonia in a small proportion of patients. The increased susceptibility to severe disease in the elderly and individuals with co-morbidities argues for an initial defect in anti-viral host defense mechanisms. Long-term boosting of innate immune responses, also termed &quot;trained immunity,&quot; by certain live vaccines (BCG, oral polio vaccine, measles) induces heterologous protection against infections th",05/06/2020,10.1016/j.cell.2020.04.042,Mihai G Netea,"Department of Internal Medicine and Center for Infectious Diseases, Radboud University, 6500 Nijmegen, the Netherlands",pubmed,0
233,32437587,COVID-19 vaccines: Knowing the unknown.,"Vaccine development against SARS-CoV-2 has drawn attention around the globe due to the exploding pandemic. Although COVID-19 is caused by a new coronavirus, SARS-CoV-2, previous research on other coronavirus vaccines, such as FIPV, SARS, and MERS, has provided valuable information for the rapid development of COVID-19 vaccine. However, important knowledge gaps remain - some are specific to SARS-CoV-2, others are fundamental to immunology and vaccinology. Here, we discuss areas that need to be ad",08/07/2020,10.1002/eji.202048663,Huibin Lv,"HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China",pubmed,0
234,32434788,"COVID-19 and lung cancer: risks, mechanisms and treatment interactions.","Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial to test the efficacy of a vaccine has recently begun, but in the meantime there is an urgent need to decrease the morbidity and mortality of severe cases. It is known that patients with",29/05/2020,10.1136/jitc-2020-000892,Alfredo Addeo,"Oncology, University Hospitals Geneva, Geneve, Switzerland alfredo.addeo@hcuge",pubmed,0
235,32425691,International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19.,"The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytoki",07/09/2020,10.1016/j.jcyt.2020.05.002,Verena B..rger,"Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany",pubmed,0
236,32425638,Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.,"As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated ",28/07/2020,10.1016/j.ijid.2020.05.040,Alimuddin Zumla,"Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac",pubmed,0
237,32425416,The role of an Orthopaedic Surgeon in the time of Covid-19 Pandemic-a German perspective.,"Covid-19 is a non-orthopaedic disease but is affecting the community of Orthopaedics as much as every part of our daily living. In this Editorial the different aspects of changes in our routine are described, based on the experience of this Editor in Germany. I will try to give you a bit of background information first, as the situation is very much dependent on the specific phase of the pandemic and your place of work. The experience for an Orthopaedic Surgeon in New York or Madrid may differ f",22/05/2020,10.1016/j.jor.2020.05.010,Heiko Graichen,"Department for Arthroplasty, Orthopaedic Hospital Asklepios Lindenlohe, Lindenlohe 18, 92421 Schwandorf, Germany",pubmed,0
238,32423342,COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?,NA,21/05/2020,10.1080/10837450.2020.1764670,Raid G Alany,"Professor of Pharmaceutical Formulation and Drug Delivery, Kingston University London, Kingston upon Thames, UK",pubmed,0
239,32420637,Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.,"Since its outbreak in late 2019, the SARS-Cov-2 pandemic already infected over 3.7 million people and claimed more than 250,000 lives globally. At least 1...year may take for an approved vaccine to be in place, and meanwhile millions more could be infected, some with fatal outcome. Over thousand clinical trials with COVID-19 patients are already listed in ClinicalTrials.com, some of them for assessing the utility of therapeutics approved for other conditions. However, clinical trials take many m",09/09/2020,10.1002/ddr.21689,David Gurwitz,"Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv, Israel",pubmed,0
240,32417802,The changing landscape of SARS-CoV-2: Implications for the maternal-infant dyad.,"The COVID-19 pandemic represents the greatest challenge to date faced by the medical community in the 21st century. The rate of rapid dissemination, magnitude of viral contagiousness, person to person transmission at an asymptomatic phase of illness pose a unique and dangerous challenge for all patients, including neonatal and obstetric patients. Although scientific understanding of the pathophysiology of the disease, nature of transmission, and efficacy of mitigation strategies is growing, neit",15/09/2020,10.3233/NPM-200460,T G Elgin,"Stead Family Children's Hospital Department of Pediatrics, Neonatology Division, University of Iowa, Iowa City, IA, USA",pubmed,0
241,32414757,Ethical considerations for epidemic vaccine trials.,"Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in clinical trials involving human subjects. On the one hand, there are compelling reasons why it would be unethical to trial a novel vaccine when an effective product exists alrea",16/07/2020,10.1136/medethics-2020-106235,Joshua Teperowski Monrad,"Program in Ethics, Politics, and Economics, Yale University, New Haven, CT, USA joshua.monrad@yale",pubmed,0
242,32412556,"Characterization of the COVID-19 pandemic and the impact of uncertainties, mitigation strategies, and underreporting of cases in South Korea, Italy, and Brazil.","By April 7th, 2020, the Coronavirus disease 2019 (COVID-19) has infected one and a half million people worldwide, accounting for over 80 thousand of deaths in 209 countries and territories around the world. The new and fast dynamics of the pandemic are challenging the health systems of different countries. In the absence of vaccines or effective treatments, mitigation policies, such as social isolation and lock-down of cities, have been adopted, but the results vary among different countries. So",25/08/2020,10.1016/j.chaos.2020.109888,Ruy Freitas Reis,"Departamento de Ci..ncia da Computa....o, Universidade Federal de Juiz de Fora, Brazil",pubmed,0
243,32410772,Emerging pharmacotherapies for COVID-19.,"Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other i",30/06/2020,10.1016/j.biopha.2020.110267,Rachana Salvi,Department of Pharmacology &amp,pubmed,0
244,32410758,Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.,NA,29/05/2020,10.1016/S0140-6736(20)31029-1,Clare L Whitehead,"Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3052, Australia",pubmed,0
245,32409451,U.S. 'Warp Speed' vaccine effort comes out of the shadows.,NA,11/06/2020,10.1126/science.368.6492.692,Jon Cohen,NA,pubmed,0
246,32407706,SARS-CoV-2: A New Song Recalls an Old Melody.,"The viruses causing the SARS outbreak of 2002-2003 and current COVID-19 pandemic are related betacoronaviruses. What insights were learned from SARS that can inform SARS-CoV-2 vaccine development? Focusing on important lessons from SARS vaccine development and two SARS vaccines evaluated in humans may guide SARS-CoV-2 vaccine design, testing, and implementation.",18/05/2020,10.1016/j.chom.2020.04.019,Kanta Subbarao,"WHO Collaborating Centre for Reference and Research on Influenza and Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne, VIC 3000, Australia. Electronic address: kanta.subbarao@influenzacenter",pubmed,0
247,32407539,Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?,"The scientific community has risen to the coronavirus disease 2019 (COVID-19) challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate treatments may be frustrated by the absence of comprehensive trial coordination mechanisms. Many small stand-alone trials and observational studies of single-agent interventions are currently running o",19/09/2020,10.1002/cpt.1891,Hans-Georg Eichler,"European Medicines Agency (EMA), Amsterdam, The Netherlands",pubmed,0
248,32406317,Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an <i>in silico</i> based approach.,"The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug ta",25/05/2020,10.1080/07391102.2020.1768902,Saurov Mahanta,"National Institute of Electronics and Information Technology (NIELIT), Guwahati, Guwahati, Assam, India",pubmed,0
249,32406253,Bacillus Calmette Gu..rin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?,NA,06/07/2020,10.2217/fon-2020-0381,Ellen O'Connor,"Department of Surgery, University of Melbourne, Austin Hospital, Heidelberg, Melbourne, Victoria, Australia",pubmed,0
250,32404020,COVID-19: The race for a vaccine.,NA,10/06/2020,10.1177/1470320320926902,Emily Lockey,"Fieldfisher LLP, UK",pubmed,0
251,32397182,Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.,"In the midst of the ongoing COVID-19 coronavirus pandemic, influenza virus remains a major threat to public health due to its potential to cause epidemics and pandemics with significant human mortality. Cases of H7N9 human infections emerged in eastern China in 2013 and immediately raised pandemic concerns as historically, pandemics were caused by the introduction of new subtypes into immunologically na..ve human populations. Highly pathogenic H7N9 cases with severe disease were reported recentl",19/05/2020,10.3390/v12050518,Peter Pushko,"Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA",pubmed,0
252,32396996,Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.,"As a zoonotic disease that has already spread globally to several million human beings and possibly to domestic and wild animals, eradication of coronavirus disease 2019 (COVID-19) appears practically impossible. There is a pressing need to improve our understanding of the immunology of this disease to contain the pandemic by developing vaccines and medicines for the prevention and treatment of patients. In this review, we aim to improve our understanding on the immune response and immunopatholo",03/08/2020,10.1111/all.14364,Ahmet Kursat Azkur,"Department of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey",pubmed,0
253,32394841,COVID-19: An Update on Clinical Trials.,NA,27/08/2020,10.2174/1568026620999200511092332,Yogesh Kumar,"Department of Chemistry Bhagini Nivedita College University of Delhi Delhi-110043, India",pubmed,0
254,32393664,Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.,"To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease receiving longterm HCQ compared to target concentrations with reported antiviral activity against the coronavirus disease 2019 caused by SARS-CoV-2 (COVID-19). We evaluated total HCQ concentrations in serum and plasma from published literature values, frozen serum samples from a pediatric systemic lupus erythematosus trial, and simulated concentrations using a published pharmacokinetic model during pregnancy. Fo",19/06/2020,10.3899/jrheum.200493,Stephen J Balevic,"From the Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA",pubmed,0
255,32393526,A strategic approach to COVID-19 vaccine R&amp;D.,NA,02/06/2020,10.1126/science.abc5312,Lawrence Corey,"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA",pubmed,0
256,32387332,"Current development of COVID-19 diagnostics, vaccines and therapeutics.","A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection.",14/08/2020,10.1016/j.micinf.2020.05.001,Naru Zhang,"Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China",pubmed,0
257,32387011,"Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.",NA,22/05/2020,10.1016/j.vaccine.2020.04.073,Gregory A Poland,"Mayo Vaccine Research Group, 611C Guggenheim Building, Mayo Clinic and Foundation, Rochester, MN 55905, USA. Electronic address: poland.gregory@mayo",pubmed,0
258,32381692,Combination prevention for COVID-19.,NA,12/05/2020,10.1126/science.abc5798,Myron S Cohen,"Myron S. Cohen is a professor in the Department of Medicine, Division of Infectious Diseases, and The Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. mscohen@med.unc",pubmed,0
259,32380316,Convalescent plasma in Covid-19: Possible mechanisms of action.,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the po",10/06/2020,10.1016/j.autrev.2020.102554,Manuel Rojas,"Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia",pubmed,0
260,32378805,COVID-19 and toxicity from potential treatments: Panacea or poison.,"Since December 2019, coronavirus disease (COVID-19) has been increasingly spreading from its origin in Wuhan, China to many countries around the world eventuating in morbidity and mortality affecting millions of people. This pandemic has proven to be a challenge given that there is no immediate cure, no vaccine is currently available and medications or treatments being used are still undergoing clinical trials. There have already been examples of self-medication and overdose. Clearly, there is a",05/08/2020,10.1111/1742-6723.13537,Anselm Wong,"Victorian Poisons Information Centre, Austin Toxicology Unit and Emergency Department, Austin Health, Melbourne, Victoria, Australia",pubmed,0
261,32376359,Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2.,"Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered",18/06/2020,10.1016/j.micpath.2020.104236,Parismita Kalita,"Molecular and Structural Biophysics Laboratory, Department of Biochemistry, North-Eastern Hill University, Shillong, 793022, India",pubmed,0
262,32375002,Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery.,"Lipid nanoparticle (LNP) packaged mRNA vaccines have been deployed against infectious diseases such as COVID-19, yet their structural features remain unclear. Cholesterol, a major constituent within LNPs, contributes to their morphology that influences gene delivery. Herein, we examine the structure of LNPs containing cholesterol derivatives using electron microscopy, differential scanning calorimetry, and membrane fluidity assays. LNPs formulated with C24 alkyl derivatives of cholesterol show a",23/06/2020,10.1021/acs.nanolett.0c01386,Yulia Eygeris,"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon 97201, United States",pubmed,0
263,32366816,An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.,"The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LN",06/05/2020,10.12659/MSM.924700,Fuzhou Wang,"Group of Neuropharmacology and Neurophysiology, Division of Neuroscience, The Bonoi Academy of Science and Education, Chapel Hill, NC, USA",pubmed,0
264,32365191,Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.,NA,07/07/2020,10.1093/infdis/jiaa234,Kevin W Graepel,"Vanderbilt University School of Medicine, Nashville, Tennessee, USA",pubmed,0
265,32363221,"An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, epidemiology and clinical implications.","Coronavirus infections have emerged as epidemic and pandemic threats in last two decades. After the H1N1 influenza pandemic in 2009, recently diagnosed novel betacoronavirus or severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has spread across 203 countries and territories in all 5 major continents. World Health Organization (WHO) declared this as a public health emergency of international concern on January 30, 2020. Subsequently on February 11, 2020 a new name was given to this disea",25/08/2020,10.1016/j.cmrp.2020.04.001,Dinesh Kaul,"Pediatric Infectious Diseases, Department of Pediatrics, Sir Ganga Ram Hospital, New Delhi -110060, India",pubmed,0
266,32359402,Considering BCG vaccination to reduce the impact of COVID-19.,NA,19/05/2020,10.1016/S0140-6736(20)31025-4,Nigel Curtis,"Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia",pubmed,0
267,32355008,COVID-19 shot protects monkeys.,NA,05/05/2020,10.1126/science.368.6490.456,Jon Cohen,NA,pubmed,0
268,32350928,Rethinking the role of hydroxychloroquine in the treatment of COVID-19.,"There are currently no proven or approved treatments for coronavirus disease 2019 (COVID-19). Early anecdotal reports and limited..in vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease. As an increasing number of patients with COVID-19 are treated with these agents and more evidence accumulates, there continues to be no high-quality clinical data showing a clear benefit of these agents for this disease.",06/05/2020,10.1096/fj.202000919,Eric A Meyerowitz,"Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA",pubmed,0
269,32350686,Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.,"The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a &quot;Public Health Emergency of International Concern&quot; (PHEIC). According to the WHO, Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA), currently there are no medicines or vaccines that have been claimed to be useful in the prevention or treatment of COVID-19. Several existing antiviral drugs, previously developed or used as treatments f",09/06/2020,10.1007/s12325-020-01351-9,Zakir Khan,"T..bbi Farmakoloji Anabilim Dal.., T..p Fak..ltesi, ..ukurova ..niversitesi, Sar....am, Adana, Turkey. zakirkhan300@gmail",pubmed,0
270,32350002,Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline.,NA,06/07/2020,10.1503/cmaj.200648,Zhikang Ye,"Department of Health Research Methods, Evidence and Impact Canada (Ye, Rochwerg, Guyatt, Colunga-Lozano) and of Medicine (Rochwerg), McMaster University, Hamilton, Ont.",pubmed,0
271,32348598,"Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.","The current COVID-19 pandemic, caused by SARS-CoV-2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune-based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those f",22/06/2020,10.1111/apt.15779,Aysha H Al-Ani,"Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia",pubmed,0
272,32346094,COVID-19 vaccine design: the Janus face of immune enhancement.,NA,15/06/2020,10.1038/s41577-020-0323-4,Peter J Hotez,"Texas Children's Center for Vaccine Development, Houston, TX, USA. hotez@bcm",pubmed,0
273,32344853,Searching for SARS-COV-2 on Particulate Matter: A Possible Early Indicator of COVID-19 Epidemic Recurrence.,"A number of nations were forced to declare a total shutdown due to COVID-19 infection, as extreme measure to cope with dramatic impact of the pandemic, with remarkable consequences both in terms of negative health outcomes and economic loses. However, in many countries a &quot;Phase-2&quot; is approaching and many activities will re-open soon, although with some differences depending on the severity of the outbreak experienced and SARS-COV-2 estimated diffusion in the general population. At the ",06/05/2020,10.3390/ijerph17092986,Leonardo Setti,"Department of Industrial Chemistry, University of Bologna, 40136 Bologna, Italy",pubmed,0
274,32344202,Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.,"The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19",29/05/2020,10.1016/j.ebiom.2020.102768,Ruklanthi de Alwis,"Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore",pubmed,0
275,32343658,Medication for COVID-19-an Overview of Approaches Currently Under Study.,"With the worldwide spread of SARS-CoV-2 infection, it is becoming increasingly urgent to develop a vaccine to prevent COVID-19, as well as effective drugs to treat it. This article is based on a selective literature search in PubMed and ClinicalTrials.gov, followed by an assessment of the ongoing clinical trials that were revealed by the search. A number of substances have been found to prevent the reproduction of SARS-CoV-2 in vitro. These include virustatic agents that have already been approv",01/05/2020,10.3238/arztebl.2020.0213,Ralf Stahlmann,"Institute for Clinical Pharmacology and Toxicology,Charit..-Universit..tsmedizin Berlin",pubmed,0
276,32341719,Covid-19 pandemic by the &quot;real-time&quot; monitoring: the Tunisian case and lessons for global epidemics in the context of 3PM strategies.,"Covid-19 is neither the first nor the last viral epidemic which societies around the world are, were and will be affected by. Which lessons should be taken from the current pandemic situation? The Covid-19 disease is still not well characterised, and many research teams all over the world are working on prediction of the epidemic scenario, protective measures to populations and sub-populations, therapeutic and vaccination issues, amongst others. Contextually, countries with currently low numbers",09/09/2020,10.1007/s13167-020-00207-0,Lotfi Chaari,"University of Toulouse, IRIT - INP-ENSEEIHT (UMR 5505), 2 rue Charles Camichel, BP 7122 Toulouse Cedex 7, France",pubmed,0
277,32341531,Could BCG be used to protect against COVID-19?,NA,16/06/2020,10.1038/s41585-020-0325-9,Gil Redelman-Sidi,"Division of Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York, NY, USA. redelmag@mskcc",pubmed,0
278,32338347,COVID-19 in Children: Clinical Approach and Management.,"COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time. Transmission of the infection occurs by inhalation of infected droplets or direct contact with soiled surfaces and fomites. It should be suspected in all symptomatic children who have undertaken international travel in the last 14 d, all hospitalized children with severe acute respiratory illness, and asymptomatic direct and high-ris",19/05/2020,10.1007/s12098-020-03292-1,Jhuma Sankar,"Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India",pubmed,0
279,32330122,Panic prescribing has become omnipresent during the COVID-19 pandemic.,NA,11/06/2020,10.1172/JCI139562,Arthur L Caplan,"Division of Medical Ethics, New York University Grossman School of Medicine, New York, New York, USA",pubmed,0
280,32327600,Against pandemic research exceptionalism.,NA,12/05/2020,10.1126/science.abc1731,Alex John London,"Center for Ethics and Policy, Carnegie Mellon University, Pittsburgh, PA, USA",pubmed,0
281,32327575,NIH organizes hunt for drugs.,NA,14/05/2020,10.1126/science.368.6489.351,Jocelyn Kaiser,NA,pubmed,0
282,32325038,"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.","Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1 MERS, in humans. This dose-escala",09/09/2020,10.1016/S1473-3099(20)30160-2,Pedro M Folegatti,"The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK",pubmed,0
283,32325037,"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.","The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public health emergency and the absence of efficacious drugs or vaccines, MERS is one of the WHO priority diseases warranting urgent research and development of countermeasures. We aimed to assess safety and tolerability of an anti-MERS-CoV modified vaccinia virus Ankara (MVA)-based vaccine candidate that expresses the MERS-CoV spike glyc",09/09/2020,10.1016/S1473-3099(20)30248-6,Till Koch,"First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany",pubmed,0
284,32320592,Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.,NA,27/04/2020,10.1056/NEJMe2012889,Eric J Rubin,NA,pubmed,0
285,32318706,Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2.,"Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics. A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based survey",14/05/2020,10.1093/jpids/piaa045,Kathleen Chiotos,"Department of Anesthesia and Critical Care Medicine, Division of Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, United States",pubmed,0
286,32317431,Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.,"A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review out",27/04/2020,10.4103/ijo.IJO_639_20,Rohit Shetty,"Narayana Nethralaya, Bangalore, Karnataka, India",pubmed,0
287,32313823,One month of the novel coronavirus 2019 outbreak: Is it still a threat?,"The novel coronavirus 2019 disease (COVID-19) is now in an outbreak not only in China but also around the world, suspected to be originated from a wet market in Wuhan, Hubei province, China. The flare-up of COVID-19, it has already been infected 78,811 people with 2462 fatalities in 1..month window. The most alarming issue is the virus can transmit from host to host and still asymptomatic. Currently, 24 counties with 505 confirmed cases have been reported. Presently, there is no specific treatme",09/09/2020,10.1007/s13337-020-00579-x,Apu Chowdhury,"School of Medicine, Xi'an Jiaotong University, Xi'an, 710061 China",pubmed,0
288,32311668,SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment.,"The new coronavirus outbreak is an ongoing pandemic that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus SARS-Cov-2 belongs to the subfamily of ..-coronaviruses and shares 79.5% of the genetic sequence of SARS-CoV, the causative agent of the epidemic that started in 2002 and ended in 2004. Considering the clinical impact of the new outbreak, it is highly important to study the potential responses of the human immune system during the SARS-CoV-2 infe",18/06/2020,10.1016/j.intimp.2020.106519,"Department of Experimental Medicine, University of Campania &quot di Mauro Gabriella",gabriella.dimauro@unicampania.it,pubmed,0
289,32306836,"Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment.","In the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms of economic disruption, the strain on local and global public health. Most recently, the global outbreak of novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 is a newly discovered virus from the coronavirus family in Wuhan city, China, known to be a great threat to the public health systems. As of 15 April 2020, ",06/05/2020,10.1080/07391102.2020.1758788,Subramanian Boopathi,"Centro de Bioinform..tica y Simulaci..n Molecular (CBSM), Universidad de Talca, Talca, Chile",pubmed,0
290,32305089,Sarah Gilbert: carving a path towards a COVID-19 vaccine.,NA,28/04/2020,10.1016/S0140-6736(20)30796-0,Richard Lane,NA,pubmed,0
291,32304435,The Impact of the COVID-19 Pandemic on Cancer Patients.,"In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently inv",04/06/2020,10.1097/COC.0000000000000712,Osama M Al-Quteimat,"Pharmacy Services Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE",pubmed,0
292,32303704,The race against COVID-19.,NA,23/04/2020,10.1038/s41565-020-0680-y,NA NA,NA,pubmed,0
293,32302280,Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.,"As of March 30<sup>th</sup>, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical tr",21/05/2020,10.5811/westjem.2020.3.47328,Cortlyn Brown,"University of California San Francisco, Department of Emergency Medicine, San Francisco, California",pubmed,0
294,32300051,Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.,NA,21/04/2020,10.1136/jitc-2020-000878,Paolo Antonio Ascierto,"Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy",pubmed,0
295,32297723,"COVID-2019: update on epidemiology, disease spread and management.","With each passing day, more cases of Coronavirus disease (COVID-2019) are being detected and unfortunately the fear of novel corona virus 2019 (2019-nCoV) becoming a pandemic disease has come true. Constant efforts at individual, national, and international level are being made in order to understand the genomics, hosts, modes of transmission and epidemiological link of nCoV-2019. As of now, whole genome sequence of the newly discovered coronavirus has already been decoded. Genomic characterizat",20/04/2020,10.4081/monaldi.2020.1292,Kamal Kant Sahu,"Department of Internal medicine, Saint Vincent Hospital, Worcester, Massachusetts, United States of America, 01608. Kamalkant.Sahu@stvincenthospital",pubmed,0
296,32295694,COVID-19 vaccination clinical trials should consider multiple doses of BCG.,NA,20/04/2020,10.1691/ph.2020.0444,B M Ayoub,"The Center for Drug Research and Development (CDRD), Pharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt",pubmed,0
297,32294922,Benefits of Exercise on Influenza or Pneumonia in Older Adults: A Systematic Review.,"A coronavirus pandemic has recently become one of the greatest threats the world is facing. Older adults are under a high risk of infection because of weaker immune systems. Therefore, the purpose of this review is to summarize the recent scientific evidence that outlines the effects of exercise on influenza or pneumonia in older adults. An electronic literature search was conducted using the WEB OF SCIENCE, SCIENCEDIRECT and GOOGLE SCHOLAR databases using the following keywords, &quot;Exercise,",23/07/2020,10.3390/ijerph17082655,Yang Song,"Faculty of Sports Science, Ningbo University, Ningbo 315211, China",pubmed,0
298,32292527,On a Statistical Transmission Model in Analysis of the Early Phase of COVID-19 Outbreak.,"Since December 2019, a disease caused by a novel strain of coronavirus (COVID-19) had infected many people and the cumulative confirmed cases have reached almost 180,000 as of 17, March 2020. The COVID-19 outbreak was believed to have emerged from a seafood market in Wuhan, a metropolis city of more than 11 million population in Hubei province, China. We introduced a statistical disease transmission model using case symptom onset data to estimate the transmissibility of the early-phase outbreak ",09/09/2020,10.1007/s12561-020-09277-0,Yifan Zhu,"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109 USA",pubmed,0
299,32292113,Stem Cell-Based Therapy for Coronavirus Disease 2019.,"The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. I",15/06/2020,10.1089/scd.2020.0071,Robert Chunhua Zhao,"Department of Cell Biology, School of Life Sciences, Shanghai University, Shanghai, PR China",pubmed,0
300,32291999,Immunogenicity and Efficacy of Live Infectious Bronchitis 793/B.08IR Vaccine in SPF Chickens.,"Infectious bronchitis virus (IBV) has a variety of serotypes with relatively limited cross-protection leading the disease to be a major problem in the poultry industry. The IBV 793/B strain has identified to circulate in Iran; therefore, the development of a specific vaccine to protect against the virulent virus has received attention. In this regard, the live IB 793/B vaccine (793/B.08IR) was developed in the Razi Vaccine and Serum Research Institute. In this study, the immunogenicity of 793/B.",31/08/2020,10.22092/ari.2019.124720.1286,S Masoudi,"Department of production of Infectious Bronchitis and Encephalomyelytis Vaccines, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran",pubmed,0
301,32290293,A Review of SARS-CoV-2 and the Ongoing Clinical Trials.,"The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a ",16/04/2020,10.3390/ijms21072657,Yung-Fang Tu,"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan",pubmed,0
302,32282303,Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.,NA,05/08/2020,10.2174/1568026620999200413145654,Amit K Banerjee,"Biology Division, Indian Institute of Chemical Technology Hyderabad-500007, Telangana, India",pubmed,0
303,32282038,The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19.,"Since the COVID-19 pandemic first hit Wuhan, China, in December 2019, scientists have been racing to develop and test novel vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The speed of scientific discovery related to COVID-19 is unprecedented. With several vaccine candidates already being tested in clinical trials, we pose the question: what will the vaccine hesitant do in the face of this pandemic?",05/08/2020,10.1093/cid/ciaa433,John McAteer,"Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA",pubmed,0
304,32273621,"If a coronavirus vaccine arrives, can the world make enough?",NA,30/04/2020,10.1038/d41586-020-01063-8,Roxanne Khamsi,NA,pubmed,0
305,32273591,The COVID-19 vaccine development landscape.,NA,06/05/2020,10.1038/d41573-020-00073-5,Tung Thanh Le,NA,pubmed,0
306,32259480,SARS-CoV-2 Vaccines: Status Report.,"SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccine",24/04/2020,10.1016/j.immuni.2020.03.007,Fatima Amanat,"Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA",pubmed,0
307,32247193,Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.,NA,28/04/2020,10.1016/j.jns.2020.116803,Saiju Jacob,"Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH, United Kingdom. Electronic address: saiju.jacob@uhb.nhs",pubmed,0
308,32243270,Potential therapeutic agents against COVID-19: What we know so far.,"The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavir",16/06/2020,10.1097/JCMA.0000000000000318,Chih-Chia Lu,"Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC",pubmed,0
309,32241928,Vaccine designers take first shots at COVID-19.,NA,07/04/2020,10.1126/science.368.6486.14,Jon Cohen,With reporting by Kai Kupferschmidt,pubmed,0
310,32234468,"The epidemiology, diagnosis and treatment of COVID-19.","In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission via droplets, contaminated hands or surfaces has been described, with incubation times of 2-14 days. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. Thi",28/05/2020,10.1016/j.ijantimicag.2020.105955,Pan Zhai,"Department of Neurology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430073, Hubei, China",pubmed,0
311,32234130,[Progress and challenge of vaccine development against 2019-novel coronavirus (2019-nCoV)].,"The outbreak of 2019-novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same ..-genus of coronavirus family. Basing on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over ",28/08/2020,10.3760/cma.j.cn112150-20200317-00366,Y Shi,"Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China",pubmed,0
312,32233561,Effects of media reporting on mitigating spread of COVID-19 in the early phase of the outbreak.,"The 2019 novel coronavirus disease (COVID-19) is running rampantly in China and is swiftly spreading to other countries in the world, which causes a great concern on the global public health. The absence of specific therapeutic treatment or effective vaccine against COVID-19 call for other avenues of the prevention and control measures. Media reporting is thought to be effective to curb the spreading of an emergency disease in the early stage. Cross-correlation analysis based on our collected da",09/04/2020,10.3934/mbe.2020147,Wei Ke Zhou,"College of Mathematics and Information Science, Shaanxi Normal University, Xi'an 710062, China",pubmed,0
313,32232474,Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.,"Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine eval",19/05/2020,10.1093/infdis/jiaa152,Nir Eyal,"Center for Population-Level Bioethics, Rutgers University, New Brunswick, New Jersey, USA",pubmed,0
315,32231348,Emerging prophylaxis strategies against COVID-19.,"The Novel corona virus 2019 which started as an outbreak in China in December 2019 has rapidly spread all over the world, such that on 11th March 2020 WHO declared this disease as pandemic. The emergency that the world faces today demands that we develop urgent and effective measures to protect people at high risk of transmission. WHO has accelerated research in diagnostics, vaccines and therapeutics for this novel coronavirus.",02/04/2020,10.4081/monaldi.2020.1289,Sumita Agrawal,"Pulmonary Medicine and Critical Care, Medipulse Hospitals, Jodhpur. drsumi84@gmail",pubmed,0
316,32229574,News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine.,NA,20/04/2020,10.1073/pnas.2005456117,Lynne Peeples,NA,pubmed,0
317,32227757,Developing Covid-19 Vaccines at Pandemic Speed.,NA,26/05/2020,10.1056/NEJMp2005630,Nicole Lurie,"From the Coalition for Epidemic Preparedness Innovations, Oslo",pubmed,0
318,32226695,"Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19).",Effective treatments for Coronavirus Disease 2019 (COVID-19)..outbreak are urgently needed. While anti-viral approaches and..vaccines are being considered..immediate countermeasures are unavailable. The aim of this article is to outline a perspective on the pathophysiology of COVID-19 in the context of the currently available clinical data published in the literature. This article appreciates clinical data..published on COVID-19 in the context of another respiratory illness - high altitude pulmo,02/04/2020,10.7759/cureus.7343,Isaac Solaimanzadeh,"Internal Medicine, Interfaith Medical Center, Brooklyn, USA",pubmed,0
319,32226288,Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective.,"Currently, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV, the causative pathogen of Coronavirus Disease 2019 (COVID-19)) has rapidly spread across China and around the world, causing an outbreak of acute infectious pneumonia. No specific anti-virus drugs or vaccines are available for the treatment of this sudden and lethal disease. The supportive care and non-specific treatment to ameliorate the symptoms of the patient are the only options currently. At",03/04/2020,10.7150/ijbs.45538,Yang Yang,"State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR 999078, China",pubmed,0
320,32221519,Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.,"The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. Among 173 patients,",30/04/2020,10.1093/cid/ciaa344,Juanjuan Zhao,"Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China",pubmed,0
321,32215622,Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility.,"A physiological small animal model that resembles COVID-19 with low mortality is lacking. Molecular docking on the binding between angiotensin-converting enzyme 2 (ACE2) of common laboratory mammals and the receptor-binding domain of the surface spike protein of SARS-CoV-2 suggested that the golden Syrian hamster is an option. Virus challenge, contact transmission, and passive immunoprophylaxis were performed. Serial organ tissues and blood were harvested for histopathology, viral load and titre",30/04/2020,10.1093/cid/ciaa325,Jasper Fuk-Woo Chan,"State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China",pubmed,0
322,32214240,Coronavirus shuts down trials of drugs for multiple other diseases.,NA,15/06/2020,10.1038/d41586-020-00889-6,Heidi Ledford,NA,pubmed,0
323,32205459,"Underpromise, overdeliver.",NA,01/04/2020,10.1126/science.abb8492,H Holden Thorp,"H. Holden Thorp Editor-in-Chief, Science journals. hthorp@aaas",pubmed,0
324,32203367,Coronavirus vaccines: five key questions as trials begin.,NA,01/06/2020,10.1038/d41586-020-00798-8,Ewen Callaway,NA,pubmed,0
325,32197097,Disease X: accelerating the development of medical countermeasures for the next pandemic.,"WHO has listed several priority diseases with epidemic potential for which there are no, or insufficient, medical countermeasures. In response, the Bill &amp; Melinda Gates Foundation (with support from PricewaterhouseCoopers) coordinated subject matter experts to create a preparedness plan for Disease X. Disease X is caused by Pathogen X, an infectious agent that is not currently known to cause human disease, but an aetiologic agent of a future outbreak with epidemic or pandemic potential. We h",07/08/2020,10.1016/S1473-3099(20)30123-7,Shmona Simpson,The Bill &amp,pubmed,0
326,32179860,Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees.,NA,20/03/2020,10.1038/d41586-020-00751-9,Shibo Jiang,NA,pubmed,0
327,32146554,Containing 2019-nCoV (Wuhan) coronavirus.,"The novel coronavirus 2019-nCoV first appeared in December 2019 in Wuhan, China. While most of the initial cases were linked to the Huanan Seafood Wholesale Market, person-to-person transmission has been verified. Given that a vaccine cannot be developed and deployed for at least a year, preventing further transmission relies upon standard principles of containment, two of which are the isolation of known cases and the quarantine of persons believed at high risk of exposure. This note presents p",24/08/2020,10.1007/s10729-020-09504-6,Edward H Kaplan,"William N. and Marie A. Beach Professor of Operations Research, Professor of Public Health, Professor of Engineering, Yale School of Management, 165 Whitney Avenue, New Haven, 06511, CT, USA. edward.kaplan@yale",pubmed,0
328,32134116,Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.,"By 27 February 2020, the outbreak of coronavirus disease 2019 (COVID-19) caused 82...623 confirmed cases and 2858 deaths globally, more than severe acute respiratory syndrome (SARS) (8273 cases, 775 deaths) and Middle East respiratory syndrome (MERS) (1139 cases, 431 deaths) caused in 2003 and 2013, respectively. COVID-19 has spread to 46 countries internationally. Total fatality rate of COVID-19 is estimated at 3.46% by far based on published data from the Chinese Center for Disease Control and",30/06/2020,10.1002/jmv.25748,Yixuan Wang,"Laboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong, China",pubmed,0
329,32110875,"Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major elect",11/04/2020,10.3390/jcm9030623,Junxiong Pang,"Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore",pubmed,0
330,32108352,Clinical trial analysis of 2019-nCoV therapy registered in China.,"So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primar",30/06/2020,10.1002/jmv.25733,Qi Zhang,"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China",pubmed,0
331,32048890,"Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.",The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP.. for immunogenicity and safety in the course of clinical trial phase II on healthy subjects up to 60 years. The trial involved 150 subjects in randomized 2:1 groups that received either RIBSP vaccine or comparator vaccine VAXIGRIP... One dose (0.5 ml) of either vaccine contained 15 ..g of hemagglutinin of each influenza virus strain recommended by WHO for the Northern hemisphere ,17/09/2020,10.1080/21645515.2019.1705691,Gulbanu Sarsenbayeva,"Research Institute for Biological Safety Problems , Gvardeysk, Kazakhstan",pubmed,0
332,32001631,New coronavirus threat galvanizes scientists.,NA,08/04/2020,10.1126/science.367.6477.492,Jon Cohen,NA,pubmed,0